var title_f3_27_3504="Algorithm for management of thyroid nodules";
var content_f3_27_3504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Recommended management of thyroid nodules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 779px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FNA: fine-needle aspiration; N: normal; TSH: thyroid-stimulating hormone (thyrotropin); US-FNA: ultrasound-guided fine-needle aspiration.",
"     <br/>",
"     * Thyroid scintigraphy after suppressing TSH with thyroxine.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Castro MR, Gharib H. Endocr Pract 2003; 9:128.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_27_3504=[""].join("\n");
var outline_f3_27_3504=null;
var title_f3_27_3505="Cleft lip and palate PI";
var content_f3_27_3505=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Baby with cleft lip and baby with cleft palate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 543px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A cleft lip is an opening or split in the upper lip (on left) A cleft palate is an opening or split the roof of the mouth, called the palate (on right). A baby can be born with one or both of these birth defects.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_27_3505=[""].join("\n");
var outline_f3_27_3505=null;
var title_f3_27_3506="Ross River virus small joint arthritis";
var content_f3_27_3506=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small joint arthritis with Ross River virus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The small joints are involved in approximately 40 percent of patients with Ross River virus infection. The proximal interphalangeal joints are a frequent site of involvement and, as in this case, may be accompanied by a rash.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Richards, MB, BS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_27_3506=[""].join("\n");
var outline_f3_27_3506=null;
var title_f3_27_3507="Upper lip defect resect";
var content_f3_27_3507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Upper lip defect after resection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Neil D Gross, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_27_3507=[""].join("\n");
var outline_f3_27_3507=null;
var title_f3_27_3508="Esmolol: Patient drug information";
var content_f3_27_3508=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Esmolol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     see \"Esmolol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/48/5895?source=see_link\">",
"     see \"Esmolol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Brevibloc",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Brevibloc&reg;;",
"     </li>",
"     <li>",
"      Brevibloc&reg; Premixed",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12935176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to esmolol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Very weak heart or slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 12 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11366 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-219.243.220.100-C5CC09C3EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_27_3508=[""].join("\n");
var outline_f3_27_3508=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166884\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166885\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12935176\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014260\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014259\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014263\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014264\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014266\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014262\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014267\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014268\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=related_link\">",
"      Esmolol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/48/5895?source=related_link\">",
"      Esmolol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_27_3509="Anatomy of the oral cavity";
var content_f3_27_3509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Anatomy of the oral cavity - Primary structures in the oral cavity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 593px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_27_3509=[""].join("\n");
var outline_f3_27_3509=null;
var title_f3_27_3510="Laryngeal inlet anatomy";
var content_f3_27_3510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Laryngeal inlet anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 412px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGcAj0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAA0lKaSgAooooAKKKKACiiigApAck0tFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADCmWySSOoHpTxRRQAUUUUAFAopRQAVg+MLm5trTT2swCzajaxvn+40qhv0zW9XPeNGVbPTdwJzqdoBj185aGNblD4halfwQ6ZpeiXa2up6ldpCkuwOY4x80jAEEZ2jHIxzXXqMAAnJHf1rjNGspdQ+ImsaxK4a0tI0srUAfxbQZTn64GPau0pIH2CiikpiCiiigAooooAQk7gMcetLRRQAyONUZyowWOT9afRRQAUUUUAFFFBGRQAUY5z3NAooAQDAxS0UUAFLSUUAJgEg+lOHWkpRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAGkJwM0ppKACiiigAooooAKKKKACiiigAooooAKKKKACilpKACiiigAooooAKO5OaWjFACUuKRs44OKWgAooooAKKKKACud8dsItB+1OSEtJ4rkkY4COG78dq6KuI+L8JvfCSaYJDEdSvrWz3jsHlXJ/LNDGty38LrKS18G2U1yztdXxa9nLdd8h3fyxXWU2NFjjVEGFUAAegp1AN3YGk60tJigQUUUUAFFFVNY1K00fSrvUdRmWGztY2llkbsoGT9T7d6ALmKTFcDoPgvT9fjm13xxoVhfavqLCRYL+2Sc2MGP3duu4HBA5bHV2btitT/AIVz4I/6E3w3/wCCuD/4mgDqqK5X/hXPgj/oTfDf/grg/wDiaP8AhXPgj/oTfDf/AIK4P/iaAOqxRiuV/wCFc+CP+hN8N/8Agrg/+Jo/4Vz4I/6E3w3/AOCuD/4mgDqsVheOvEH/AAi3hTUNa8iO4+yIreXJN5SnLBeXwdoGc5welUv+Fc+CP+hN8N/+CuD/AOJqxqPg7RrnwpdeHrG1j0jTrjBK6bFHDsbcG3KNpXOQOoNAGLpXxI0x7KObVLzR5HnuTbW6eH7uXWPMcRlyp8uEMG2qxxg8Dr2q2fiJoAdpTfwmwNpBdRvGkzzSGaWSJUEQjySWjICgl8hgUXAJpa34J1i+v/D0sfivU5Dp99JcyXcyWonjRraSILEFt/LOS4zvU8E4OcVmzfDrSX0RbnwleS3F9bxwW9rP/aCIqy29zLI0hkEMo8zfLMGBRgT8u1eTQBoXHxJ00azpphuEj0N7XUJb2a6tpoJYZLZoBt2OFYf61gQVJJxj3df/ABR0aDUtHtbW31K5+23clpOo0+6We2KwNKCYPK8w7sLgYHBLDIVsZ2ifCxLjRtviy9nuNSkN+ZGt5hgfapI3J3+Wm51MMZDBUGc/LjArRvfAmnWbJq2oeJtWi1OG7W6/teeW2V1byjAqYMXlBSshXGzOWznJoAZ4d+J+m6va29xcQvpsbT3kcpvI54lVLcy5dHaEI/yxFmG4bMkElhg9boGu2WvWz3GnLeiFSPmubGa23AjIK+ai7hjuMiuYPwx0iSN7e7vtSudOMl48dlK8Qji+1CQTKpWMOQfNYjLEg4we1dN4d0mfSLQ29xrOo6qBgI98IdyKBjAMcaZ+rZPvQBq0UUCgBaKKKACiiigAooooAKKKKACiiigAoorwPxjpNz9p8Svd+Gm1TxLJqLS2NxdaPcXsc1tgeVHDcROv2YqMAksvIJwc5oA98oryPxDfePINI1S/sZ79nXWZLRLZLNVMVkJDiZMQSu7cAAhHG1idpI3VzniLxT8RrbwzZNYRazPqywTTLNb6fIYpyJWCRyRtYb/M2gZ4t1YHKnngA9/orwmeTxboQ8UnRW11ru41wTvG9h+6jtZFTM0Mi2sm98gJtAkIUElMgmuk8BXXjTVdVs49c1C7hsI7Tz2kSwMXnuLmQCN2mt4yD5YUMFjTOAy7c8gHpa3ds169mtxCbtI1maAOPMVGJCsV6hSVYA9CVPpU9eSfEC08S23jTX9b8NyalDLbaBaeSlvaJMl5KtxcEwncjE4VgSEKt8wORRf614zTxLeRW51cyLeXMa2Y0xTZLZrCximW48v5pSwT5fMbliNgAzQB62aSvI5/+E8kg03bresxSS+H59RuDHptv8t6ogEdvhoTjJaQ7T8x+bBGBt9P0Ka5udE0+e/jMV5LbxvMhUqVcqCwweRg54oAu0Vyv/CUav8A9CJ4k/7/AOnf/JVH/CUav/0IniT/AL/6d/8AJVAHVUVyv/CUav8A9CJ4k/7/AOnf/JVSad4safXLXS9T0HVtHuLuOSS3e9a2ZJim0sgMM0mGw2cEDIDY6UAdNRRRQAUUUUAFFFFABQeRg9KKKAAcDAooooAKKXFFABiiiigBM84waH3Y+QAn3NLWDrfizSNHdUu7oNKxI2QjewwM8gdPxpNpasaTeiN6ms6J95lX6mvG/EXxJvtSup7TQv8ARLQHAuOsrjAzjsvOR3rlZZmumzdp9oYtuLTkucjvz+Nc88XTjs7m8cNN76H0Q15bK21rmENjOC4rH1PxhoWnKxn1CFmU4Kxnec/hXg80qhSqRpwcBAAq/kB9KgsvKa8iiMSqhOMYJ57VzvME3aKNVg+rZ6ndfEa4lkeSxtoktP4GmVize55GBnPHWp/DnxMt73UFtNWgis952rMsuU3dcHPQH1rElNnZeHrbT0Q3N6CXaV1AB3c4/DOK8h8UJqEN8d9y6RhsNkmTOTgY9CPUVcq8ou7FGjGWiPr1WV1DKQynoQc5rzr4jTNeeMfCelKR5Udyt9MMdcOqL39Xz+FeQ+EvFXiPSbY2Gm6sIIJWykD2qvtJz/q2PQ56jmt6TxTOvi7XdUjY3NrBd2ekwTS5PMbM7SNjqSRgVvCvGaMnRlBn0NRXlsHxRaMEXVtBJt+8Y3K/41s23xN0OYDct0pI/hj3fyoWJpbcxLoVF0O5AwKKzdH1zTtYQtp13HMRjKjhh9Qea0q2TTV0ZtNaMKTvS0UxCVxN/wD8Vd4vXTl+bQtDlSa9I5W5vAA0cPuI8rIw/vGMdmFavjfW59I0yKHS0SbW9QlFpp8L8gykEl2H9xFDO3suOpFXPC2iQeHtDttOt3eYxgtLPJy88rEtJK5/vMxLH60AatFFFABRRRQAUUUUAFcX8YrC71H4e6jDp/2z7QrwS7bOISysqTIzbVKtuIAJwBk479D2lFAHkVx4l8UWt5cWVr/wkN8s99phsLqbRWUm1ZoxdGUiFVQ8SZDBWAIIAHI5vSbzxxoul3dr4Zg1ie5SXVpprK90wxW9uDcSPC8MrRAyu27cFDOCD0GAD9A0UAeM+G9S8e6lcaZa3GoahDa3OovFNdHTnE0EH2SRvmM1nAn+tVNrCMjLBTu6GLVn8Q6toGt2WrT+I59WW7VV04aSBZiJLyPZJHOsHzsYwGP7zu3yjGB7XRQB5P4N1jxxdfEKe210SwaaJ7pXt3tZfKEQJ8lopBaBMkBSd1w+cngH5R6xRRQAUCiloAKKKKACiiigAooooAKKKKACiiigArkdW+IXh/Tp762a4nlurUSqVS0mMckscZkaFZQhRpAoPyAlvauurirn4dabcahPNJqGqfY5Lma9GniSMQJcSoyPKPk35+djgsVBOdtAGZB411VPg7P4tuRavfC3W5WM2E9tGgO35SsjbnAyfnBAbggYro9N8ceH9RuorWC8lS5lna1EVxaTQOJRF5u1hIilcx5YZxuAOM4qa98LWV54LXwxLLciwW1jtBIrL5uxAADnGM/KO1YHjb4fR67Z6sllM0dzq99a3FxNJKVNusSpGxh2rncYlZcE4y55A4oA0IPiN4XuJLRYdRkdboRFJRaT+UvmnEW+TZtj3/w7yM5BGcisfxJ8TrDTfB2p6hbOk2rxWt9NbW9vb3F0mbd5Iw0u2NSib0AZm2qDkBiBuOpf/D3TLrUXnju9QtLOZ7Z7nT7d41t7g2+3yt2ULjAVBhWUEKAc1n3nwq0qexuLW31XWbJLq3urS6aB4c3ENxNJMyNujbADSvtK4IBwSaANPxd4rl8P6V4evmiDx397Db3ASCSZgjxux8tEyxbKgAAHr0NE3xI8LRWkNy2oymKRJJDssp3aFEco7TKEJhCsCpMgUAg+laHiLwxDrWm6bai/vrF9Pnjube4tfLMiuilRkSIykYY9VrnW+FWlC1eK21XWbaS5hmt7+eKWLzL9JZGkkEpMZwSzvygQjcQCBigDYXx94aOrtpv9oMs6ztbGR7aVYBKE8wp5xXy92wFsbuR0q14c8W6N4jnkh0q4meVIln2z2s0BeJiQsieYq70JB+Zcj3rNm+Hmiy2/2ZzdG2/tI6mYt42lzCYSnTOzaTxnOe9N8BfDzSPBEs76S7MJI1hG+0tI2VQeAXihR37cuzdM9eaAOyooooAK5j4iWFzc+HxfabGZNU0iZdRtEUcyPHndGP8AfjMkf/A66eigCrpd9b6pplpf2UgltbqJJ4nHRkYAg/katVx3gT/iT6lrfhZ8LHYzfa7EetpOWZQPZJBKnsqp612NABRRRQAUUCloAMUUUUAGKKKKACikZgqlmIAAySe1cZ4j+I+gaMHRbg3tyMqI7cbhu9C3QUm0tWNJvRHaVxni/wCIOl+Hx5VvjUL4nHkQuML/ALzc4/U15N4m8ban4gE3nM8VmzYEKsVVB292P14rlIUS4uvJt4ZLmZOdkK7gGxwW9FFcNTG3fLTV2dcMLpzTZ3WqfEDxDqbskV0lnG4z5MKDKjHTceT/AJ4rmY4nuS4cNk4LZbGR79zW5p/hXXZcFLSCMMQ293HHqcdc9K1I/BzI5XUL0nHRYhn8c1jKliK2+xsp0qexyMMiw/JFEXZflG0ZL/8A1qdLcTecqXJW2U8KONzf4V6FZeHdCh5uvOmbnLOWPX/ZXArSEehQo32e3ZmP/TPYPxz1qo5Z/NIl4zXSJ5lFEjhme4RUz83fJ6df89qcIrS3mQm9jWUEkfNytehb7TK4tGXIwx3DP4cVRu0jkDFVIOeMitVgYR2ZH1mT3RzqXaEYOo25IwAfMHA/GsGe2W4uNyalBK2SMRP1Ppz/ACrsRYsDwvfk9Mmp4beFUIa1VnPdhnPvzxVLCx6sPavoY/gbSoUvI5L0KkFijXEgU5wqAtkDt0riLMNa+A7Meei3EupW1xO+/dvZ3fJz9XFd98RJRYfD6/t7G2jju9bkTTIkAwPm5djj0GK4XxT4e0u+mjisLSG3LMQwjGwyMBwCc844NaOikrIzVRt3NC58wyKNiSZ+XeOv6d6sW1nbmJQnmox4OTWTYeBNRsTaf2Nq0tnIWKvC5MkQ9Dg8DPeuy0211eK1b+3NNjE0Y3LLYOJt4zgZj+8D+dcNXBSt7mp1Rrq+pnW32i2bcjurIQySKTkenNegeH/Ht2lxHHqhSe3PBdRhl46/n6/nWHDapJEHhYyK3YEfKccjHYj061Dc2a8uFZWGME9q5YTrUJaaFyjTqLU9ssryC9gWa1lWSM9wamkdIo2kkZURQWZmOAAOpJrwzS9UudMuDJbzOjA/w9x/hXWa1q//AAl7af4bDiG2uY1udZkDYAtskLAD6zFSP9xZPVTXr0MRGsuzPPq0XT9DV8GI/iLVp/GF2rCCaM22jxMP9XaZBM2P70xAb1CLGOua7SmxhVjURhQgAChegHbFOrpMRDRS0YoASiiigAooooAKKKKACiiigAoGcc9aKKAFpKWkoAKUdaSloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooADSUppKACiiigAoFFFAHHeOv+JPqmieKE+WOzm+xXxzgG1nZVLH/ckET57KH9a7Gquq2Fvqul3mn30YltLuF4JkP8SMCpH5E1hfDq/uLrw99i1KQyappUraddswwXePAWQ/76FJP+B0AdPRRS0AFNkcRrliB2GfWnGq17eQ2NnLdXbiOGIEsx9KAJw/Hz/KcZPtUf2q33hfPi3HtvGa8T8Qpc+LtTmub1rhLGN8x25b5Fx0z29/xrDvh5ZCSqwTJDq38JPQrjtzUcxpyH0RdXUFpbvPdTRxQoMs7sAAPrXDeI/ido2ms0dhLHfSIMyGNxtjHbJ9TXz34nWBIo7uyvCFSL5xuy4ycHj+8D0PpXIT69dC0nS5SGK4DFJJB8zOwySVPbjBBrOpUktIo0p0ovVs9S8RfEjWPEMtzDJM0Nmc/uIztRlHqcZI+veuTn1QmeGOENPM5CpFAuTKxHAHt6nt+NS+DfCOseNb6zuNNja00hVMb3b43v8A3imR1z36CvfPDHh7RvBtl5WmwDzXAMs7jMsrc5Jbueay9hKrrUZp7WNPSCOK8K/Di/v4be78RXBtYxki0VgxUHOcsO57+1dxZ6fo2hR+RpFjGi9MBf8AOade3/myP5kjRrn7q9TUBMjJuCiKPtk8n/PtXXClGCskYSlKTvJlue8uZEXJVIyOABg1RYnP3zigAc4+bPemsnOcE/WhiSIs4JwD9aXbnHPXsBTwDk57UKpyfypXAj8tSeQc04RDZyMCpguABRjg5PPrRcRCsaFhuyRVkRIE3BefrUYdRk5/Gql/fKnJcBOmTxzQGp558V7973xXoWlR7THptvJdmMHG6SThBn1wAeewNb2gaHGZDNdrvOSVXoFB/may9Q0h9T+N+rK+wLb2FlvyRkL5QyAPrivTTG0YxGwAHFFrlRlZGS2nowyhdcdMGs2JJ7C6E9pIVmC43EZ4PaumljZus4z7LVOWIYbfKxU+3/16drbApHIv5rX1zcpqD6fqEp3FkjDRTf7TKRgtx97ritXTtVg1GZLC9Q2mpSLhDndDOQM/KfXqcUXlrAeN/XuR0+tc9qOhJdoYvs/mhxjHrzx+NZ1IRqK0kXFtao6LU7IaXbPd3cUk0SEARR/fndmCpCn+07EKPTOTwDWRfPNpcASaZJLyaQ3F5NF915sAYX/YUKsaD+6gPUml0i+isrzTF1CeSTTtOmkgt5HO9TP8ySzk+keTAh7nzSP4a6PWfDa3iNc2UzP5gyFBBU85GDXFWoOnC1Prua06qlK8yt4X8eXWnstvO6S2+ejf0Net6Tqdrqtqs9pIGB6r3U+4r5v1HTbqxfMy7GP8LDH8qSzvL3SrqG5tZTDcx8xsMZU/TpyD3rChjZU/dqK6NquFjP3oH0/RXCeDfiHY6x5dpqTLaagRgZGEk46g9j7E13devCSmuaOx50ouLswoxRRVEiUUtIaACiiigAoprBsrggDPPHWnUAHeiiigAooooAKXvSUCgBaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooADSUppKACiiigAooooAK467/wCJD8R7W64Wx8QxfZJcngXcKs0Z+rx+Yp/65IK7GsHxxpE2teGbu2sWEeox7bmykP8ABcRsHiJ9tygH1BIoA3qWsvw1rEWv+H7DVbdGRLuFZDG/3o2/iRvdTkH3BrTGcc8/SgBHJAwuMnpmvPfixcXDSaTp0bAW05eWRe7MhXaM/Vs/hXoZ+8K848fXCv4ptIwm4W8HzE9ixyP5UnsVHcfaxQaVoT+dCzQGEqmDyGBHIz715H4j1ARmVkJDTA/vGb3H+Ndh4v8AEk0eh3OnrJGitl/nGCrAZ/pXgPivU2uvLuIHSJT0JOQSOuP7xBGKlmsFbco69qf+lXUTZHlZVdpO0+5+pzW38IfCK+N9Wu5tVeY6VZ7RJHGcMxcnCg9gAmTjnGB3rgtF0y81nWrfS7FN93dyBEXp8x75NfcHgDQLHwT4St7WNRsgTG48GWTqzfic/wCRTsiZSJ4rW10DSY7GwhSC3jQCNE4AHXA/PP41z95fzSE4JDdOP4aXUb3zWbDFmJyTVEYbryQfWi/YcY9WWbclSrj5pTwWbn8h+VXVUt807ZPXAOarRnam0D5sYJ9asR4AzTuKRIrEZC4Woyfmx0p+SajfA4HWle5NxVXIB9KcOaiLcdeadkA8ZpASd6ikPBGadv454pkjDd17UAQzHAwOn1qi1jd3Vo7RbY12kB25z9B3q9Dbh5g0rYjHNWXk3knnHYDsKdurHc4H7Bdab4jk197przV7hIred3UKpiVAudoH3sKOa7TS7/7TbpJKeuDgHnp61Xmi3tyMsTkGoLdPIlKgDZ2A7GlcqxuMY3PyRt6ctnNRzbfLOI1/KoEYN1yBgcU2VyqtyM/yp8xFinMAzkjFVr1ph5NnZymC/vQwSZRlrWFcebcY9VDBU9ZHTsDUkksMKzT3UwgtYEaWeZuRGijLMfwHTv0qGyEyefdXkRgvb0KXhY82sK58q3+qhi7+ru3YCku5o+yK+p6Ray28MFpDHFb26LDFFniONRhVHrx+fJPNYumavqXhXUbe0tkkm0vndBweemEz90DORj0rrAcqNwH5dar6hYpcwHIBZeVOB25xQPyOjgOm+I9NjuoGMkD5AbHKnPIIrlNe0QwLKrLk/wAORn9axNPub7wtqMd1b24msbptl3GuAep2sO2Rk+melemXeqaTL4Xl1aadW09ITKZYxkkdMKO7EnAXuxArjxGG9prHc0p1XT0ex4drtjcW6FbRt6HBKsSCK6Pw/wDFXxNYtY2QRL8H93HBNGFkbHGMg/rW7cWF8sAl1RdGs5pE3Pa/2ZcXBhBGdhk+2oGYDgkKoyDjisnR9VttO1CSHTrrR4ZsAsw0OY5xz31DJNY0ITpS5edGtSpGpG/Kek6D8T7K7ZotWtJrCVRycb164PuK7+1uIbu3jntpUmgkG5HQ5DD1Bryo6bquvwpI+peHpSgO1f7CnVue3F9WJB4h1HwusxtL3T4QzhJVTQJ2wfUg6h+o5r1NVucFk9j3WiuNsU8Y39nDdWniXwzJBMgdHGgz4IP/AG+VY+w+OP8AoYfDf/ghn/8AkymSdVSVyv2Dxv8A9DD4b/8ABDP/APJlH2Hxv/0MPhv/AMEM/wD8mUAdJe3dtY2slzfXENtbRjLyzOERR05J4FIby2F8tkbiEXjRmZYC48woCAWC9doJAz0yRWQdHvtU8PalpXiu7sL+O9jeBjZ2b2yiNl2kFXlkyeSc5HbivKLjwt8QbnSDqM4aHW0mttPljt7j95PYwRvudGWeLaZJn8wr5qHaoBPGCAe61kX3iXRbHTJNQudUtBaJDNcb0kEm6OEEylQuS23ByFBIry210LxtDP4ZeT/hINQa3CpcJc3YtoUX7S7ZkMV8zM6xlR8wuAyqoOCz1mw+CPFFt4RvdEstO1eMNYaxbTC41YSwXTzKwtiitM20Hd3VMEknuaAPeIZEmiSWM7kdQynHUEcVVfVbNNah0lpsahNbvdJFtbmJGRWbOMcGRBjOefrXkum6N4zsHjvLK019NOtr2xl/sq61WOa5mVI5VuNrGdkCMXiIjLgfuyQF4FRJoXjhgdUm0u4m1E2GqQrFLqQEiedqEMkUYkSVWGIVbG11A2hdy0Ae2Ud68Y8G+GvG0stra+IptZg0sancu/8AxMmSX7K1soRSy3MsmPN3YHmsw6ggYr2egBaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooADSUppKACiiigAooooAKKKWgDjfDH/Ej8Za3oDYW1vM6xYDGBh2xcIPpKQ5/wCu4rsq4/4kI1hZWHiWBWMuhT/aZgvV7RhtuF98IfMA/vRrXXRusiK8bBkYAqynII9RQAyWRYwzykJFGpZnY4AHf+VeOajqC6lf3epShwkrExhuoUcL+gB+rGu3+Kt7Ha+D545X2PcyxxRYBO5g2/afQEIwryDxprcWi+GM3EcasZBIZOSTxjaSM8ZqXuaQXU4Tx7rr3+vDS7a1drqN1ELAnLMeMe3XBqDWvB0VpYwPrczTag0W1YkwIoD6Ljrz1NbPwutJtV1WXxLfwqlnCZGt8nLNI3BPHYDpn1rS+IBB0wGZcSSljjjOMcAc989fauKvValyROulBNXZi/s7+H49S+IFzfsdyaeBGhK/xtkZ/AA19F+ObyO2hhtUwAoI+pP+f1rgPgnaR6Z4Q06e3TbJO7XDjAzuJ29e/AFa/i+7M0pyeeSfrmu1Kyscr96RnRy5dRz6nFXFIB7e9ZVofkXng8cmr6EdeMjrSNOhfR8DJPH86f5oVuKpB8n39aNwHJ79sdqCLGiHDHJY+wFKSuMkc/WqAkyMCpAcquev5UXFYl3Z6Y4oz15quT+8OTgHn605SpUYHP8AWgCYnpSggYJpgZiDx+NKMFQM4P8AKgAkmAGOgFRvcgeiiq10Q4IB5GeKqqh2Nu7HikUkjQM4cYz+VRySHqF5FU4z8qhgQTz9KeJRuwBjNFx2LaSkKO4+lOeZSp9f51Uz8oz1FNup5LO2SS2jSa9mkEFnFIcLLMQSN3+wihpHP91D3IpifcjuFF5qItXUfY7B0muxjImucB4YD6hAVmcephB/iFWmUlmZ+STnJqK1hisoIbWGV5Yoss1xIPnnkYlpJW/2nYlj6ZwOAKmLFvujg8UMI+YiuFYBhz0oU7gcFs1E2ScA5qRcbcZHXHvSKGXlpHPbMjng8EEcGsbRYLLQ7yCzup5G0PTr8yMSP3bXxBZV/wByEYJ/6asP+eZrXu7qeGKIWOwahcv5Fn5gyivjLTOO6Rrlz6navVhUV1pUDaL/AGbbeYbSNPLj3nLvzuZ2Pd2YszHuWNMl+87HV+IrBb+z86E7hIAd68gj1B75rwrxZBfeHc39kDLGrlmQoSGOCfw6c12fhDW4vA9w2n3yzPo1wylZs7zA3T5h1weOR6V2OuWJYbQA8Mi71YY5B5FcGIp8klNG9GenKzgvh14/immAudsEpRSY3PBzknrXa+OtPtNUsft9plZHjInjI+9gdT6ED+VeIePvC7Q3hktInYzOWXLAKjsRu/AADH1rsfg54pgu9DGi3tyq6hCxjjjdWLTAE/xcjPbn0rbD1+ePKya1LlfNE6j4F+LhbaxL4Zu7jfBNl7PLA+W653IfqAWH0PqK92r4o+JGlP4W8XrNan7HbSyi8hJGfmTnAxzjJ/Kvp74ZeN7XxP4e02WT9zczxjahPUjqM+ox+VdSdtGc81fVHc0GiiqMzB8e6vceH/BOvavZxGa4sbGa5jTjG5EJBOSOBjJ74Bxk4Fcl4f8AHv2Cwt7XWrXxDd3EBgTUL+5itALSScjy1kELAYIZCNithWXcQc16Bq2n2uraXe6bqEfnWV5C9vPHuK743UqwyCCMgkZBBrFvfBHh+91OLULmydp4zCxUXMqxSGLmMyRBgkhXjBdSRgelAHnGqfEzVLf4ZapJZpe3niS3sLm8e7gigEdmgnmjieQOVB/1R+VVYnaSR6+11xuo/DPwnqFsLe502YQ+S9syRX1xEJInkaQo+xxvXe7MA2cEnGK7KgAooooAKUUlKKACiiigAooooAKKKKACiiigAooooAKKKr6heQafYXN7eSCO2tommlc9FRQST+ABoAsUV8/aN428VeHbHVtT1y1v0m1iybVNOj1SRJIFlEpJhjEcjMieTLD8rbDmNzjrXd6t4o8TaP4ks9AuYtNur3VjEdOnhtpUiULIxuRIDIxJji2sDldxPQdKAPRqK8Et/jF4iktdcuHstHhaztJp/s00sKy2jpKqBZUW5aVlwTljHFg46g1pL8RNVm1O28r+z9dhtr64igvNJMsUF7t06afYiiV1dg6hDuLryCAGAIAPaaK+f7nxxe+J5NPsbnUtC1KGK+0C+83SonQQyy3wDQuWlfJXYOcKeeQKPEXxH8Q6p4a1WKzvtNgujYz3U0NlFKLrRzFMi7LhhL95lLc4TkEgMKAPoA0leDal4w1S21DxbJJ4r0TUoTp9rc2dvbCaEXI+YM9uUuSVUEHcVJzwCRjnvvCXi251rxVqVhearolq9rdXFuuimM/b9kbFVmZjL91hhxiPGGHzHrQB3dFc7qHjDTLC8mtZ7XXmkibazQaFezIT/sukJVh7gmoP+E80j/nz8S/+E5qP/wAYoA6miuV/4TzSP+fPxJ/4Tmo//GKktPHGiXN/a2bHU7Sa6fyoTf6Vd2iSPgkIHljVSxAOFzk44oA6aloooAZNGk0TxSorxupVlYZDA9QRXE+CNUg0HRL3RNXuRG+g3AsUeU8yQEBrdh6kxlVP+0jeldzXjPjW/tdR8UC8sQhimxpU0mch3yTbyD6SmSEH/p4FROXKvMqMbswvi14rl1O0a7WIrYafOriPqXXlSfqdw/KvnnxN4pvvEc6wSKrRCT91GvuRge57V9Dafbo0LrIA0bcFWAwfrmrthoek6Tvks9MsobiZtzukSg+38682ljWruZ3zoLRRM/wrZTaV4S06zuIwJxCGmUD+MknH6gfhXH/E1POWOQbkEbCMBcYy3GSPTNejmOWVpCrEAfMc81xPiCB9S8TaRpKwEpLL5rMeojj+Zm/MqOajDxc6ik+upVRqMLI9V8OW0eleH7e1Rhi2iWIH6DGa5jW5d91xng4IFdTdOsGloADuZST69a455o2nPG5smvWZwwVy3AuEHcY71KrZjAA5FVFmVoxnIA9Kl3gZ7A0jWSL8Z460pG7r0HTiqkdyViION2emKcbkfKAeO9BBajQMQCTn3ryxPEmp3HxF8TaTdazrFtp9j5Zt49N01bhhuUZ3EQSHHPfFejy3vl5wM4rh7TRb/T/GOs65peqWkcmqbFkhuLFpRGFAHBWVc9PShCafQ1bvxbc2vijSvDdlYG/urrT/ALUt3ez/AGZuN3DqIvlJ284UYJxtFctrfj6PWPDmjXqQ6pYTrraWFxBaX3klZACSGfYfMTBGRgZ9RiptatdZl+LGi3trtVo9JaOS+Nk726ybnyNu8YzngF+4602X4eRLoFhp0WpuZYNUGqXFw0APny4wcKCNo6Y5OMd6NCbNmxq3xIeC88RDTtKS7s9CXFzcSXXlF5MH5EUI2eRgkkdPpnIXxRean8RvBFxHLcWljqGmSXMtmJyYyTGzDcOAxHqR2rH8W6PNZjxZHoj38z6yAZbMaTK6mQ5JZJ+EUfNk5z3711GieCZYL7wnqVzdqJtI04WcluItwcmMqTuz0BJ7HOKBpMqS/ExW0lteGkt/wj/2r7L9p8/99jOPM8rbjbnj72fak0LxH4gu/iV4g0tFs5tPtliaKF59gjRlU7gyxEsSDkqcAZwCcZpT8MlOknQV1dv+EeN39p+zeR++Hfy/N3Y25/2c+9bsPhSWx8aXWvabfwxJeRRw3NtJblwwQADYwddpwuOQw9qNCrM4bR/FWvah4G8VXerHzIbSeeIT2t15E8e1UwiYixgZPznnnpWrbePIdMtfDVgFQ3N7p6Xhn1XUPKjVCpHzzbDuclT/AAjPWr8HgGe20fxBpFrq0S6bq8ks+yS1LSwu4A4cOAwG3pt/GprvwRJc+HLLS2vdOmgtbRbVTe6aJtjBdpkT5wVbp3IGKNA1Ov0aWXUba2eWJY5pM/IsiuvXGdw4Ixzn0PNLZOL121b/AJYSxmDTgRjFsTlpumQZioI/6ZrH6msfQfDsGi6HZ+FbaaaW1EHmX0rN8y2zO37vI6NO25B6RrIfQ10ckjSOzsFBJ+UKMBR2AA6AdAKWwbsQDGAo9sjoKE5zgnJ/KkkdQVG8DB5AHWiNiQRz6HikUOlUqMHGfSlRA7nLrGgBZnc4VFAyWJ7AAEk1HI+GOD8w71WuQL5hpkqA2yqtxqORw8ZOYrf/ALaEbmH/ADzXH/LQU0JuxJppM7NqjIyG7jEVpG64aC0zuXI7PK2JGHYeWv8ABWnA6sCjDgdRVK5uN8rNJIWdiWYk9zUtnIC27qpPWi4JWRneJdNSWxaIQtIshGQqA4x7n2rS8E6uNe0i/wBPuo/J1DSCsRAPLxY+R8dsjj8K0bqFJ7UqVJC5yBxkVwtncPo3xF0BoHb7NcyPazq5HzKyEjJzzgqMCplDmi4sd7ao6HVbKOeFo5F+aMZUgZIrxm908+FtXF/Zn97FMJAWGMr6EjqTmvftbtVhvJFAODhlIHauR8R6aLu2eSWNQIxhcD7wPb8K8S8qM2d8bTiUPiXaweNfhouq2KqZrUCVXIJIU8OOOmD1rjPgR4glNtf6L5hiuLb/AEu3mQ5K4IBA9s/nk11vwv1SPQdTmt7v5bS+2oyOCUEi8DjnllP/AI56muM8R2w8P/tAyCzgjtdOupUZFQYRo5Ixkge7A/lXsqp7Wjzrc4HH2dTl6H1p4V1ga3o0N3gLLykqjoHHXHt3rXrzb4O3vmnV7RTlI2jnXr/GGH/slek1rTlzRTMJx5ZNBSdqWkqyQooooAKKKKAClFJSigAooooAKKKKACiiigAooooAKKKKACob25hsrOe6u5Uht4I2llkc4VFUZJJ7AAVNUV5D9ptJ4N23zUZN2M4yMZoA4vwd8SNG1vQdP1LU9R0LSzqLf6Hb/wBqxySOuFIVshdsoLYaMbtpxyScCvceLPD0B1DxLrhstPv9MmvNKtDd34QTBGBYIGwoZyi9ATwBkis+8+Fc76Nbabaa5FFE2g2/h++eWw81pYYc4eL94PKc7m67x904yuamufhndJfXF7pWuQ29zOb9HNzYGdRFdOjMFAkUh12DD5IOeVoA6+BLPxj4NtW1K0zZ6paRTSW/mHgOqvt3DB49Ritt1DoynOGGDgkH8x0qj4f07+x9B03TPN877FbRW3mbdu/YgXOMnGcZxk1foAxtA8M6ZoU91PYJdNc3IRZZ7u8mupWVc7V3yuzBRuYgA4yT61s0UUAIaKU0lABRRRQAVT1nS7LWtMuNP1O3S4tJ12vG35ggjkEHBBHIIBFXKWgDjPDuqXuhapb+GPE1w9zNKG/szU3/AOX1FGTHJjgTqOvZwNw53BezrO1/RrLXtLlsNSiLwuQwKsVeNwcq6MOVZTghhyCK45PFGp+HrabRPEI+063FEz2N4qBU1KJergDgSoOXT/gQ+Unam7K7Gld2LHxL8TJYWE2mWjt9rmXDvG2DEpxx9SMj2zmvM7KFNSW4tppDbwXEJgMiD5os/dce6MFce6iljga9El1dsTI5JUnk8+tSSA27RpESXY+nbHWvErYiUp8/RbHp06KjHk7ksd1PNLFPNAIbhokkuo1wVWXGXCkcFd2ce2KvMHuJkXcQDg7vX0FUZSoDW5PBCj8D3rrfDtmmlaVPqeoNgbiYg3IyR/TB/Os6UfazbfqVOXJEyvEE40XS28zmUpkqWxyeg/rXGeDZYdV8VX938oezhWLhSfnlOW59ljX/AL6NV/EF3Nd3F/q/nG4C7pYY2PybRweD7ZrovhZZz3Nql7cwCKa8b7SVODhTnaD9FAr2aNNRVzhqvob/AImkNtbRruHK8cdK46OZWeR9oAzgYHatv4g3LR3XlANnIQjPIwM/4VykRdsKV2jO457fStHuOmjbhwO+1h2zV1dxYK2eOc9azoSpBXcB23Ec1b3kKUB5A6/40hyJztAU84PWqr3IOcJgAn3/ACqRE3L8xI5yfrVO6lRWAI7kY9QaASGs2T1xk/maljKoA3Ye1UjICGwADjoTz1xURLxTEmTEbKBsK989c+tA7GqJ9xyoOG680/eNwyTjHXOaoJNt3hdpA65/WnRzJIqsCXQ8/LyaAsakJUptXaGz19amwS3BIx79azI7iNIgxB2njrmpxOCNynAHAyO1ILGihYE8Y55zTVYLyeBVTz1PMbfJjrSecwTGVLA9TQBZOCMNnrjmm3Fylrby3NwkklvCB+7j+/M5IVI0/wBt2KqPc+maiXc54O5j046+1NjZZLpZSVa3093it8HiW7wUllHqIgWiX/bMp/hBpomXkPthJCkkdw0ct/NL595LHyrTEAbEP9yNQsa/7K56k1I020HoDgd+M1XIAXGCGJwAcdfWm7j52G6HIyDS3GlbQlWQqSwf5iematJJvOMgN6YqgMnLA5PQcYyacrSNJDHEpeeU4Cr3yeAPekOxeup1tLd7jyDcFWWOG3VsG4mc4SIemT1PZQzdBVfyTZ2fkNOtxcM7TXVwowJ52xvcf7PAVR2RVHam2jpc3AvVdWtrcSQWHPEjH5Z7kexwYkP90SH+MVKNgOHHT1FVtoQtXchRhtGQB2xmrNvOY5I8D19qqSttkBXAGemPekaTY2QQ3vSKOx0mYPKrMBz1XOeted/FW1e2s3vrZ3E9oyzxjnDMrq2P0xXWaXcBpDz0YY5/OpvG1uLzw1dx7CzGMLtJ56/yqiOpbs9QXxB4d03U1CpLLAsjx7gSuRnr+BqhPEZYtpAIHIB9T2ry34NardaZNqGmyyNJbQShWUDdsDZKnH4EYFeo6jcLbBpIwzKw3Fk4P0Ge5rzsbS95TXU6KErLlPOPFGjCO5MZcKzHdtVvmXp8w9wcEVmaqmr+IdS8PRX1tHMdJzv1Lfh5YwCQGToD9O+a6+6t5ZluJpolTcwZFH3lUjklupyQeO1Zx2x3MYcMhHH5jGa5o1XT91G7gp2bOt+DWqNY+Jzp0wAW8iaNMno0fIx65Bavca+XZ3kLQXkEpiurZ8BwxHzqRyD9MfnX0R4P1ka7oFteMAtxjZOg/hkHX8DwR7EV6GCqXjyPoceKhZ8yNqkNLRXacolFFFABRRRQAUopKUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABpKU0lABRRRQAoooooAK8U8Za2Nf194THL9ihk2QvG+2SN0Y4njYfdcHODzkZByCQfQviPqi6b4anVbhobi4Ijj2feIyN2PT5c8+9eT6PHsEk0iAIf8AV56gVxYuu4WjF6nVh6SknJlyOSZx9kvhCNTRDKGiXZFdxA/66MdiMgOnVGP90qaqxOxTzSPmLY6Ut48UjRLOZYgjGaGeAjzbWUDAkQnjOCQVPyspKnINaHhi0/tPUWguVij1JY/Ma3iyI5kJws8OesZ7r1RvlPYnhlH2y5qe/VfqdEX7PSe3Q1vDOiC+1JGkAIblj1wAOKzPjZrzWqafoWlRs080ht1KnoSPmb8BXd6reW/hnQ2hiZVvmTO4dvc/hXhVndp4p+KKN5geLS4XOXJ5eTAJ+uM12UKKh7nXr/kYym5Pn6dC34u0pbbwvbabHlnvXhgRgv8AtjPP0Br03wtCIJykY/dooX6cYxXAfEq9tp/Gfg/TLQsZLe63yKMjny2OT79Oleg6GzRi/dQN4WMg57nd/wDWru2ZhK71PPviJqCf8JM9rxscnL55BGBkcVkKpjeEKjNnHI6fWs3xjcj/AIT1zLJs2xblLdCS36Vp2sweMtvGOny/0qWbQNyLJ2nkDsTVqFcLuPJ7+xqnZq7BfMwf7uM596la4SEAcHGenrUjsPmdo4yUXBON2e1Z9zKQwB6g4wOnNJPd73G5iQTwBxk1kXl9JHv2FflP3ffmmOxbe5K5EaLjn+LjrVZb0SYJHQ9NwJFZM98J8mV/LUgZ7fWsy71QRrizfO04UADj2oA6v7SFBYcgNg89OPWof7WUsqiMYHCjdgH2rlWvp5ZmxGXzwT1P40+NLl0BW3fYwzjrg+tAHTDWwmCsZxjrnBUe1Sw60JFCxqy44PPIPYVgQ2F8xJw0eBtLMfX+dWW0m8Rg2MZ+ZsnH40E3Ogj1LzsMo4AycN0qUaiApYqNvUNvGCK51IH2usjKY14OB17/AFqa2gF2/lSS+RBGrSTSvkrDEo3M7ewGT+HrRYd0dPbaixtN0En2a7uNyRXAwfs8agebcf8AAAVC+sjxjnnEVxqtuoggsYRBZwIIYISSAiDgDJHPqSepyetZOszBIGiKPBLMqb4W5e2hXJigPv8AMZJP+mjsP4BWWjSGUyqcOAc7sgD6ew4ofYiKvqdhBfR7SuULZywB4FIbsSuMEEZOOP6VgAzmI7pRJnkqvGfU06K5bzQx+cofuAcfiaCjqIGV127sIPmJA7e3pSygzJHZwPJDc3gdpJ0IDW9qDtkkX0difKQ/3mLfwGsrT7u2/fS3UjJawoZ53QbiiDsB3JJAA7sQO9aaiaFZGuUWLULllkuo1bIgCgiO3B7iNSQT3dpG/ioXcmWrsieEbiFjiSKFEVIoU4WNFGFRfQAAD8KssVdODyBzVGGTy8A9SMg9qtl9uCpAOO/akOwSlfuuQB1GaqCZBuAyQDzx/Kq1zukfcWySfy+lVFLITuBBzwT0xQGxtabcxrMQM842L36V1ck4m0ubbuJ2kDK8g+lcBBcrHcIi4AfJx6H1/Dmu60yM3FgWADRuo45xkd6ZL2ueIxXkWg+ObiFg8P22M/vWPIdDngcZHJFdteeLLaWYwzwZhXKSXSMNgYDnjrXmXxotm0nVrK6gDrKZJCpc528joPTkiue0a7mmtDCLlpbu4iwiE7gmTlt3sRk4HPNTOmqkbMqDSZ9AaJeJqFs8MjLOowquOQ49ao61pSxB3VhjHAK5BHp7Vy/hW6Hh2ZIbuV47WaMGLPIDAgNj0HzfrXp3kx3toAwDErjkfrXmVqXs/dex0wm3qjzSeXypVO1maQBhtP3cdTjp0NenfCvVhZNHCAPJumCtuOMHnDfrg+2PSvOPEWlTQJcxTIU7wOpyQT1/pVrwZfyGGOG82+aDg+i+v680UZum0x1IqaZ9OUVh+D9Ql1DR0a5bdNGdjN/eHYn3rcr2E7q6PMas7CUUppKYgooooAKUUlKOtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAaSlNJQAUopKUUAFFFcp8QdYOn6aLeKURS3AO588qg6/nnFTKSiuZjjFydkebeMNWl13XXkePbbqvlxLnO0AnP0z/npVW7lMFqO5GOM4qtBtkkzGOrcEk8U3UWYw7FI3ZOFxmvArVHKV2etTgkrCwn7TLDCqHe/v2rvX8OW50CwAmksNSsmM9leRgM1vJjBOD95WHDKeGHocEZngjRAj2+o3cZ8mFTgyHqfaovH/ieOyiHmXSRIc7mJxgD/wCtXTh4yp+/1exjWam+RbGT4v8AEtxd6LdG+tYYdTgCx3UIfKkudsbxkj5opP4W7HKnDA1znwY8LXumajdatq4RTeoG27siMZIAPqQDWb4T1DUPEV86X/l2sMSmXT5Gj8zbvPKyDjdE4HzJ7BhhlBrt5tWjs9Hu55S9hcWZEN1ayPvMDY+XDfxRsMlHx8w9wQPThHl97qzmb+yzifEOpJqHx00e3iZSsNw6E5BPER9vf9K9N8ISvLrPitXJKo8CIpGBgRnj88185eFb6Sf4xWV8wIMly7BSfugowxn6V9P+GDb/ANqa0A4VmSFyD7hx/gPwq+pD2PBPFd4k3j+0CyfK8UgKEYyQeAR/9auh0/gRdAmcc8YP0rk/iPeSW3i22mhjZ5bK6KqpX5mU8kA9xjNddYXNnfWiyaUwniJ+YgEFGI6HPcc0jWL3Oi8zZCv3RjuP/wBdZN7MfmyQD6E/hVpA4jBLNHgcj6enrWNqk5jLlpCCTjOATjvUmhXnu/LO+QgBR8uG4HHNc1f6zLE6OYFZQcbG5P1z+VSakXuWP7xfKX7rE9R6gViyRLKcpvKgcnPf8aYBJcS3KhZT5XzfKnqc56/j0rTtdMll2lCCVOFAJ/n602x08Mo+RiM/Lnuc/wCfyrutI0gQRbVX/eye9BLdiho2gsi5ZA3OSGB/UA/4101tochbO5Tn+FVxg1qaRZiOJW29R9084rajtgFG5SecgdKCHMw/7Ih/iIBVeeScmqk1odrAMvHBymeK6oLCG+VRuzUM8IdsquB3PrQTzI5H+ykYbnRcdTheKgNtDZvNHtUiFkkuQwz5k3DwW5B6hflmcf8AXFT9410l7I9pbhooknvJJBBaQucCWdgSoY/3FAZ3PZEb2rm78LDGlrHI8yxsxM8gw9xIzFpJm/2nYk+wwOgFGwL3nYxprVjMzySb5nO8sxyWJ55Penw2kUe5lBwRyT2qe8YI0ceAD3J69KsWsYlUMp+bH3hzj2pXNhixKV2bQAe2D/OmiKMI0kmRjAyvNXHt2cj5QoHUY5I9amtopIPKmtvLF7M5gs1kXKJIBuaVx3SNQZG9cKvVhT3JbsrjYYEtC6IQqWcoZs8CS8ADIv8AuwBg5/6asg6xmobOUwJ84Y89O5HrmlvY0QpbwCRrOFdkIkOXfksXZu7sxZmPdmNVkjkywJZdp3bv6Y7UMUVbc2IWWQE9xjOPSp8E4+c4GRk1Qt5GHMhUg4yOlSm5jbd87KRxjHWkUGCHZ14wcEdc0yRdy7R8y9ABxUwYuMsBx0PY1Slcmd9khAfgHsDTJYW7lmVtu58fLz1PSvR/DEyy6LcRjHySbQQOnH1rz21tJ5WWOBDNLI/ARckDqTxXUaJrAXRRZaFZf2ncrI/m3EcwSziOejz4IZh3SMOw7haEhSasea/HPRdS1ZbBNMspLhy5DBBnaoxyT/Co6knAHesTwN4KSCTTrqWaa6kVzldP+zmOU4IKrNPPEkh94vMA9e1dN8XNZuNI0gm7vEvNRkYeTbvAFs48H7yQHIkYf3pi/XIVe3N+Apb291KHUNXvbi4lmVJFkkctyDjknnp0A6VWyJSbd9ju/EXhf7btdtK162t85Ill0xgfx+3DH/162/D0zi2jjsdL1i9VQMmO40xwePa+OOMVvXUEV7pnl5EhJ4JzxXldlcT+FPFpgEB8uVgbcK2ATjJx+R4/2qynGM1Zo0tJapnfeJYJL6GNpfDmuWnl5zI82mn+d4MVyNhpdtY6grvDqTy9fLM+lKefb7dXr1lNb63pvmRENHIMEEcg45B/OvEviXZTabfXBslPnR4HlkZ37jyT9M9a5rRv8I4OW3Mep+ENeudLaSK28P6zeLPjbHHc6bncO4xeHPH8q6v/AISjV/8AoRPEn/f/AE7/AOSq8X8G6y8jRlSqTw7WGR/EOR9ea+iNMvEv7CC6iIKyKDx2PcfgciuihUUlypGNaDi7nP8A/CUav/0IniT/AL/6d/8AJVJ/wlGr/wDQieJP+/8Ap3/yVXV0GugxOU/4SjV/+hE8Sf8Af/Tv/kqn6wNV8R+C9UitLbUvD+rPGwtfOmiEiyLhkbMMjrtLAAjdyMgjBrp6ZcTRW0Ek9xIkUESl5JJGCqigZJJPAAHegDwu5+JOsS2EnjDTopE06aa20hIrnCwWr+W0txNIjyxKSJCsILSIAUPzcgG2/wASvFcmgz6lbx+H4/sOiS6vcLt+0rceXPKm2N4ZyiBljB+9JtJI+auy8U/ErQ9L0jT7zSdT0TUvt94LKGR9Ujit1baWYvKofaFA7KeWUd62NZ8UQ6P4h0vTtQSGCC7sru9mu5JwkdusHk5zkAEHzc7iRjb78AHnGmeMddsdW1y1GsaTd3cviKO0i0+5jk862gm8sK/+uJ8vDYACgbsnPOBO/jjVtL1O+sL3UdF04f2zLaT6xfpMbSMpZ28gURvOBGXaRtqiRVAU8FiS3o0XjDw1NYC+h8RaM9kWdBcLexGMsqF2G7djIUFiOwBPSrT+INGjtVuZNX05bZvN2ytcoEPlAmXBzj5ArFv7u05xigDxOfxzqPha41+TTjp8yah4gk83UpBH9mXbp9oy48y4iUbySVzL0Bxur2jwjqVxrHhfStRvYoIbm6to5ZEgmWaMMVBOx1JVl9CCeO9NsPFXh7UApsNd0m6DTi2UwXkb5lIyIxg/ewCdvXitKxvLW/tluLC5hubdiVEsLh1JBIIyOOCCPqKAJ6KKKACiiigAooooAKKKKACiiigAooooAKKKKAA0lKaSgApaQUtABXm3xJKXOswRsARbwhm4znLZx+lek14v4ou2m1jVp4pvMSSfbuJyFVAFwPbOa5cZLlpm+HjeZhXEohjeddsePXmn+H9Ln16/iigKqobLNjOBVOdmuJPIT5ty52gD869D0WKLw3oxuJQsdxOASTwduMV5FKCnO72R6FSXLGy3ZL4s1mz0rRmUskVrbJhmLY4AwSa8DuS/j25+0NvjtIC2xG6Nk4yw49Oh9c1r+I9bufEuu3Gn2TA2KEK7BdyyyKc4z6Lx9TXUaZo1loloV2gOWV26kd8gV69KD+KW5xtqKsi3ZWlvolqJtq7tipt9lAAz9K4nU/FVtfa0YrxooUjBjimlG6LaTkwzbeTCxAPHzIwDrggg6fivWmlYQRKynHJP93NeP3pd7hyOYCTtOOvPJI/Ct0TbmOgn0UaL420zVrCCVLL7Z5DCRlY20hUnynI4PB3I4+V1KsO4H0boclv9pdmYCe5tQwTHZOv/AKGK+cPCPiYC7j0fUGhAAEVvLMxCSR5JFvK2DhN3KSYzE3I+UsD7h4buUuNc0yW1M4higuraSOUAPBKrRbopBz84HocEfMMgg033M32Z4v8AFeyuLTxqZrVZFleTdGWIAJC/dA9cd+K1/ByvLbPe6S8ShirT2zAtg88bScg+4P8AKtD472Qg1OC+CKskLht/mYI5Xsev4UW9p9rtIta8JSNa3cjAXkYUMMnoCD75PHvSNIvqzTvL8oGW5tZo41wDIPnDflg1kX0Ed1F51pNFcCPJdRyVJ6A00+Irg5g8QaPJFuGFuIsmInHJ4OeaiXw/fXG4eHb7bePhlgmYKZlPTacDkeh9aRakYV9Kd2wqCduA2M5+vpVm0tUkeMtlUxgjp+XasTU5tZ0++uLXUT5Nyh+dZYVLD6HvxUFvPrE4ZLWZkjziMLEpz9RTsDl2PRdMto4sNFgjkBj9TXQ2DxxYL/QDHX/GvHDL4ojumS31CYurYwkC8EngdOO1V5td8WWlzMseqySTRnEiGNDgjqCCOx4osZu7PoOzu4o23dCeARWkZzKF24yTk5PavDPDXxCuLbbb+I7SbcuR9oReB1PIr1Pw94p0jVWEemahb3MgXmNT8w9ODzSsSdRGSgGFJJ9KcfnODkE9u9VorpmGCMD1NTORsZgAevQdaBWMeV91zdajMjRogezsYnBBWLdiWYjs0rJgekaL/eNY11GFVpANznk5Ga1L51DckR7m4Lcmsa6njjIMkmM8Ee9Ju5tBJIyhamdpd0h2N94kcn6VetrVbaQk5weMnjA+vpWJfeKdIsp3EtxAhXjGdxJ9scVx+vfEi6mV49JhWIDnzJhnj6UWYcyR7JaW/wBoYAlEjUFmkZgAigZLE9AAMkn2qOAmWMXqIyfaohHaxyDDQ2eQy7h2eVgJW9B5S/wGvM9M1KbSvCdxqWvytcNdRxySxOSBLG2TDb4BwPNYF2GP9TGf+eoqh4cm1/xRfy3t3JcyL5jmSVZTkk9sZ79PbNVayI5uaR609sSQsbBZOh3elUUsL2CRpS6tGDgqE7fn7/pVSzVreTBt7iA4BbcxbP5n9RW6z3UkPn6dPNcKhAeEBTu+hxU7Gj1KkcK3G7YPLkQ8qT1+neqxtnDksSo9zW3DPDcyKpR4bsAARuRuyf51HM0P2ma1kSa+1BOXtLRV3Qe8shISEf75DeitTWpDdtzItklM6xwAzSMdqomWLe2O5qaOKHdKiRvf3MZ2SRW0qrFAfSa4b5Iz/sDe/wDsVLeJFAnlarPbrHKNosbR2SJh6SSnEs30Hloe6GqM14SYomEdtaxoRHHGojiiXPRVACqPwp6C1lsN1a6hisWiumW8ErCGOxhjMdozE4AcH57j/todn/TMV6TJLcaL4Jt11JhJdNCApjRUWNV/uqBgemOn0ry7w5ar4g8e6XbWebm2tt1xM6N8sRAAXPucnFd58S9TighnLsUtbdFTYQOACOg+vNJvQcYLmPBPifJc6xqFu4IlSGT+I/xEHIz/AMBFWvAwUW1uhwb2B/MfJI7nj6YrmdXvmluZ2ikeSBpTIB6Z9/WtDR7tyqCSTAxkY4IH0o6Fpan0J4bvkuN1oWUlQMNnODycfpWP400lZ4luyqmW1bcrDhge4z2rB8EX8puFZ2J6Lkj2r0S8txPbb/lKyLiT5eppFPQzfBWqx2tw6sAscoQsCx+Xr8359f8A61SfE/QzeWsl/AMs0ZDLjOTiuf8ALktLllLE7Dwu3qpzn8q7/TJ4dT0UQSHJ27WHt2P9PwrGqre8idnc+ffCdzLpcnl3bM0ZwgkB6YOMH0xX0z8NNVS+0IW4AEluefmzkMSc/nkV4J8R/D40u632EZCXJyvJOWyN2fTitz4OeLpLfVbeO6cRxMxhmBGBgnCnP5VhTmoVL9GaVIc8D6Oooor0jzxKx/GGhR+JfDGo6PLM0C3cRTzVUNsOcg7TwRkDI7jitnvSUAcDa+Abt9ZttX1TWLefUE1SLUZfs1j5ETiO2kgWMIZGIOJdxYs2cYwBjGj408JXXiDULS9sNZl0m6trG7s45YotzKZzCd4O4Y2+TjA5O7ggiutpRQB5f4Z+FUmla9b6pf60t/JHqf8AaTRtBKwZvsjW4G+aaV8gkPks2NoAwMYR/h3LqereOmuWksrLUre4stND7ZRC1zEoubhVB/icL8pIOVfoGFeo0UAeea38NE1X+1IX1NYrHU4rGC4jS1HmLHbb/wDVuWwjMWX5tpK7eOSCOv8AC2mTaL4esNMuLiK5e0iEIlitxArKvC/ICQDjGccZ6AdBqUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAaSlpKAFFFAooAgv5/s1lcTnpHGz+nQZrwG5LyWUcJkPmSgSPnnljk/qa9h+IUkieFLxIn2PMUi+qswDD/vnNeTIPOlxFFtzxlv4sentXnY93SidmEVryNDwZYR3OpSXUq/uocbQR2Bz/Osv4teKY4LBolG6Wf9zDFn7xyOenSuulKadoO4/JJLg4H93sK8Yj83xb44fI3WlhkEBuOvI4/zxUUKOvL0RpOd/eOh8D6CNI09LiYrnYCTkkhixYk+5OP5Ve1jWlKlXUICCRubH4Vu6vMsFukMZwqgfLxXn2sytdXyooZk5HABDY9R/npXonOzNuIZbm4/0jkPuMYxyAev6Vh67ZmGFFjiLx8qoA5UADPT8K7yHENu0hTqMKBjp61zviKd/KeIAkn5Q2eG7k4/IUjSJ5VqIYX7fKvzIOcEbR+Fe2/CDWbrUdGzYzCTW9PKwyxSMEXULXkpGzdFkUbhHIfu42nKMceM60zx3DgoMt8vT7vt710vwZ1ZbLxZ9ikkCw3sfl/V1yV/maoiSTdme2/Fm2h8TfDO41HS5mlEO4SRyRYlikUgPG6HlHGOR7emDXnHwl16IWN9aSuiS3EKx7ifuuAdrY/n9a94tNPs7zQNUkjUG5uUH2kgY84Ku0Fh3IHG7rgD0FfMAt5/Duqazpbr8w2mBz3XOQV9eOv0NN9yY72Z1ya+LrwnNrLQxSYYJeRH7rDocenarULnUPDs1zZXRi8v95byKS7JIo7H06Y+tctZ39ssOpaUsimO7hLhV6buDwD60eBrqUR6jamL93vzCMA5YA5VfxA496g1t0JB4ifxHItnrcbQalbthL9V3M/qJFPJHvXU2/hy3W5DwSRxvjgREgD8CT1rgoP9NvZ7u3j2XBfbLErYzjpj3wK7zwqHmLLJCy3akA4BGfTg0MqJtw6Mu9Vlj/eKuPNU5LD69653xjpSK0RCtOyHcpyA2R1578E8V6YTHFFFHPFsk28Nnp7Vwfi662oxikztJbk9MUkEX3PKvF1yixMwbPm/6tMcjIwSf89q5ewkktLiOeKSSOVCGBTgj8c+lWPEd615fnL7lToOwJ5OKdp6Kcb3OUO4cdO3P0FaI5pPmk2er+G/iLf2EMFpqdoLsqm5ZTKEfb15yDnjFek6D4ih8Q3tvY2CTtdPGZBEY8EqBkk8+leA6fZpqGpW1qhkUzHa7P8AMdjHk47bv/rV9XeE/DEFj4ysbizjKCzsnWY7jyX24GPwJpNILnCeL7nUtFSSWbSNTERdIll8nbHubgDJPqcfWvBfEvi3VtVjSEloIZQG+VuXHb6fhX3B490+PUvC14kgz5O25XnAzGwfn2+XFfKHxw8MWmhawBYWhitJFMkQJIUMTyAfrg0JWDmbR5NbtibYQGO7OSfT0rqfAeiLrGpiSWE3Nla7BJArYNxIzYjgB45du/8ACodv4TXK3CqFjcHkrgjuCPWu58EXt5Noc+m2kcMQbzMXKybWi8wBZHYd2MeYweNqu+BliaolX2OwvNIl8R3qy3UizaNaSszTRnC3cxA82VV7IcKiD+GONB2NdBZaRBp+rLfaXiFgo82F+VlGMfgcd66PwnpsdppEUEdqvkBBhGIBH5U67trC0uIYriWYXkwMkVjEhmuWU9dqDkL/ALbbUH94Vne5srRRTj1ayngQ3UMiOTjaRnBJq7KsFrepB5k8t6yiT7BaR7pwvZnBIWJT/elZV+tRu1zBbxQ3QmsbVW4hsJRJdYPXzLkABB/sw8/9NDVmaKS30tf+EaggFngkRwgqhckZdwclm9WbJPc07IOdvYcsD6g5F9PDbLtOLLTZWDMvcS3ICuwPQrEIx6swrGhvW00RWLwCKwWR1jigQQxRdTnaBjn16nOTk1W0PxDrWh65JDrcLSW7fP5yxAgDuvTIx/Ktbxfqul6ptfRr61GF34VhlT0OQen60mVBK5yXjkCHyWliN1HcLhYmBBZhjGG52muL8QDWBYW7RapHdWU/Rmi27MfwMe5H9K6jVNRkgDxXckbwRws8cn3iOBwOa57QYDqqppMSxyC6dWjAGAGb7xIxxkf1oRo0j1X9mXw++l+HNW1O85nvJUQbzjIQHp9d3X2rm/izr6ym5so8eW7FpHJ6kH7gP6/hXqeuQ2/gnwRpelWkqpOImLKSdznALN7d/avnXxLcSOLq5umkKY5BPLNkHaM9ulG7MqfVo5i6jkjhic8ne2VAPHTAP51o6EYnCOctMDwoyf1rn5JZJ4mDzkIuXCBsKCTyB+GOTXYeGbFZbUFxiQqNzY4A/wAKbKjqzvPBkZR0lSVxG434PY4Pr/nmvXLRjNYKoHOA6k9q8i8KwPbSNEysUU4jwcAgn+gFemaVd74QDuOOOfapKaKviCNd8F1AoZlOGx3GO9P8O3DWtxAUK/ZzkHJ/hJ4P4Vr6xAJLI7UYq390ZKn+lcrar5SbJYpMNn7rHPXoM0NXViVrobHxH0htR0lpIVzNAGmiGONw7V4PpdzLpWuYjKBSyOQGDDk5/wA/hX0l4bb+0baWzuWWWeMBonYf6weh/wBr/Cvnr4g6Y2m+PrwNaRW0CqGjxnODgluevzZXGeK4507RZdOWtj648M6qNY0eC7xtkI2yLnow61qV4l+z/wCJ0u5LnTpbkFJFDwBsAswzu49cfyr22uyjPngmclWHJJoKSlpK1MwpRSUooAKKKKACiiigAooooAKKKKACuY8WeMIvDup6bp/9lanqd3fQ3E8cdkIflSHZvLeZIn/PRcAZJ54rp65Hxh4HtPFXiDRr/Ubm4S20+C6ge2gmlhM4m8vrJG6kKPL5XkNu56UAT6Z468P31ib06laWtmVR45rq6ijEitAs+cb9y4jbJDhThScbcMci7+JWn/8ACS6Roti+mtPeyTl3utUijVIoZRGWTZ5m92JYrGdp+Rt2wqQCD4b2tv4sg1aG5iS1t9RS+isRbDagSwFokYO7jGA4OOMAY71WX4XxPPqpudVkaDULXVrV1jh2Mq31wsxIbceU27enzZzx0oA6208WeHb2ze7s9f0m4tUkELTRXkboHPRCwONx9OtVW8e+D0ba3ivQFYp5mDqMIO3aG3fe6bSDn0Oa5uH4bXM94t5rOsWl1ciawbFvpwgiMVozsqFPMbLMZGy2eOAFwMVoSeAIpNUmvHvUZpPEEeu4NuCRst1hEWd3+yW3ds4x3oA6uLVtNl0g6rFqFm+liJpjeLMph8sAkvvzt2gA5OccVQl8YeGoWhWXxFoyNNKYIw17EC8gIBRfm5YEgYHPNZUPgkRfDjV/Ca3wxqEd/GLkQY8v7VJK/wBzdzt83HUZ29s8Yfi/4VR69fwXFvqK28Q02PS57WRbnyZYY2ZlG2C4h/vkYYsOmAOcgHaP4q8PJfXlk+vaSt5Zo0lzAbyMSQKMZZ1zlQMjJOOoqGXxp4Wi02DUJfEuiJp87tHFctfxCKRl6qr7sEjuAa5W7+G15c+HNV8OnXIU0S6uXvIAlm6XUUxuBcDdMsw3qHBHCq2CPmBGapN8Kr1LBVs9btbTVPtE1w2pRxXzThpEiUlWe9LZxEuQ5dG2plODuAPQbbxHod1q76Vbazps2qICzWcd0jTKAM5KA7uhHatSuM0HwdfaV4uuNWGsqLKYyM9lBDLGsztj95IGmaPfxktHHGSTzxxXW3ttHe2k1tM0yxyqUYwzPE4B/uuhDKfcEGgCeiuV/wCED0j/AJ/PEn/hR6j/APH6P+ED0j/n88Sf+FHqP/x+gDF+I2pCfUbfT4yDFagzz45+cghF/AEn8RXMabbTXE0ksYGB8oPTBqtA1vc2klxBPrBjRtpJ8QamO/H/AC81qW2n20loZml13IXOB4h1IZ9f+XivOm4VKt2/wOyPNCFkjkvjbrctjoohhGbm7IggRH5U9jTfhr4bk8NaVEL1la6uDukKHIz1NZl14lmbxE9lYvfNaxj52bxBqjMDjIGRdDHUdu9djbQj+zPtlzJq6A9APEGpjP8A5MmuunBRWnUzlKXUyNelkEkhOCcnv09q5gw4kaVRu3Zx3wPT26mukuLyOd2jjubgrnHkaldz3cDn2lkZ5oW91LL6oetQQacktw0KGeO7ZDKtnNt811HVo2X5ZkH95CcfxKp4rSxKeupVvV8u3OMLhQAcVyviAIlqryMXK8HaOxrrr5QyMc546ntXMazE0llll255YD0+v4VJseXa8Gdy5IyWJRcYKj0rJsbj7FqFvcgktDIsgwccg5610OuwoIGLgqc57/LXNuNpBQZyME/X0qkZy7n2T4T1SJ9Ks9QXcIL359jHOMjpXkPxy0r7Bq1hfWcqsZywEg6KV5xn8cYrs/hTO178MNPDNueAsAcc8E8e/FdTq3huw8V+HZLC9i25Q+XICQ0bHnI/Gkn0FLufMdtco97oswDDZKeQMFR3H51oNLNplrM/y4a6kmikHYcHn8cCsrWbS90XWLrT5CGubVzG2zAAfghx6AjH41avdSS8tLRt6IftCyzgfw5I3A+vY0GsXdHX2EcN3qJmhCRPcoruHBbJ9R7g5/Ou40e1kjuCLhVZhg5DD8K4jTbhrdEDbZYB/qpE48sen511uk3D3UcbOen3pV6j61LNNjp74JJAHMgVgMK2cgnn/wDV+FeX+PrgWmjTGRh8xIRwOp9K7976J7cxyyDcp4bswryH4tylIoYxIWikcsg4IHqM9aI7kz92NzzItliW5ro9BVWLyOh8pANqtz5nseOg4rn7eJ5pAkYyTXS6amxFI3SzyDG9TnYp9uw/U1ozjiejfCTRJrrxMJ5EZ7iRTufB/cDPHPc4zjHQCvqPwv8Av7zVroKVVpxCmfRB/wDXrx74IW6Wmi/apAGdQzMR7ZP6DH+c1618NRI/gzTrmdCk10puHB/2ySP0xRYb2OjuYEubeWCUZjlQow9QRg188/tA2Can4d0++VS3OYkIycMM449Af0r6KryD4mW9tN4SbTp7iOyl+1PDBvy0kgRiVWNFBeQ7ccICaYonyHqETOJAygyBlzt7kjJOK6n4eaBqyXttdyxta28/zW3mIzS3BH/PGFQXl78gbR3Yda7bS/D+m2WriG1g361Irt5coha4OxC7EIxMFv8AKpOXMj8fcQ1x3jvV/FWn3DfarG+0WG5IaQSRuJLnGMebO2WmHAON20dlUcUht9T3XTYbp7WOKW6/sqHOMpJHLfSnvlvmjgHsnmN/tqa6a20mztbQx6OoiWbDy7QzyTN/elkYlpG/2mJNeTfD/XJNS0m3m2R+e2ST/CrdOe5NetabLKm2SKbc4Gdoqb9C7aXMnVbbaQLkrGoG4joRWM8S2cElzo90I5m6KTjcx9jxXRata3M7brsbAehY5Az+ted+MobK3s5EkMcoZiNrg4z6+34VPU0iiDWfEmp3E6xma3IjI81JYwpI6Y6/rXD6xFoqNI7iW0bIH2iJ9+BuwCRnp/jVmS9ngWGC0toUt9vLYADnHA5zxx1rAmnkuJ2aR0Izt8ps4PPX6cUy3oi5ZzppEc88d9a31tJCd6qpTcOASOSAwJH15r2L4R+EDZ3Eniu7EcFnFH+6jzliQMeZn0+bpXjngPwtN4p8ZxaPbI8UNzull7hI1POO3PFfRXxO1iDw7YRaVps0arHCI0UfNtUDo2PpQyG7rlOF+K/iu31G6tjGWE9uWON2QFJA5+v9K8j8UXDT2rM7fMxzu6AnjH5Vryp9svYoEVXjHzsuDgDqMkkn8K5DxFqD3t7HGMqyk4C4H8qaKfuxG6daE+bHvO5gHOOMD3zXoGh2qYGHPmsAR8uWH/1uD+dcv4ctZAzs0aIoUuQuSfYEnqf8K7fS5XEtqxRlLZLEjn8R2/KhlQSSOq0+OI2xVNw2LypHK10ugn93AA2Qq4x64rnNPOUlYgjseMY/xrd0nEWETAYenp61AS2O3sZFltdrKWB5AIzmuV122mjklCb4myGRhyAT7fhW9pcpLjn7qj/9VTa3bmaxMsQzIo4A6n2qjCLszl9LvL61v7WVFDxo3yxrw5J6kse2OQMdaX4z+HDrWhR69ZCNpI1LsCOQuMMoYcDpnn0qENKMiCQQ3AOVDruGe3fp3611/hqePVNOu9Iu4gUdGIRjgtuzuH57v0qJw5lY0k+V8yPnfwDqUmh+I7EbtlxEqShs8Pk+3Y9setfYWjajBq2l21/anMM6Bx6j1B9wcj8K+Q/G/h+XRtX8ic/vYADBKA2WQsVVSepK461738B/EY1bwqtlMQLm1yccDcpJycezZ/MVz4WdpODLxMbxU0enUGiiu84RKUUdqBQAUUUUAFFFFABRRRQAUUUUAFef/EvxleeGtRsbaC70nTLea0uLk3uqxu8cskezbboFdP3jbiepOF4Vu3oFFAHlPwtW81nx34p8Qatb2KXO20hSNrQ/abUPaQTeUJS5wgLsGUKMtlsj7tcbqPxFu/A+iaqumS2f2s6rrd35N3bqVmCXknCyNcRYPX5UWV+cheOfoiigDzG28YeKNR0zxRqmm2+mNb6PcBI7QwSPNcJ5FvOw3eYAG2ySAcHJK8Dad1KTx74k1KXT5dE/si3sNSg1K+s5bu0llZra28kRsQJU5kLu2eMKycZBz6nqNnDqNhc2V0Ha3uI2ikCSMhKsMHDKQRweoINOs7aGztILW1jWK3gRY4416KqjAA+gFAHjN58WNV3WUiS6Hp5mj0l49Puo3kuL0XZj8x4WEi4WMORna/KHOOKjm+LOtx6Vqt5H/YtxcwaZeXz2EcMnm6XJCwCR3R8w7t2T2jOQcAjmvVdV8L6Xq2p299qKXc8sDpJHCb2cW+5G3IxgD+WzA4IJUnIB7Cr2t6VZ65pF5peqQ+fY3cTQzRbmXehGCMqQR+BoA8Y1PxNq3iXWNBtrLUtCvWsvEcC2urWVu72chexumdNolO8p32yAHcOhyKreIfjTqulaNp84/sw6j5UklzavbBUmCXMkJMTvcowyImO1EmK9+K99ooA8zm8Y+IYbHWNbkTS/7F0jVZbS6hW3kM32WOXa8wfzMAqhLFdpyFPIzgZl/wCO/Fw0/wC1QQ6PaEaHda/5Nzayu/lI/wC6iOJV2uYyu49mz8vavUta0qz1vS7jTtThM9lcALLFvZQ4yDglSDg45HQjIOQTV0DAwOlAHmWmeP8AULzxxaaMzaWmn3BVxebJCN5iDmyznb9oGd+7ONn8Ga6X4kaydE8JXk0ZZZ5x9miZf4WcEbvbAyfwrqK8Y+O9xLdappWmRSkrtLmMD+InAJ/Csa83CDaNKMeaaTK+l2cg0SwgkYLPMBJIf7vc5/CrnirUV0fwzIY42eRgCqjq2DgD8a2YrRBChdASkeD268V598Vbhp4ba0t5DEwcRAqOm7j8OeK8+lD96dcpXiY3w/0iG+8WpZ3JJmz501wUz5jlC4Tjg7VGMe9eifEFktY7KyVgWBbdyB8xPesr4YWaQXpu5YSPLhZ0XPyxtwB/LH41n+I7+W51GR5HXBYqOenNeqrKJzS1kYdmDK7gcjO0KfTNazvH9lW1uYI57PcH8mUHAbsykEFGHZlIYdjWZoqbriQldoAGAPcVfumCvyMLx1qTSKTWpLIss8ZU+fqcZ7My/bo8+h4W5HsdsnvJXMasfIiFzAsdxYqxi8+PI8t+6uGAZH/2HAb2rf28rgnAA49faqmo3SpdhrtpPPePy/tMWPP2Dosm4FJo/wDYkBHHBXrRcOVrY8o16JTHM0ThopeqZwcDoa4+fEbR4IO0k5BzmvZNe8O2l1bvcQPbW+zgzxki0JP/AD0DEtbHp98tGc8SDpXlGu6ZdabeSWt9aS206jcEkGPkIyCOxB6gjr2zTRLdz1H4AeJobP7Ro9yyhbl9ysx4Q4PJ9uAPxr3zwpIVmu7eZT8x29emBx/OvjzwRhdejQAsW5XBx09+1fU3hbVXkuM3XX5OcYIBA6+tLZjS5o2Z578f/Arw3LeIrJkSY/LKmSPMHGPxFeNxRvc20vlxhrmMBmY8NkH5WGenOcjvX2z4v0611vwjKbqAzb0xsTIYn2x3r5H8W+Hp9C1FkjE0TSB3VpMEN9fwHf0psVMyIdSjtZlaMzxM/DQk4xx0J6Guog14i0fyVuFWPADMevqK4GZxdXKJIhe5YjeVztYe2K6rRfDS3SOweeHByPLJYY9MAg/WkzRNvY27fxM89vCk6DHK+ZnrzyMdq474gXyXl1CYwwALcHt0puo6Te2N1IbOTz4UAfK8Zz1wO9c7f3DXEu6RizepGPwppdSKkny2ZHbxtKxVW2jGSxOAB712vhW2iuHkjh/dxIpd5iOvHGQe3oPWuJhXe4UkBepJ7e9eneENPV5YDHAY7eRgyKSd0zAcknrjnPTimzGJ7t4Wji0z4Xy3Sx7R9m2AHAYgk4Fev6TaCw0uzswxYW8KRAk5J2qBn9K8g8SxZ+G9lp6SMrXdwAQq5J+b5Rge/wCle1UIUhJFLIyhihIIDLjI9xnivIpPAqaJrd7LF4j8QXF/dRBnubkWM8sqsSCm6S1YhRj7oO3npXr1ch42lgsLq1vbueC2t/LdZZp5BGiBcMCzMQAOvU0MSPna+vrG7n1LRBJNpVxPZXlql3cR6ZEiN5DqEcpZKyq/C/KwOG4NcFoJi8ExlW8e6rKNxV7DRInMD+u5p9qkf9s2Fdv8QdL0nVtduZ9O13wtLbT4JY63aKQe/WSvPNT8K3U0rPFqfhplJ4U+IbH5fp++oQ2kepeFPGNjrdl/oPh21szGxjNwu1ZZD1LP5SxxZOecIK7bRtTt4lExRimMMen4V418O9MfSJrgajrHhyKJsFQPEFiee/SU+1ehW13pASLzdf8ADQdcgf8AE6syqj6eZgmpkrmkGrHYTanb6kubSNcqCrLEOc57k15zql0sHmC6a5jmVsZkxk4yMcdR7Vtx69bafE62OueGGVuQi61ZLz/38rktVAuo+Nc8NFj9/GuWOW59TLSsy4ySOU1G6iuczT9OQE27d3PX6D+tc208jTs0ZaVx8gUgksTwBXSX2i3Nw5Kan4aVV4A/4SCwzj0H76tjwFocFn4qsbvWPEHhm3tLV/MD/wBt2TljzxhZTjrVJBKa7nr3wh8LXHgvSLu5nnRtW1FFLt/DAmDhfqCTn3FefavcSXmoTsrAksVRQvDLnlm7113ibxOl1fzw2PibwwdOMewFdZs1356/8tAfzrk4YbGEEp4g8OFmJ3sdcs8kZ6f63pUu5VPlWrZz/iW8t9Fhik8st5gJOwgHJx3rz+wEd7qYkEZEXJcFuv1PfrXdeOdNk1GeMWGr+GbhNuS512wUA/jNn9KxNC8Nz20pefU/DUZPGR4gsD+P+uqktBTmnK19C5bQSKxaRyucAHrtHYfrXZadbRszSBVUsuCxXqOBWXaafCkheTW/Dgb1/t+yx+Xm1u6b9ghUmXXfDaseMf27Znj/AL+1LuWpR7m/p4ZbdVOBx0INbunQZkG5VAHTFc/a6hpSZJ8R+HF9AdatD/7UrWtte0eEZHifwzwen9sWvT/v5SsyZTT6nUxLgAKcAHkelbFo3mQNEcZPArkrfxR4fx8/ifw0pPX/AInFsf8A2pVy38VeGVUD/hLfDSYHT+17Y/8As9UkYNjPEFnJbyLs5IYbNueKpWs7xTRXkSK0ilWRk4bryD7cc1d1PxN4XvLbafFnhvzV4U/2vbdP++6xIta8PIGVvEnhpucq39tW3/xylY05k1qbvxi01dRstH12ydTDFLmXHI2suMn8xXlfw111vDXiq2nYn7OLkwSxr94I3HPsD/KvWdH8WeE7jRbuw1jxN4ajhkBVIzrFswHoeH4rxbUNMsrfU5JNO8Q+GZbd3AJGt2YOBnDcyD2rir05xqKpBG9GpFwdOTPsWivL/APxM0h9FEPivxN4at76A7FkGsWr+cvZjtkOD6103/Cx/A//AEOXhv8A8GkH/wAVXoRd1c4WrOx1VFcr/wALH8D/APQ5eG//AAaQf/FVa0vxr4V1a/isdK8TaJfXsufLt7a/ilkfAJOFViTgAn6A0xHQUV53qXjfUrO91TRhBZf26urQWdipDeW9tMvmCZhuz8saT7sEZMRx1p8XxV0lrSO6l0zWYLe5txc6e7wxn+0EMscSmIByQS80WBIEOHBOBnAB6DRXn/iv4oWHhKxt7rxHpGo6eJQzGKa6sfNRQcZ2C4y+euIwx46Z4rQ8M69eXFl4uurkteDTtRuI7aJAikxpEjKgPAJyTyx78mgDsKK8g8HfEue18I2t74itNf1G8fTo9av5VhtBHZW0i/K4COpMXyyFQd8uFYsBwKtp8QruCz121W3vtV1dbrUTapaRwj7PbQMFV3Lsi7QWUd2PoeaAPVKKyPB15PqPhHQ728fzLm5sYJpXwBudo1JOBwOSela9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEN5cx2dpNcznEUSF2PsBmvnXU72bVvFb3JD/abltyRjBZB2/L9K9h+KOoLZeFJ08xVknZUUE4yMgsfpgV5h4BsxqniZDKzGGPMjNnGcdM+oz2rhxUuaUaSOvDrli5s7HWbs6daLljuk+bnrivM7S5e+17V5ISCxli8vJzlApBx7ZrpviZfyvp0/2G6jFyu2BS0YwjF8Y9+DWPoulxQXyz7XaeOMQ+apwWA9VH40qEdZMqT0R2GkxGDRL1wSPuxjjjAx0/E1w90oNxPIxwS3me1d9rZ+w6CsSvjzBubnPJ5riViU+Y7LtY4Wu5rZGC1ZHp1v5EEfOGIx9eafMglckDgnlT/jVtlRNqJgD+tMWMNGxKk4OAPTFQbIrhV288MOdo9KxtVR2WUhlBOFBzyRXTvGgR2ACvgc1h6pEqYdkBGwlhjPapuVE4vz5tPu5LuzllimhBKtG2D0xj6EcYPWmR65pOpWUdjrNrbW0bswCGNhahj1ICAtbN3LRAoT96I9ak1GPetyEI3SDuMHnj0rk7pAbbymTIjJ4Zu+e5q0xThfcqPDYaL43gSylee1Rl3CTy5MZ6qHRijjGMMMZzyqnivfbKYW8GCrER4DDqdpHH5ZFfN8CeTdQzPsH7wAYOfc59a9/uL02/2a5hcPHJgvkDABHAokTTVj2bw/LvmWYsHe4BjIBwABXlXxw8Jx2xe8Rt6jMyR84UkAHjoPYjvzXS+DNXKXgtmddsjHYx9SAAK63xhpqazpDeZGflVlcHt/jRurk/DPyZ8W6fD9o15YTNDGWk8za6llyT/Dt6/417QLFIrQq/znqXdQB+Q7Vz/hrw/qMGvGKSz8sRs5DbF/d4J4B9CDwRznrXZ3hEMRHTI7DOPxqWzWNrHm3iKBoroyohBU53J/KuC8V2Sxzi5i+6/3gOxxxXrmpAyh02I8UiEj5uSewry/VE893tlOTLkYLAbWUZ/z61USKiujlYseYu4EjPIFeyeCcya4qXcnm3EJVVRGzs9AfYV42jMjgqcEGvZfhJDHDqIaP/W4BkkY7mII6AdBz1PWqZzRPcNUEk3ijwVYxFDG1y0r5zkhF3cY+h6+1et15noUP2j4j2DMuY7TTGZMn7rOwB/QV6ZQgkFc74uLJJpsqOVKyuMjryjV0VYnitN1jC/HySjr7gj+tDEtzwf4ueIdY07U4DBrGrWsTR8NBeSIpPoQD15rxfVPHXjCKSQDxXryqrYXbqE2H9wQ3SvW/jTM0UCeXguCVIccY65/pxXzzqIXzv3ZbHPyk5I9f8+1CKaOq0T4m+MrG8DnxJrNyHG3ZPeyyD6gFutei2utfELV7eI3Ou6hptsw3bI5pDOw69c8VT+DPgGCXT4tf1OIyTyEm2hcfKq9n9yecV6hqyR2kEk0gbagydq4P0AqXLsaQhpqcjd65r9jpixR63rUgUcSPeSM5x6nOSa5bWPF/imBHa31vXTIeP8AkIv8pwP4d2RXSW/9la/IY3SYOpxjcV2/XsDV2T4Sx6lp89yuoxmNWwyeWFdAcfeK9epwSDSVzR8qPI7nx94tg3LL4p8QK4PT7bLj891e6+CG8TaD4PfXfEHiDUr+SeJWigluHYJuPGCx5OCP1qrpvwx8IaSputRjfVriEh0Vnbyk4+6V6Nk885rK1/XbnxLqJgWdxYplnYAIOD8oXH+eKpvQiMeZj08S6/eyy+TrmprxnP2p1G484AB7e1Sya7r8FuZLjX9TKRg/duJM9uvPNc9d6xZ2kqR2JDmIFCFOXc9MDrx159q4/wAW+IrgaYbcvtuHPCg42r68f1qFc2dktih4h+IviybWJ3t/E2uQxbjtSPUJlXHTgBq1NC8Y+LBIsU/ijXJWYBstqEp69uW7V55ZrI9zuj+ZhyWI4zXZaZaqgiKAmQfMR2yeTn/DpVsxgru53Vp4y153cJr2sM0S4IN5Icn/AL6rXs/FGvs58/WtTz6G6kwOPXNcZpIaW5BmKq6n5GRsKp5/PpXV6fCjIzMoY5zj3qWbpI6ax8RaupAfVtRZjz81w5z+Zrfs9Y1SRUDaleHPU+c3+NclBFtcOTuPAAI6V0Fipwozhyc4pXJaR0sOo35AUXt2TjqZj/jV2K/vBg/a7gj/AGpDxWRCQvCjoKmWUkYyCKpGDidGt7cSAg3EqgDrvIrl9TvtRtbpC1/eiMtx++fHt36Vq2D/AMD9D1zRrNlFPak7SSBwF+nFD1EtGYV9ruqaYINQF5dyWcbgzRtIzEqe/J7VF8VdR1W60y1vdI1G/sonAJFtO0eVPXGCPqKS1dJ7F4rwEDBRg3btVvQootV8KT6ZcEPLbblUbiWADEZz3GOM+oNZVouUGo7mkWoyTZ5XpnizxDYaxE7+INTnhglQtHLcSMGB6qwLYP419TafdxX1jb3du4eGZA6sO4Ir5L1SH7Nrd6kyF1DRgEggkHpn6f8A669E8BeMr/QoY7Gdln09HJjBAGFLdj2xnofeuDC4pQbjN7nTiaDklKKPeKKpaZqllqcW+ynSUDqoPzL9RV2vWTT1R5r0Oaew8OXvxAS9MCy+J9OswvmgSfuYZGYKGI+TJO/APzYLY4JqpD8NvCkUVzEulsYp4vI2PdTOsMe8SbYQXPkgOqsBHtwVBHQVzl7Bqhm+I2laPK0PiK7uIL+1ZZRHJNamGGP92x+6R5U0YP8ACxB4zWZruieJ5o2/sXS/F1vbmzkjs4JfEA822vS3E8zm5fzIsbcLufG1v3fzUwO01H4aeGdSiKX8Gp3O6BrWRpdXvGeWEksY5G83LrkkgMSBnjFT6bfeGLKa8sLOTy2v9SltZwVl2vd+UpZCxGFJQDGCAccZOa5LUvDfi6Wy8Q3LXerTXrapCbeC21MwiWy2W3niEbwsbMVmA3YKnJXbuLHNj0i807wxJpk9heWeo6t4qgutOt7u8FzcLGkkEjSPIHckqkUhJ3H0zgjIB3158O/DF5bWFvPpz+RZWkdhHGl3Mivbx42RSBXHmoMdH3Dk+pp2ofD/AMN35Zp7GZHaSeRngvJ4WYzEGVSUcEoxUZQ/LwOK6qigCvp9nBp1hbWVnH5dtbRLDEmSdqKAAMnk8AdasUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVyvxE19tC0CR7f/j7m/dx4GSM98e1TKSinJ9Bxi5OyPIPGmtf8JF4muHhUqoGxHc4wi9hz9SfrXS/Ce0RLu6vHVt8ahQf4fm5zXnluUmlCRKAmQvJ+Y+tes+GFTS/Bd3cKVVyxyfUgcV5GGm6tfmfqelXj7Olyo818Y3q6nLNbzglZSzEbeRt+YD68cVseGh9oSJFk8yVQgl2Docd/ciuDv7iefxNaWkEqK0wfjIIUZ659eG4r1Pwhb7HYFVSQOSwHHI4H6V6FJaephPQXxjdme4miVWCQoOcDB5HQ1hwqERQ+AeSADV7Vt07uJQSzkgkdBjoTVaOLEKeoOfm9f8K3bvqZRVhGUnaxwcnp7Uix/uyjsQc8cdKnKHyx5nXPIHGalVAqAjJOKg1InBELLxgDoKx9QX5QWBJIIOegrbcBgVHoPbNZd3DkAOM5B6jikNHE3wZo5Vt228/lzXKa/G0NwgD/AOsGDiu31RPLUswHyDgYBrl9ajDRO0hYSDG8+g7fTvVIuRw122+8RCBsU7ju6AdOa9L+HhubvQtQslcs1lJkKR96JhkAD8D+dec6wm2UGIsXHOV5BGeB+des/C+CDQtIgvJkYyaltWd2bkMCdvHp85H5U3sZK6kaek3xgktX3B1L7lY9j7HtxXq3g/xbbSstndlzLIoAJboVJIH5Hge1eceJLGKCCaW0XYhG4KBnp6VgPd30Ma31jIOgZAwxhvf36Uk7aouaUlZn0Trmk2+oRQ3MkSiUKcSrw2T2JFV5vCyXFvAZNvz4yMc815v8PfiDLq1ikU0zfalKp87dSRzx6V3niTxHdWvhXVGtCfthhFva4A4uJWEUQ/77kSqupHM4ygeeeNNJ0z/hFIfE1h5iQz3H2eON8BpFEhQOBnoQu8f7OOnNeSeLbB2ffuXzPvEkD5sdvrivpnxVpOmQeFNF0q3RZrfTkjhgUjgKqbAfrgfqa8O+Junpb2Ru7cfLESzup+52z70nozSEm1qeM3GnyXHnXVqoCAltncY64r0b9nlPtWvXNvj7iiXr15xWNoNmZ9Pa6lMYLDEgdCSBuIyFxjJGDXa/AWwg0/4hajHnbG9oTGD/AAkNyp96dzOUbao978ExlvHviSTL7IILaBcnjld/A/EfnXf1xvgOIjV/E85OTLdRAH2WBB/PNdTqcl3Dp9xJp1vFc3ioTFDLL5SyN2BfBxn1waaM3uWaw/GLsmkKU6meMH8WFJ4a8T2eume3VJrLVbXAutOugFngJ6EjOGU9nUlT2NV/iAxXQY9pAJu4Bn/toKGC3PAvjDdrb3oaQhrVufL7nHr+v41wHwg8IweIfEZ1TUIH/sKx/ebHPMzk4VR7biCfpiuk+KNlca14qn8nzIrKBAk02B8wYElYx/EfUnpXoHw80c6T4XtLO6jWC4vZC8UIJLLApyMg9CRj86SZpY9F0vTlfTluSI4YmPyIOprlPiSttBp86wqHndFIB+7u6muo1nVEsbnyo1UNCiJjrzjkfma4PxvfwrZtG7K8x5fd0QcHJpMqOrPHdNvJrO+KLcI0u/LEf6tf+A/xH09O9ejPq/2fTwb6Vvs+397FFxNK3TjsB6+1cRo+nG8e4vGk2ASDyCy44+nvWlrDQsixQKokkG0kH5sAjr+lSbcvQk8Q6he+I5I5Ejj07TUAxGuSSvfj1PSrPiKG007QQdRUyJKq7bUH52GQcnoAOAas6FaM91G06qLcNvK5+6B2PfrVPxjIk37yX5yoDMWXOcHIUenb60FpW0RykmoR3Um23tvLSPOyILt3NgZJA4+lefapK0+rXAVi5LBXBP3iPr2Fdzc3pstMub+df9IjJjVsYKt/kGvN4mIzISpds5Hf6/rVoxqPZFyzjY3JUEbF++enHtXWaSnlMGT+9lgD19hXL6fESymPLOc5rttI8u2iCZw5+YkjljQxwRr6bbOswZQY+jHIG5Seefaus0y3ZY03sS7DKgnoO9YulA4aTAZiR8zD16c101tHhUUAbgMZ7jPaoNGaFnCdxKjLE88VtWy7O24/yqjaIDyPoBitOJMOowcjvQiZFldwUgYyf0p0WfkJ6UkaY57Hv61JtxgCqMy35gCgAYJrWsB50JR+QR+VYkYDsMk8cjPetOzmKTKFI296ZEjnb6NY7p1Y5RicEHJX1BqrpMo03X4LiFQIBB5EhHAHzArj8jn8K2vE0awyrPCAu9h5h25DGsW7iM67VeE27ZaTAxvI6DPbp19qS3KS5omH8T/Dc1tqT3VswSK5YSIwyMED5hn34ri49TmsdMW+EbTRRs0ckKrlkcHHHsfevdWhXxd4bWORdt9akvGW7N0II9O9eR6XDBZ+KrvSCZoJJZC+yQgrK3dck5B7jHavKxOEXtG+h10K94We6NSG6Fs/ltcFtiCSOaNyoHovrmvWvhXrj614db7RJLJc20pjkaTqQfmXHtg4/CvLvGGlfYoYWSMbmTdCYzwQe9d98FrYRaRfzHd5skwVs8fdXHTtV4BThNwexninGUFJbno1FFFeqcAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADJpUgieWVgsaAszHoAK+f8A4g+IU1fWZWVc2+QE+bHyjjp616T8Yr+a08J+TbbvMupViwvUjkkfpXjWkafPNfq10U+T5n4wuR0HPXHrXlZhVbaor1Z34OmknUZPp9oEcSzDGwbm2DgdsAV3vj28j0HwHFFL1ZTIeM+2MfU/pUng7Robi4VTFIUVsvI2Ocfzrnvj3fpdajpmkISIySp2g8Ef06VnQpezhKq/QupPnmoHllol5f8Aia1mI8p4bgwmRugwNwx6khiPyr3Pw6heZySTtHz9ua8g+HF0uszyWtwivK0jrcZGMSoThgfTbt/GvbNIh+zW82MAAfXORXq01ay7HNN3OWvVP2mZ92QxABznioG2pHJxnAAqacfPMqKfkJB71VfcBnOMDnHX1psSL2zeVKkYIBpxyB14PT6UsYO1GbrjJApXXcqgHvwRUs0KbZwHVPmU9R1PT+lMuIdwMm04xwDWgBt3Z9fzqHUFJizzzyMfypDichqsRNyoHfk+mPf1rjPFIkedEC7o8/MV47A4Fd7qkUomyRkFSCSenpXF+JI2kikkd1DDJcdN3TpTRb2PPtTfbclYlykjbU3ngYHI9a940KzksdFtofLVXWJdy7RzkZ5/OvB9U8pIvODr5gOFwffkfXpX0Lp05utFtLoqNksEZO04AUjg02ZrcW3mWSCe0vsKm4BWUYC56/rXPPp9zp2sSJcxI0bnKuOVI6ggVs39mZrUyKrBxhWBJw3PXNWLeE3lu8MwMhswPKc9drZyPfGKRTZyU+hRXNxdXtpcMsTMjTRggFHU9SOo+td5baibtdEiDb0hkl1CTnBYQqI4x+Ms6MP+uJ9DXO6jpi29/KFCotxxvB5bgYJ9alud+nQXCxZPlyJYqRnAECl5MfWe4lX/ALZD0FNET1sjv3vkuNPjLspO3GMe1ea+K4JLwzRJJiNUDNk9cgn/ACKt6TqxuMRzKcLw2D9cfyrZghtrhp4y+XyvmAdOnSkDXQ5fTfD23SJba1i8wKBLEJCF3Pj9BxjpWBHa3cIFxGofUbdlnjCEIdytnB+oyOetetfYBFFH9nA2s4B+grmtY0+K3vxJEoVmJ6t269O9MN0eq/B+/i1fwrLqtuHEV7dySDcMH5cIf1Qj8K7ivLPglqawW134fZVjSF3uLYAcEOxaRc+oZiceh9q9Tq0cslZmH4n8MWOviCWUy2mpWuTaahatsntyeu1u6nupyrdwa4Dxrqurx6Q3h7xHJb29+0sJtdYgO23n+cYDgn9xI2CAGO1j91iflHqOqX8GmadcXt24SCBC7H6V5BG15fST3mrhLqa5j2SoUBRkI+4VPBTk8HNDY4xvqULTTl05kS4twsqAqkBHVvf0HFaGjwrogutTuZTPqUwKx5IOwZ5x6Ae1V0tp9LKrYRS6hYRrj7Fu3T26/wDTuzHMiD/ni5yP4G6LXOa3e3Fxeae1nPHPoUodXmRTw64/dnIDIwJ5RgGHcCpSsaX5tC5dazM8sn2eBpCCcsDjJ7Dd0rAdXuZxJfzBv7sMf3FPfnvj1qSS4EsqQ2mEhX72VIFTtFE2c/OuBuYnFSzaMSm5ZxtgU4fhWHAVfQf41Gunw2k63t24S2bAZRku7E4AwO2T/Orl3d/Y40AWQyzdAEP+cUlvaSXFwuoaoGWSDIhiRvlBPBOPcGkapFwFoY5zJsTIATH8KiuZ1SRrm9gsbYK3O98+p9K27u682RhI+PLADgDPJ6Cs63jIWS4dfmc+XEucFs8dfSgqxxXxSJtNLsbRMiEt83HXaODn35NcDGInki8yXbDnkKMnIHJx2r07x7E+oW2oSvKjJp8YZ1UfKshwEA/AufyrzKMr5xjjAIPLP1JOM1cdjmqL3jc0RWcgydPuqQfv8cZrsbCFpAZPvP8AcAyO3viua8PRDKLuzsGXx13ccD1rsNMhSYOksjrsO1QvQjr1H40M1gtDb0uElgN/y9Nu3pXTWakBAhyw4PtWVpoBjCqhEY4966CxjBjXPQnsMYqR+bL9mpTHBDHpzWpGRFAZJSqKoyzE4GKqWUXOX6D0q5AVufMhZABGdrIeQR1B9wapGM2PhKyDzEYFGxjacgj1qbAPPYfpWbiS0uza2rRpA6GRd/WPBGQB6c1ZgmUQiS4kVmBKnZ0JB7etMgvRrleKlhPzYJOO31qpbyzSOd8DxwkZVy3X6jtVtV+UHpj160bkstahELywIBw/Y9ce9YqiRX8uV0LY5CjGCK27b94/lnIToDnrVtNPEhZ8jzh8oz7UWuKM+UwkM9m739s672UAgk5Yj+XFQa3Y6R4piN3OJra5KmKVk+QuFPRlxyOOM9jXXQ6JI7RvGEjUcHfk/l7U6fwhZXEvnyyzLcEYLxttH5fpUzg2tAU1e55d4/1k3tjDEkKw21qpVQrH7vr+lel/C+yksfBWni4ULNMDO4H+0cj9MVRm+G2mXNzHJd3FxLGmAIgQo/Su2ijWKJI0GEQBVHoBWdGi4Nyk7tlVKiklGK0Q+iiiugxCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4L4ivINV0wEEwIrEgjjcSB/LNQaZpllcl5ZJFxkAopyvJ4rf8AHOjy6rpsbWkZkuoHDKobbkZ5/GuDhl1HTNQZLoSWoK5VZTtBPr6Hj8q46sWqnM43R0Qd4WTszuNV1G08P6Zc3txKsSJHhXxjH4V8/arJdat4ztrmWfzYLRSuG5Yl23AE9BkV6Nrs95cWM5vyshz/AAHK47AiuHi0u9knaDRbaS5vZT5nl9RuzwWI6AVjVqSqyVOKsbUoKmnJsqfDXw/JHJeyqnl28srlSD820sWRvxBxz6e1e128Cx6U/G7GCzE4zxU2n+DYdNjhMAYzIgRnBxvHUhvxzj0rSvdOaPT5I1BDOMHaa9FRscjnc80IJLOxxnoD396gK/Ow3fL2yc4reksdqFXHAGR7n0rJaDbOMqckZwe1Q0bJpkkY+VTjmnMvIP5cdacAUBPJHvUojDbevrjNIaIGHztnqRUc8fy8D5hk4z3q46jgkE46YFNkjywAQndkjHIH1pFHM3saky8/PjPJ7/8A6q4PxIY1VkwMBSqtg9T6/Su+1b90ZiBtYA7R/ewOfxrz7xFCrSFH3hZSSSc+nAHr1NNFI871dnW1Yrs2Bjg7cZGO2ete1/C2+i1Dwfpm18mFDbyIR3WvKL3T4g7w3LeZ8pP7sgiNQOSB7nArr/BCf8IXfQWmpMEsNWCksScwuoAB/NxVPYi9pXPS7eQQSmykyyzExjA5U9Rmm6W32PVYRO5RXzAy9Qd33f1Hf1pL6GSK9aVtyTqRyv3XHY0apM7QwXCxjepG4YxnBGKk0eqLF8bSwvHe9UvY2cb3UnPIjRDI2PqFIqjLBd2dhbQzkSXkEO66Qj/l4cmSc/jK8nNXLq2juobFTtZr64SGSMnP7qPNxMPoVi8v/tqKx5pLu1n865kLyO7M7Hodxz/On0Mo/EVb61E++exZcRsTIgOCpxyMduoP/wCurVjPKsKXixt5YXy92QckeuO9c94pnvbOxTXvDqEGZSZYGGdwHBOPUY/EVd8L+IYrjSYrvTQtsbphFLbzLvjSYc7W9Aecd6EW+x6VoN7FcwR7HB5O4Z6GpfEOlC5tTLbErLGSSCBhh6ZrmPC8n2maW4jzaXocie0z8mf7yjtxg112m3RuY54nX96FKMnY9wRTXYyZ5R4judQtJpLnSp2tL2JBJFNHjcrjGBzwQeRz61xg+MOttYzm+1S/u7iSVWiUuFWJOjDjv/8AWr0/xFaAz3yMBiGf7K31NvBOD9MTgfVT6189eE9AGseMbbSZdwiMrCTDDOxck8/QULzJk72aPYvAF/rviuOHVNf1C5u4I2KWcEzhhGMjLdBk5GBntXsIjFvasGx6k+h9KxNA0+30+wjWCJI44U2xoBwoxwKsx3UhgPmup4yARg/WgbWljM1W9a0kcKAXx24rmrfVoNRvp5fPS11A4jeYoXjuNvRJ0480DoGGJE/hb+GsXx/4hnjlntY1VYsopk6lmb+EDuapWMCaRcWb37O95dAtFCCNkMeMbyOpLdc9uppFxgnudXLYRzXYjaM297saU2jvvEijq8D4AlX14Dr/ABKOpqvPmMSQgiU8KWUgIM9qqadrCXVqYbqP7ZamXO4kr8y/dkVlIKSDPDqQ1atwyzWrz3UvnwKPmvmTEkI/6eUTgjp+/QY/vqv3iWuWnyb7dymLu3gUCV2kmcFgcE4x6elZ2o3U8o+zwP5Nw+Fyqk+Xz1Pbpn3ralspLNFzGhk2BxKWBQgjKsrfxL3BHBrPk+z2C/6MGmnkYkyMfX0FSbblCa3aKx8vfIxGN7uMGQj+VJb3xlRxaqZLjhVc9AxB49+lOuXnuBtlXzJBg7VOAPrWzp9jBYW/2hmZY0JcFu2ev8/1oJbOF8YQtomggBSJ5ZHklb72WPAyTx/+uvM7RWbcwXc7HKgcknrj2r0b4pXu2whiZkWSd8mP7xwPun8uo9TXDaZ+7diTtQDLPjvVx2MJO8jrPC8SrAHIPmP0A7AjoDniursbE214u5SC3bzMgjryKxvCqjyXIIClvlPfOP1rtrSJEUY+Z35J69qTNlsaenRhwFJyo7Y6VrXEf2aAXfm7BCpYr2f2P9PfFYGm3rPIq2SOsbSCKW5mQhUY9AAeWyePbitfWmntVgmN2Y9gL8qNjSDG1CPTr360iJM1bS7eQQTRx7LEoXd5MA4x8vHUc+tLqFwZ3ZLCJrm7t3G+H7isMZwWPGCCDVNLaK3luGSYo1wAxRf3jc/eXb2Genpk1r2FoVtliZTHaYwISdzH3ZvwFUYtlHToJJGmnaC1M0knRSTHCB6Ej5j16YrXhjSIcfO55LkdasRRKwwq4QdAOK0rLTJLhl2ISp4JpqJDlYopHJIcAfXJq9aaZPMy7Eyvfmun07SIrZcuNzVpIioMIAB7VViHJsw7PRWQgykZHvWxFbxx8qozU1FAgpueSB2p1Rs3OOSfSgB2Tk54HagHn3pBnPoKE+8Tzz60APooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApkkaSD94it/vDNPooAry2VrNnzbeF89coDRZ2VtZIUtII4VPZFxViigAoIB6iiigCu1nbsSTGuSc9K5fVfDzeY7woCDk5BxXYUU7gtNjzCXTZYVJZOB7iqvkMD9088gV6jPaQzIyug59qw7/Qt5DRc44PPUVLinsaRqW3OGMW0gMD19c0ofYmDnJz74rYvNNa2XLg5B5+lY9zEVbgc9ahxaNVNMwL+HdO3G7n1+nFec+LPLt5tsxZZAx3bRnI/DJ7H+teoXcZIkKgKQN2/HFcZcaestytwUzKhGxmHTfncR3zgCkXFnPabpiLolrfX6CBrqb5V6lI/4ckZ9s123irS3uTZtFFDNEHVZS4zhSMEr7nimeILAtpCxoTkKS3bJ/zit6wh+3aPbSMD88YJAOMEf5FFymtDG0US6fANInJFszj7CzNuwTklCfT0rRa1uLR8yjdG3U9hx2HsatyaYL4M2VDIQMdCD6irjeZczDT0K7mKje3p/wDWoEtDFjney1BpHCl7K2WAccCW4bzZB9RFDbf9/T+Nt5LfU7N48qJFGdh9+pqGycXemR3Zj51CWTUdp/uSYEI+ogSAfhWdc25tHSWDKgn7o6/hTYoK6uPsrUmO609l2tH+8UH+8SSB+I5rl4tMS1vLsBBHb3YKTbRkA+uPUGuojvI55A8jeXKWxuPQkH1/Sl1e2jn2ynMEv3i6co/uMdKA6nO+H3e01CSGWQG4tCobGcMnUHPvnPtkg16vbBGvlmiGAy856kHtXmDWcVwoMRRrxFK4P/LSMc4YV1+i6orxRyMCqn5s570A1cZqEe/WNYwOmpjr/wBgzT68b+Etq0vxWvHVAY4IZTjPQEBR/OvbmWKS81+dmBVNSVgP7wOmafzXlfwognh8e6zLOEhe5jLIjdcZJAHrwKfcxXQ9nvUEVgqs2H+8ce44Nee+JtULWgtI5JFnmcEFAd3HJAx0rrte1CO7gtoJYpsohR/LcJuXnuQcV419uutQ8W50C3mW7eMs13eSbxCmMEoMADIx2J5wKbKsy6YrG21C3lv4ftF9gtDbKxJJ9+uM9yfzFN3EvMs0iXmt3LDzUU5WBeSFH9c8n8q0hb2WjGQTXgW6c7ppXXzJnP8AT2Hb3q1aW1to9kbmDTXV5PuBxmWVj3Y9Oai5slYZY2em2MEFz4iuvsqux2hAXkc56BV6Vbt/Fto8vn6RYXKTL86EvsGM4+8f51h6pbtcXIutdnAneEI3lfKka/3V757epqxprStdFbhEt1YnEA5kYADBJ6ADnj60Bqb1hILq38u1tI7YSAyPp0kgjgZieWhfH7iQ8ngeWx+8qn56bFYRr5z2wkYRELMk0flz2znosiZJXPZgSrdVY0sDG6XJUqoO3AXLOfY1rJau8du1w8sU8ClIbqEjzoFJyUGQVdD3jcFT6A4ai99xKLjrEzbCzDLtKqWHJq3NCYIHudQfEUS7iqqSF5/Mmr8UiwTxJfwww3Ex2QTw/La3jdlUsSYpP+mTk5/gZ+gdeLcSxeVODGyNzGAQSw45z6UmPmT2PEfiSlxLqCahPAY43VobZQQQqjaBk9ifmPrXN2FnJdzQwxRRggBNm/G84z1JxgYJzXv+qeHINS0pbO9QS2pb5scEHsVx3964yTw0LfV7WO2gkR7V9ipK2SVyNpJ7jgn8KpMhxs7sd4f02ay04LOFUseDjOFHAGen411lrE+6JIozy23djoMZqz9iSQKsoUhflXHb61v6XpgaZchucKMdh61NmyvaJIpxrFPbT20cZuMZWRUwBz6nsfpzVjTNPlENsL1/OmhA2KPuJgYB55Jxjk11OleHXc4hjEaZ3ORxkk8mujs/DUEZVpzvI7A8VoodzCVRN6HL6bpM95I3lRAAdSeCRW3F4cnyvmYxnnkV09raxWqFYUCjrU9VojJybKFnplvbxqvlqzDuRV5VVQAoAHoKWigQUUZpM0ALRSUHpQBHI+3vxSZ2ITgs3fAprHa4I64oGc8nkjqB2+lIBwAbHOc+1PQY7U0JyGIGc8VIKYC0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAGkpTSUAGaWkooAKKKPxoAXNFJRQAtFGaKAIpoI5kKyICD6iuf1Tw8JQGgwWGeDjnpXS0U7gef33hq5S0kXy8ggjGQOtc3B4duUZyYGwD8inHY9TXshGajaGNhyin8KVkylNo8eudImDyq0R4HQ4x/n2qzaWRgt0VVCA8EdP0r1FtPt2dmKk56gniqU2g2rsSu5c9R2qeRGirPqcAkBSTeowDyRmszXoidIvEt/wB1dX2zTYXHVXnYRbh/uq7P/wAANejy+HI8ko2frzXM3mkm48a6XpiFmWxtptTmJH3XYGCEfk9yfqgp8oOrdWMe7SLzdsURjiRQI0H3UQcKPwAArPnhEj/N19R/Ouyk0WaIMSvJyM9ciqT6U2cEZHX14qXBlxqI4a50uaMiRFaSNDncG5xjHIrOhuns1JSRGc/fQnAHvz/SvQJdPlgkOwEOOfu5rC1TSre72vdWi7wcgqcZPtSsVzLoc5c4ubRhbSpBdMMglMnI96qBrpXLs5tHY4eAgGPp95O49SK3U0XSoHXbHNETxtRxx+laUOkQEgrIZ4lHBkwSP05FFmUpIybqeaBrwrG0wN6hkdD/ANQvTu3v/SqWjXVtdky2k5S6U5JlUg+4O4D9K35tPgujrSyBkWPUYwGibBQf2ZYdM8Y6flWY1nGXKWuoRzMADtmhwR6nPehkQa5dSS8vHYfPdQoT8o2qW7duPr1rkNU8Pz6jcrNJ4iMajhfKtWXYPYAc8eoNdaNM3qBJcsrP0UYIP6VestLIlDKsoBJ+aTt+GKWpejOZ0Tw9baNFu0+Ga9unPzXN6Sc5POB1/QVuG1PlGSXLEYO5+ST2rZSxlJCxoqqD/rHOd30A/rTksJLlflRiFJHz8Z7fhSsynJJHFS6Y11O00q5wMKGbhc98ev8AKremaUVfzJIwZiOeOFHHA/IV2KaC5kQiMkueNvatqz8LzFvnQgsKfK2SqkI7s5W2sjgHof51rRW467Bz2IrrrfwqE2ljyO/+RWnB4fto15LM3rximoEyxC6HBNZtJZyQXMCz2kg2SwyoHSRT/Cyngj2rL+x3unRZigu9S0qMn9xzJeWqj+4es8YH8DHzAPul8ba9ai0i2jJJ3sT6mrUNrDD/AKtAPc81aiYSqNu55xoWkrr1h9rsriG70+Y5R4ZMjjqDnkEHgg4I6EA1qXPgxrnyS5jWWL7sg6j2q9rPhWaLUJdZ8J3MemazId06OpNrfY7TIP4uwkXDDvuHy1Y8OeKotSvG0vU7d9K8QRLvk0+dgS69PMiccSx/7Q5HAYKeKEkiXNsdaeFrSMgyAMe4xkGtm1sba1TbDEo98VZoqrkgAAMAYooozSAKKM0lAC5pKKKACiiigBO+KO/tSkdOcUg96AEKgke1Jt5yeafSHoe9AB6daUdaTnFC9aAHUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUYoooAMUYoooAMUYoooAMUYoooAMUYorJ1bxNoOj3kNpq+t6XYXc+DFDdXccTyZOBtViCeeOKANaiiigAorN1jXdL0aC4l1O+ggEEBuZELZcRggFggyxGSBwDyQOpq1YXcd/ZxXUCzrFKu5VngeFwP8AaRwGU+xANAFiiiigArkPAv8AxMNU8Ta6Tlbu/Nnbn/pjbZi49jKJ2/4FXU2t3b3YlNrcRTiKRopDG4bY6nDKcdCD1HUVj6EuleHhpnhS0nk+0R2TTQpICzyRxsivIzAbdxaRSehJYkDrgA3SAeoFN8tP7i/lT6KAK8tnBL99B+VU30SzYYMa57EjOKn0vVLPVFuWsZvNFtcSWsvyldsiHDLyBnB7jirtO4GNL4ftJAcqnIwf3Y5qD/hF7QNlFRR0OE/+vXQUUXYHAeHdGgvdc8YxSYK2+sRquVz/AMw6yH9K6FPDVmpHyx4HQeWOKp+Df+Rj8d/9hqP/ANN1nXVUh3MM+HLXAC7VAHZBUkWgWqMC2WwO9bFFAXZnrpFmowIlH4VLHp9qg4hT8uKt0UXEMWGNRhY0A9hT8AdKKKACiiigAoormbXxz4futcOkRXdx9sFy9mC9lOkLToCWjWZkEbMACcBieKAOmrJ8R+H9P8Q2aW+pQkmNvMgnjYpNbydnjccqw9R9DkcVoWVzHeWsdxEsyo4yBNE8Tj6q4DD8RU1AHDprmp+EXFv4vY3ej52xa9GgHljsLpAMIe3mr8h7hO/bRuksayRurxsAyspyCD0INK6q6MrqGVhggjIIrmrBNH8IXum6Hp1rNBHqs8zQRRsWhhZY97BVLfu1wpwqjGSeBmgDpqMVS1LVLPTWs1vZvKN5cLawfKW3yMCQvA44U8njiobTXbC8Dm0kmmCXb2LmO3kbZMpIYNheACPvH5ffkUAaeKMVjX3iOzsteGkzRXbXBtDeboYDKNnmLHjC5bOXB4XAGSSMVs0AGKQL6nmlooAQLg5pcUUUAGKKKKADFGKKKAG7felUYJ5paKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzeaw1bSPEHiw/8IkPENtrc0c0c6z26rtEKR+ROJWDBFKMRtVxhzxnOfSKKAPG7zTfH5lk0+GDVTHFdavMNQGpRhJo5opvsiKPM3/KzxjDKAhUEcDIh1fwt46tLSe30O81aS2kg06WYT6k88skoMwuljZp42Qn9ycLJGpwQpHIr2qigDwy98HeM9U8OR2GoSavcxm1x5c14IHWT7dG6q225k3FYg+HMjHAAJ3cVrt4f8WW3iZ1sxrjol7mG+fWC9p9hEG0RGF5CzS7v4ymd3zGTtXrlFAHjy+CvEs2leF47q/8AEP2ldEuP7UZNclRvt/lW4iBKygHDLLyvykgliSxLdH8PdD1/RtXc6pcajPZ3GkWbzG8vzc4v90vnhQzMUGDHwuE6Y6V31FAHjVp4b8RaHf3s+l6ZrsjJ4ibUZBHqytFfWbl/kRJJwAwLgsHVM7epwKzbvw34yuprPUb/AEnXpr37Lq0SCz1mOGW2kmu1ktg8gmXMYRRwpYDao2nGK93ooA8SsPD3xHj8VxzarqGoTIrKftFo4+zOnkBSjI12gX58ncLdmBwQx7XIfDPiSz07wo2pp4o1dBpoGrW1lrphuBe7IgGLmeMFAFkXCOAWO4hiS1ew0UAeFa/4V8cq8g0kX8FhLqOoXDw2dwBNmR1MMpK3cG4bd3BkOD1Q5yPadFS5i0ewjv5HlvFgjWaR1Cs7hRuJClgCTngEj0J61cooAKKKKAOV8G/8jH47/wCw1H/6brOuqrn/AA1p91Za14snuYtkV9qaXFu24HfGLO2jJ4PHzxuMHB4z0INdBQAUUUUAFFFFABRRRQAUUUUAFeXWHw61DT/Eba9BcwT3g1u4vhaz3MrWxgm+XcqEFY51UthlXnJUnByvqNFAHiM3wcurvSpIr9dHnvo9Ft7C0mcsTBOlzNKzq2zKjbIoDDnIIwB1ta/8LL9l1Ox0K18Px6Dc6ml5FYSRRgQoLWOIlBJbzRxv5iuxwhyG+8pJr2SigDzK/wDC2qWXwMtfD15cpPqNla26TGITTR3AikRmixGhlKOqlDtUnDHg9K5Lwn4E1bWNM1Geys7bwrDPqOoSW8UEUkPkJNYR26PEjRxsMSKx+ZUPGQORXvVFAHh7fCW9lVZ30LwjEkNxZypo6SO1pN5SyrK7u0PyvJ5i5xGeI1ySea07L4aX9tqUslvY6DYb9cOq/brVz9oaNhJ+6I8kfcZ/l+Yg9cL0r12igDw3TfhNrMFs0f2Tw5ZTDTobOW5tZpGkvpUuYpWnmJiB3MI24Jc5PUg8dZ4H8FX+g+OdX1Z7XSrexvBMdyOtxdOzyhxmX7PG4Tg5R3l/hAICjPo1FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeX6ZreoXtpqPiO/8VvYW9hqk9tJpEdvbmMRxTMghYuvmmaRVBBDgZdcKR1afileQaZ9pvdAg8+W2sb21htdSE3mRXNwkI3sY12OC4OOVOCA3BI7uXwzoM2srq8uiaW+rKQVvWtIzOCOhEmN3H1ptl4V8PWME8NloOk20VxIksyQ2caLI6MGRmAHJVgCCeQRkUAcjd/EDV7DWLm1vvD1mLayvbKyu54dTZ2V7ooEMaGFd4UuuclfbNJ4U8c6nrdxbadpemxXVysDXd1NqF+ISsRuZoV2eXAfMP7luNqgDaCxJzXdzaTp07zPNYWkjzSRzSs8Kku8ZBjZsjkqVXBPIwMdKpXXhTw7d/ZPteg6TP8AZGL2/m2cbeSxbcSmR8pLc8d+aAPMfHXxKnvPhxM9jbyaffajpWpzpLDdkSWrWzBAQQoOSSeeMY71p+I/ijc2mv3Wi6fp9vNv+121tfRzT7UuIYHk2yFrcRZBQghZHI7jrXcf8If4aM91OfDujefdhxcSfYot0wf74c7ctu75696kHhbw+NYbVhoWlDVGYs159jj84kgqSXxuzgkdehIoA83j+KOuadpOhwXXhxtW1e50mPU5RYvcTeZGwABXyrZgJGO4lWCIOBvOa6n4ha7rmnS+Dz4eitydR1QW80V5KYN6m3mcRsfLcpygJIGQVA6Mca0vgbwlLZxWkvhfQntIWZ44W0+EojNjcQu3AJwMkdcVqavo+mazZfYtY06zv7MMG8i6gWWPI6HawIyKAPOPEPxHe48OXcMFo1pd3UmsWCOl1h4Ws45j5owoOSYxxxt3Dk96q/FO+0XT7ew1XQ/O1YwWBgFtdS3Syi4EgUylIS6P+5YlVRycjBPWvRT4T8OHUJr86BpBvpgwluPsUfmSBlKsGbbk5UlTnqCRTbfwf4attMudOtvDujQ6fcsGntY7GJYpSOhZAuGI9xQByen/ABH1C7aCN/DE9pMLOa+uUupZITHFFMEYorwh33Kdy5Vc5AO3kjP1nxfrE2neDdbvrWLTdOutSSdY7DUGuHuIDZXUhSQeWi/wodoLgkdeAT6PpWhaRpCxLpOlWFiIkaKMW1ukWxGbcyjaBgFuSO55qtp3hPw7pkvm6boGk2cvmiffb2ccZ8wBlD5AHzAO4z1w7epoA574b+O7zxhJJ9o8P3enWzW0d1Bcsk/lSKxPyFpYYxvA2n5C6kHhjiu7rJ0fw3oeiXE8+jaNpunzz/66S0tUiaTnPzFQCefWtagAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Superior view of the laryngeal introitus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Orebaugh SL. Airway anatomy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_27_3510=[""].join("\n");
var outline_f3_27_3510=null;
var title_f3_27_3511="Sq ca lung in situ bronch";
var content_f3_27_3511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous carcinoma in situ of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bronchoscopic image showing a focal area of mucosal erythema and elevation at the entrance to the superior segment of the right lower lobe; biopsy showed carcinoma in situ.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_27_3511=[""].join("\n");
var outline_f3_27_3511=null;
var title_f3_27_3512="Etonogestrel contraceptive implant";
var content_f3_27_3512=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etonogestrel contraceptive implant",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/27/3512/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/27/3512/contributors\">",
"     Philip D Darney, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/27/3512/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/27/3512/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/27/3512/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/27/3512/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/27/3512/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single-rod progestin implant placed subdermally in the inner upper arm is available for long-acting contraception in women (",
"    <a class=\"graphic graphic_figure graphicRef66665 \" href=\"UTD.htm?43/2/44078\">",
"     figure 1",
"    </a>",
"    ). The 40 mm by 2 mm semi-rigid rod is made of plastic (ethylene vinyl acetate) containing 68 mg of the progestin",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    (the 3-keto derivative of desogestrel), which is slowly released over at least three years, initially at 60 to 70",
"    <span class=\"nowrap\">",
"     mcg/day,",
"    </span>",
"    decreasing to 35 to 45",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    at the end of the first year, to 30 to 40",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    at the end of the second year, and then to 25 to 30",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    at the end of the third year [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This implant was originally marketed under the brand name Implanon, but was subsequently modified and marketed as Nexplanon (",
"    <a class=\"graphic graphic_figure graphicRef75912 \" href=\"UTD.htm?22/12/22735\">",
"     figure 2",
"    </a>",
"    ). Unlike Implanon, the Nexplanon rod is radio opaque so it can be detected by x-ray and does not require magnetic resonance imaging (MRI) for locating impalpable implants. In addition, the redesigned applicator makes subdermal insertion easier and failed insertion unlikely because the new cap will not open if the implant is not in the needle and a finger pressure activated lever ensures that the trocar completely discharges the contraceptive implant under the skin. Implanon and Nexplanon are bioequivalent.",
"   </p>",
"   <p>",
"    Use of long-acting contraception is increasing in the United States. In 2009, 0.8 percent of current contraceptors used an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant, up from 0.4 percent in 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/2\">",
"     2",
"    </a>",
"    ]. Accumulating evidence supports the efficacy and acceptability of implant contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2346895\">",
"    <span class=\"h1\">",
"     ACTIONS AND INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestins cause changes in cervical mucus and tubal motility that are unfavorable to sperm migration, thus inhibiting fertilization. At high doses, progestins also inhibit gonadotropin secretion, thereby inhibiting follicular maturation and ovulation. This dual effect allows contraceptive efficacy to be maintained even though ovulation is not consistently inhibited in implant users toward the end of the three-year period of use. Although progestins suppress endometrial activity, which makes the endometrium unreceptive to implantation, this is less important since the major mechanisms of contraceptive action prevent fertilization.",
"   </p>",
"   <p>",
"    Contraception is the only approved indication for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel implants",
"    </a>",
"    . However, they have been studied for use in progestin-responsive disorders, such as endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16205996\">",
"    <span class=\"h2\">",
"     General population",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant is among the most effective contraceptives available, surpassing sterilization operations in efficacy. An analysis of 11 clinical trials in which 942 women enrolled for two to four years showed the etonogestrel implant was well-tolerated and effective: no pregnancies occurred while women were using this method of contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/6\">",
"     6",
"    </a>",
"    ]. Six pregnancies have been reported during the first 14 days after implant removal. The manufacturer cites a Pearl Index of 0.38 pregnancies per 100 women-years of use, which is similar to that of other long-acting methods of contraception. Pregnancy may be intrauterine or extrauterine [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16205961\">",
"    <span class=\"h2\">",
"     Overweight and obese women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant has not been adequately studied in women more than 130 percent of their ideal body weight (body mass index [BMI] greater than 30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ).",
"    </span>",
"    Available data do show a decrease in contraceptive efficacy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4233?source=see_link&amp;anchor=H8#H8\">",
"     \"Contraception counseling for obese women\", section on 'Contraceptive implant'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16205989\">",
"    <span class=\"h2\">",
"     Women taking certain medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraceptive efficacy may be decreased in women taking medications that affect the metabolism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    (eg, hepatic enzyme inducers) (",
"    <a class=\"graphic graphic_figure graphicRef67297 \" href=\"UTD.htm?30/16/30989\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS AND ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the analysis described above [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/6\">",
"     6",
"    </a>",
"    ], unscheduled bleeding was the primary reason for discontinuation, with a rate of 14.8 percent in the US and Europe, but only 3.7 percent in Southeast Asia, Chile, and Russia. US users were more likely to discontinue because of prolonged or heavy bleeding than women from other countries (7.0 versus 4.3 percent).",
"   </p>",
"   <p>",
"    The mean number of bleeding and spotting days per 90 day reference period was 7.3 and 10.4 days, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/6\">",
"     6",
"    </a>",
"    ]. One third of 90 day reference periods had fewer than three",
"    <span class=\"nowrap\">",
"     bleeding/spotting",
"    </span>",
"    episodes; one fifth had no",
"    <span class=\"nowrap\">",
"     bleeding/spotting;",
"    </span>",
"    17 percent had a bleeding episode that lasted more than 14 days, and 6 percent had more than five",
"    <span class=\"nowrap\">",
"     bleeding/spotting",
"    </span>",
"    episodes. The number of unscheduled bleeding days was highest in the first three months of use, decreased during the first year of use, and then plateaued for the second and third years of use [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. However, this decrease may have resulted from patients discontinuing as a result of a bleeding irregularity, leaving for analysis those less likely to experience bleeding.",
"   </p>",
"   <p>",
"    Women who experienced more days of bleeding were more likely to discontinue, especially if the bleeding was prolonged. For example, the mean number of",
"    <span class=\"nowrap\">",
"     bleeding/spotting",
"    </span>",
"    days in women who discontinued and who continued implant use during a 90-day reference period was 45.2 and 16.5 days, respectively. Frequent or prolonged",
"    <span class=\"nowrap\">",
"     bleeding/spotting",
"    </span>",
"    was reported in about 90 percent of women who discontinued the implant but in only 22 percent of those who continued its use. Since bleeding disturbances are the principal cause of discontinuation, several approaches to their treatment have been used, including nonsteroidal antiinflammatory drugs (NSAIDs), combined oral contraceptive pills, and supplemental progestin or estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Management of unacceptable bleeding patterns is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22698?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of unscheduled bleeding in women using contraception\", section on 'Contraceptive implants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common adverse events besides unscheduled bleeding that were deemed possibly, probably, or definitely related to Implanon included headache (16 percent), weight gain (12 percent), acne (12 percent), breast tenderness (10 percent), emotional lability (6 percent) and abdominal pain (5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sustained-release contraceptive implants do not induce significant bone loss, despite creation of a relatively hypoestrogenic state and in contrast to another contraceptive progestin, depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (DMPA). A literature review concluded that the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant does not appear to have clinically significant effects on lipid metabolism or liver function, although there may be small changes in laboratory values [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Users of the long-acting injectable contraceptive depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (DMPA) appear to be at increased risk of HIV acquisition and transmission compared to noncontraceptive users. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link&amp;anchor=H21#H21\">",
"     \"Depot medroxyprogesterone acetate for contraception\", section on 'Effect on HIV acquisition and transmission'",
"    </a>",
"    .) There is no evidence that lower doses of other contraceptive progestins, such as the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant, have similar effects.",
"   </p>",
"   <p>",
"    A large epidemiologic study using registry data from Denmark did not find an increased risk of arterial events among 24,954 implant users compared with over 9 million nonusers of hormonal contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/12\">",
"     12",
"    </a>",
"    ]. For thrombotic stroke, there were three events among users, incidence",
"    <span class=\"nowrap\">",
"     12/100,000",
"    </span>",
"    person years, RR 0.88, 95% CI 0.28-2.72; for myocardial infarction, there were three events among users, incidence",
"    <span class=\"nowrap\">",
"     12/100,000",
"    </span>",
"    person years, RR 2.14, 95% CI 0.69-6.65.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INSERTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insertion of Nexplanon is a brief office procedure. A clinician who has been trained in the technique can do it in less than two to three minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/13\">",
"     13",
"    </a>",
"    ]. The FDA and Nexplanon's maker, Merck, agreed that Implanon and Nexplanon would be distributed only to clinicians who have received three hours of training in patient selection, counseling, insertion, and removal. Those already trained for Implanon can take an online course to qualify for use of Nexplanon (www.nexplanon-usa.com)",
"    <a class=\"external\" href=\"file://\">",
"    </a>",
"    . When all registered Implanon providers have completed online Nexplanon training, Implanon will be taken off the market. Questions regarding training can be answered at 1-877-467-5266. Merck is required to coordinate and provide instructors and materials for training, as well as to monitor clinician reporting of adverse events. This reporting system has not revealed any unexpected problems with insertion or removal of Implanon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual contraindications to use of hormonal contraceptives apply:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Known or suspected pregnancy",
"     </li>",
"     <li>",
"      Current or past history of thrombosis or thromboembolic disorders",
"     </li>",
"     <li>",
"      Hepatic tumor or active liver disease",
"     </li>",
"     <li>",
"      Undiagnosed abnormal genital bleeding",
"     </li>",
"     <li>",
"      Known or suspected breast cancer or history of breast cancer",
"     </li>",
"     <li>",
"      Hypersensitivity to any components of the implant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Large epidemiologic studies have not identified an increased risk of stroke, myocardial infarction, or venous thromboembolism in users of progestin-only oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/14-16\">",
"     14-16",
"    </a>",
"    ], and none of these events occurred in the trials on which approval was based [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/6\">",
"     6",
"    </a>",
"    ]. For this reason, the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) believe progestin-only contraceptives represent a reasonable contraceptive choice for women with risk factors for, or a past history of, venous thromboembolic disease (",
"    <a class=\"graphic graphic_table graphicRef65586 \" href=\"UTD.htm?39/25/40350\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/17\">",
"     17",
"    </a>",
"    ]. Subsequently published data support this conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This recommendation differs from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant package labeling, which lists current or past thrombosis as a contraindication to use. Etonogestrel is the synthetic biologically active metabolite of the synthetic progestin desogestrel. Controversy remains as to whether desogestrel or its derivatives may be associated with an increased risk of venous thromboembolism compared with other progestins. Evidence of this increased risk comes from studies of oral contraceptives where desogestrel is administered in combination with ethinyl estradiol, rather than alone as in the implant [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One case report described contraceptive failure in two HIV-positive women using the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant and on antiretroviral therapy (efavirenz-zidovudine-lamivudine in one woman and efavirenz-emtricitabine-tenofovir in the other) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/19\">",
"     19",
"    </a>",
"    ]. Both implants appeared to be correctly positioned and there was no obvious reason for the contraceptive failures other than a possible decrease of etonogestrel efficacy related to administration of hepatic enzyme-inducing antiretroviral medications. Although it is not currently possible to assess the magnitude of the risk of contraceptive failure in this setting, prospective users should be informed about the possibility of increased failure rates. This risk does not preclude use of the implant, which remains highly effective for most women on antiretroviral drugs. Furthermore, HIV-positive women are typically advised to use condoms to protect against transmission of HIV and other sexually transmitted infections, thus they typically have back-up contraceptive protection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2347974\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of early pregnancy can generally be assessed by review of the woman&rsquo;s menstrual, sexual, and contraceptive history, with laboratory confirmation if indicated, although there is no evidence that the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant or other hormonal contraceptives have caused abnormal fetal development. Most of the few pregnancies reported among etonogestrel implant users were present before insertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Timing of insertion depends upon the patient's recent history.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If she has not used hormonal contraception in the past month &mdash; insert anytime during the first five days of the menstrual period",
"     </li>",
"     <li>",
"      If she has used combination hormonal contraceptives in the past month &mdash; insert anytime during the hormone free interval. Women taking combination hormonal contraceptives continuously, rather than cyclically, can start Implanon at any time.",
"     </li>",
"     <li>",
"      If she has used a progestin-only method in the past month &mdash; insert on the same day the next progestin injection is due or an implant or intrauterine device is removed. In women taking progestin-only pills, insertion can be performed anytime.",
"     </li>",
"     <li>",
"      Postabortion and postpartum &mdash; insert anytime within the first five days after an abortion or within 21 days after delivery.",
"     </li>",
"     <li>",
"      Breastfeeding &mdash; insert anytime (",
"      <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"       table 2",
"      </a>",
"      ). Note: While breastfeeding is associated with subfertility, anovulation is likely only when all of the following conditions are met:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The woman is less than six months postpartum",
"     </li>",
"     <li>",
"      She is breastfeeding exclusively (ie, not providing food or other liquid to the infant)",
"     </li>",
"     <li>",
"      She is amenorrheic",
"      <br/>",
"      <br/>",
"      Under these conditions, there is 98 percent protection from pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/20\">",
"       20",
"      </a>",
"      ]. If these conditions are not met, time of resumption of ovulation is variable and the risk of unintended pregnancy while breastfeeding is high [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/20-23\">",
"       20-23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No back-up method is necessary if timing of insertion follows these guidelines. If insertion occurs at other times, then back-up contraception is advised for the first seven days after insertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following equipment should be available for Implanon insertion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A 25-gauge needle (1.5 inches in length) attached to a 2 to 5 mL syringe",
"     </li>",
"     <li>",
"      1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/17/3350?source=see_link\">",
"       chloroprocaine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      without epinephrine",
"     </li>",
"     <li>",
"      Antiseptic solution (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"       povidone iodine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine gluconate",
"      </a>",
"      , isopropyl alcohol)",
"     </li>",
"     <li>",
"      An adhesive strip for closure of the puncture site",
"     </li>",
"     <li>",
"      Elastic pressure bandage, eg, \"Kerlex\"",
"     </li>",
"     <li>",
"      Sterile surgical gloves",
"     </li>",
"     <li>",
"      Sterile drape",
"     </li>",
"     <li>",
"      Sterile, preloaded Nexplanon applicator",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Position the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient lies supine with the full length of her arm exposed and supported by the table. The manufacturer suggests positioning the upper inner aspect of her nondominant arm by bending her elbow 90 degrees and rotating her arm upward and outward so that her hand is opposite her head (",
"    <a class=\"graphic graphic_figure graphicRef68831 \" href=\"UTD.htm?0/25/400\">",
"     figure 4",
"    </a>",
"    ). However, we find the procedure is easier when the arm is extended. This allows full exposure of the insertion site at the crease between the biceps and triceps muscles.",
"   </p>",
"   <p>",
"    Identify an insertion site approximately four fingerbreadths superior and lateral to the medial epicondyle of the humerus. This site should be at least 6 and no more than 10 cm from the medial epicondyle. The optimum site depends upon individual anatomic features, such as the length of the upper arm (avoid placing the end of the implant too near the axilla) and the area where the crease between the biceps and triceps muscles is clearest.",
"   </p>",
"   <p>",
"    Place a sterile drape under the arm and clean the insertion site with an antiseptic solution.",
"   </p>",
"   <p>",
"    Some clinicians mark the skin to help guide insertion. One mark is made where the rod will be inserted and a second mark is made a few centimeters proximal to the first mark to serve as a direction guide during insertion. However, insertion directly through the marked skin should be avoided as it can result in \"tattooing.\" We do not find skin marks helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Administer anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inject one to two mL of 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/17/3350?source=see_link\">",
"     chloroprocaine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    into the dermis to raise a wheal along the planned track of the rod insertion needle. &nbsp;Inject the local anesthetic just under the skin with a 25-gauge, 1.5 inch needle on a 2 to 5 mL syringe.",
"   </p>",
"   <p>",
"    A burning sensation is common during injection of the local anesthetic. This effect can be eliminated for most patients by adding 1 meq of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    to each 10 mL of anesthetic (however this buffering shortens shelf life to 24 hours).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Insert",
"    </span>",
"    &nbsp;&mdash;&nbsp;The operator should be seated and should view the insertion site from the side, not from above the device.",
"   </p>",
"   <p>",
"    Most women feel no more than a pressure sensation during the insertion procedure. The sharp, beveled trocar easily penetrates the skin, making a separate incision unnecessary. Grasp the applicator above the needle cap on its textured surface between thumb and forefinger. Remove the clear plastic needle cover. Place the needle against the insertion site holding the applicator at an angle 30 degrees to the skin (",
"    <a class=\"graphic graphic_figure graphicRef55935 \" href=\"UTD.htm?37/42/38567\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef77440 \" href=\"UTD.htm?40/56/41871\">",
"     movie 1",
"    </a>",
"    ). While applying counter traction to the skin around the insertion site, puncture the skin with the needle tip. Lower the applicator so that it is parallel to the skin and advance the needle in the subdermal connective tissue while lifting the skin with the tip of the needle. Advance the needle to its full length. If the needle is not fully advanced under the skin, the implant will not be correctly inserted. Unlock the slider with downward finger pressure on the lever, then move the slider fully backward (distally) and remove the applicator.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Verify placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately after insertion, palpate the skin to verify correct placement of the rod; both ends should be palpable. Ask the patient to feel her implant, then place an adhesive closure on the insertion puncture and wrap the site with a pressure bandage. If you cannot feel the implant, check the applicator to make sure the implant is no longer in the applicator. The applicator obturator is purple, while the implant is white. If there is doubt about the presence of the implant, use sonography or an x-ray to determine its presence. MRI is not required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Post insertion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete the Patient Chart Label for the patient's medical record and the User Card, which must be given to the patient. This information is useful for other health care providers who may be called upon to remove the implant.",
"   </p>",
"   <p>",
"    Most women do not experience pain after insertion, but if it occurs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , or nonsteroidal anti-inflammatory agents usually provide relief.",
"   </p>",
"   <p>",
"    The patient may be discharged immediately after the procedure. She should call the provider if she develops pain, discharge, or swelling at the insertion site, or fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications are rare, reported in 0.3 to 1 percent of insertions and 0.2 to 1.7 percent of removals [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Potential complications include infection, hematoma formation, local irritation or rash, expulsion, and allergic reactions. The implant may migrate a short distance (less than 2 cm) over time [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/26\">",
"     26",
"    </a>",
"    ]. The incidence of complications is minimized by clinician training and experience, and the use of strict aseptic technique.",
"   </p>",
"   <p>",
"    A single case of injury to branches of the medial antebrachial cutaneous nerve during Implanon insertion has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/27\">",
"     27",
"    </a>",
"    ]. Nerve injury can result in impaired sensibility, severe localized pain, or the formation of painful neuroma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     REMOVAL AND RETURN OF OVULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rod can be removed at any time, but should be removed at the end of three years. The hormonal effects end promptly after removal; circulating levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    are undetectable in one week and more than 90 percent of women ovulate within 3 to 4 weeks of removal (",
"    <a class=\"graphic graphic_figure graphicRef60519 \" href=\"UTD.htm?14/12/14542\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Implant removal is an office procedure requiring only local anesthesia. Equipment is the same as that listed above for insertion (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Insertion'",
"    </a>",
"    above), except the Nexplanon applicator is replaced by sterile mosquito forceps (curved or straight) and a #11 scalpel (",
"    <a class=\"graphic graphic_figure graphicRef71918 \" href=\"UTD.htm?2/50/2850\">",
"     figure 7",
"    </a>",
"    ). For removing deeply inserted implants, modified (&lt;2 mm diameter) vasectomy forceps can be useful (",
"    <a class=\"graphic graphic_figure graphicRef59134 \" href=\"UTD.htm?19/14/19694\">",
"     figure 8",
"    </a>",
"    ). Removal takes about four minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend viewing an instructional video and then practicing removal on a model arm before attempting the procedure on a patient. A removal kit containing a model arm and a manual and compact disc illustrating basic technique is available at no charge from Merck (by calling 877-467-5266 toll-free).",
"   </p>",
"   <p>",
"    The patient should read and sign an informed consent, which is filed in her medical record. We suggest that the patient also be given a copy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Position the patient and prepare the implant site as described above for rod insertion (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Position the patient'",
"    </a>",
"    above). We prefer to have the patient extend her arm for the insertion procedure but bend her arm for implant removal (",
"    <a class=\"graphic graphic_figure graphicRef58638 \" href=\"UTD.htm?15/25/15760\">",
"     figure 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Palpate the distal tip of the rod (the end closest to the elbow). If it is not palpable, then removal should be postponed until the rod can be localized with sonography or x-ray imaging (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Difficult removals'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Push down on the proximal end of the rod and inject no more than 0.5 mL of buffered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    with epinephrine into the dermis immediately under the elevated distal tip of the rod, raising a wheal about 5 mm in diameter. Too much anesthetic makes it difficult to locate the rod. Massage this area to disperse the anesthetic.",
"   </p>",
"   <p>",
"    Use your fingers to again apply pressure on the proximal (axillary) end of the rod so that the distal (elbow) end pushes up against the skin. As the rod is pushed, the point of the #11 scalpel is held so that it is immediately available to incise the sheath without releasing pressure on the rod. It is best to keep the scalpel in one hand with thumb and index finger while manipulating the rod with the rest of the fingers of both hands. Pushing the rod against the incision with finger pressure is critical for success with this \"Pop Out\" technique. If pressure is released, the rod will slip back into the fibrous sheath in the subdermal tissue.",
"   </p>",
"   <p>",
"    Make a 2 to 3 mm longitudinal incision through the skin over the end of the rod. Deepen the incision until you feel a rubbery sensation against the point of the scalpel blade; this is the rod encased in a fibrous sheath. Nick the fibrous sheath covering the end of the rod with the tip of the scalpel blade. It may take several nicks in different directions to fully open the sheath.",
"   </p>",
"   <p>",
"    The end of the rod will come into view as the sheath is opened. Continue to exert finger pressure on the proximal (axillary) end of the rod to push the distal (elbow) end through the incision until it can be grasped with mosquito forceps or fingers and pulled out. Confirm that all 40 mm of the rod have been removed.",
"   </p>",
"   <p>",
"    Close the incision with an adhesive strip (eg, butterfly bandage) and cover with a pressure bandage to minimize bruising.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Difficult removals",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the rod will not move toward the incision with finger pressure, it can be grasped with a hemostat or modified vasectomy forceps (filed down to a 2 mm diameter grasping ring) (",
"    <a class=\"graphic graphic_figure graphicRef59134 \" href=\"UTD.htm?19/14/19694\">",
"     figure 8",
"    </a>",
"    ), but the incision will usually have to be lengthened in order to admit the clamp. It may be necessary to inject more local anesthetic, and to dissect around the rod with a straight mosquito clamp. The disadvantage of instrument removal is that it can be more painful, cause more bleeding, require a larger incision, and increase the risk of breaking the rod.",
"   </p>",
"   <p>",
"    Once a rod is damaged, it can fracture with further attempts to grasp it with clamps. To decrease this risk, the rod should be grasped by its end whenever possible and with as little traction as possible for exposure and removal.",
"   </p>",
"   <p>",
"    If it is not possible to grasp and push up on the end of a deeply implanted rod to open the fibrous sheath, use a scalpel to cut longitudinally, not across, the sheath covering the rod. Rarely, removal of a cut or broken rod will require an additional incision at the proximal end of the rod so that the remaining piece can be removed. When the rod must be grasped around its diameter, rather than at the end, the vasectomy forceps are particularly useful.",
"   </p>",
"   <p>",
"    Rods too deeply placed cannot be palpated under the skin, but can be seen on x-ray. Such \"lost\" rods should be located with a high frequency (10 to 15 megahertz), linear ultrasound transducer prior to attempting the removal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3512/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Use a transverse orientation to identify an acoustic shadow (the rod itself is more difficult to see), measure the depth, and draw a line representing the rod location on the surface of the skin. A thin wire (eg, an opened paper clip), held under the transducer may be used to help mark the skin surface in relation to the impalpable rod. If the rod is very deep (&gt;1.5 to 2 cm), sonography should be used during the removal procedure because movement of the patient&rsquo;s arm may change the location of skin marks in relation to the underlying implant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     REINSERTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient wants to continue to use implant contraception, a new rod can be inserted immediately through the same incision that was used to remove the old rod. Alternatively, the new implant can be placed in the other arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/22/1378?source=see_link\">",
"       \"Patient information: Long-acting methods of birth control (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"       \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"       etonogestrel",
"      </a>",
"      implant is a highly effective long-acting contraceptive for women (",
"      <a class=\"graphic graphic_figure graphicRef66665 \" href=\"UTD.htm?43/2/44078\">",
"       figure 1",
"      </a>",
"      ) that is placed subdermally in the inner upper arm. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unscheduled bleeding is the most common reason for discontinuation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Side effects and adverse events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to Implanon, the Nexplanon applicator makes insertion easier and more precise. Since the implant is radio opaque, impalpable rods are easier to identify. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insertion is an office procedure with or without local anesthesia by trained clinicians. The usual contraindications to use of hormonal contraceptives apply; however, because it contains no estrogen, there are few women who cannot use the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"       etonogestrel",
"      </a>",
"      implant. Complications related to insertion are rare. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Insertion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rod can be removed at any time, but should be removed at the end of three years. Implant removal is an office procedure requiring only local anesthesia. Ovulation resumes shortly after removal. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Removal and return of ovulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the patient wants to continue to use implants, a new rod can be inserted immediately through the same incision that was used to remove the old rod or in the other arm. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Reinsertion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/1\">",
"      Wenzl R, van Beek A, Schnabel P, Huber J. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon. Contraception 1998; 58:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/2\">",
"      Finer LB, Jerman J, Kavanaugh ML. Changes in use of long-acting contraceptive methods in the United States, 2007-2009. Fertil Steril 2012; 98:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/3\">",
"      Tocce KM, Sheeder JL, Teal SB. Rapid repeat pregnancy in adolescents: do immediate postpartum contraceptive implants make a difference? Am J Obstet Gynecol 2012; 206:481.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/4\">",
"      Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012; 366:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/5\">",
"      Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study. Contraception 2009; 79:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/6\">",
"      Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 2009; 91:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/7\">",
"      Bouquier J, Fulda V, Bats AS, et al. A life-threatening ectopic pregnancy with etonogestrel implant. Contraception 2012; 85:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/8\">",
"      Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008; 13 Suppl 1:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/9\">",
"      Mansour D, Bahamondes L, Critchley H, et al. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. Contraception 2011; 83:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/10\">",
"      Abdel-Aleem H, d'Arcangues C, Vogelsong KM, G&uuml;lmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev 2007; :CD003449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/11\">",
"      Suherman SK, Affandi B, Korver T. The effects of Implanon on lipid metabolism in comparison with Norplant. Contraception 1999; 60:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/12\">",
"      Lidegaard &Oslash;, L&oslash;kkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/13\">",
"      Levine JP, Sinofsky FE, Christ MF, Implanon US Study Group. Assessment of Implanon insertion and removal. Contraception 2008; 78:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/14\">",
"      Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998; 57:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/15\">",
"      Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999; 4:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/16\">",
"      Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004; 164:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/17\">",
"      ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/18\">",
"      Hennessy S, Berlin JA, Kinman JL, et al. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception 2001; 64:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/19\">",
"      Leticee N, Viard JP, Yamgnane A, et al. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception 2012; 85:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/20\">",
"      Kennedy KI, Rivera R, McNeilly AS. Consensus statement on the use of breastfeeding as a family planning method. Contraception 1989; 39:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/21\">",
"      Shaaban OM, Glasier AF. Pregnancy during breastfeeding in rural Egypt. Contraception 2008; 77:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/22\">",
"      Israngkura B, Kennedy KI, Leelapatana B, Cohen HS. Breastfeeding and return to ovulation in Bangkok. Int J Gynaecol Obstet 1989; 30:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/23\">",
"      Van der Wijden C, Kleijnen J, Van den Berk T. Lactational amenorrhea for family planning. Cochrane Database Syst Rev 2003; :CD001329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/24\">",
"      Mascarenhas L. Insertion and removal of Implanon: practical considerations. Eur J Contracept Reprod Health Care 2000; 5 Suppl 2:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/25\">",
"      Bensouda-Grimaldi L, Jonville-B&eacute;ra AP, Beau-Salinas F, et al. [Insertion problems, removal problems, and contraception failures with Implanon]. Gynecol Obstet Fertil 2005; 33:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/26\">",
"      Ismail H, Mansour D, Singh M. Migration of Implanon. J Fam Plann Reprod Health Care 2006; 32:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/27\">",
"      Wechselberger G, Wolfram D, P&uuml;lzl P, et al. Nerve injury caused by removal of an implantable hormonal contraceptive. Am J Obstet Gynecol 2006; 195:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/28\">",
"      Singh M, Mansour D, Richardson D. Location and removal of non-palpable Implanon implants with the aid of ultrasound guidance. J Fam Plann Reprod Health Care 2006; 32:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/29\">",
"      James P, Trenery J. Ultrasound localisation and removal of non-palpable Implanon implants. Aust N Z J Obstet Gynaecol 2006; 46:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3512/abstract/30\">",
"      Shulman LP, Gabriel H. Management and localization strategies for the nonpalpable Implanon rod. Contraception 2006; 73:325.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3266 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-8AD9A5E0CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_27_3512=[""].join("\n");
var outline_f3_27_3512=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2346895\">",
"      ACTIONS AND INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16205996\">",
"      General population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16205961\">",
"      Overweight and obese women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16205989\">",
"      Women taking certain medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SIDE EFFECTS AND ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INSERTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2347974\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Position the patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Administer anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Insert",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Verify placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Post insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      REMOVAL AND RETURN OF OVULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Difficult removals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      REINSERTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3266\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3266|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/2/44078\" title=\"figure 1\">",
"      Etonogestrel implant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/12/22735\" title=\"figure 2\">",
"      Nexplanon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/16/30989\" title=\"figure 3\">",
"      Effect of weight on serum etonogestrel levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/25/400\" title=\"figure 4\">",
"      Insertion track",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/42/38567\" title=\"figure 5\">",
"      Insertion of Nexplanon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/12/14542\" title=\"figure 6\">",
"      Etonogestrel levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/50/2850\" title=\"figure 7\">",
"      Removal of etonogestrel contraceptive implant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/14/19694\" title=\"figure 8\">",
"      Modified vasectomy forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/25/15760\" title=\"figure 9\">",
"      Arm position",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3266|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/56/41871\" title=\"movie 1\">",
"      Nexplanon insertion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3266|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/25/40350\" title=\"table 1\">",
"      WHO criteria for contraceptive use in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/13/12506\" title=\"table 2\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4233?source=related_link\">",
"      Contraception counseling for obese women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=related_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22698?source=related_link\">",
"      Management of unscheduled bleeding in women using contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/22/1378?source=related_link\">",
"      Patient information: Long-acting methods of birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=related_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_27_3513="Significance of minor red blood cell antibodies during pregnancy";
var content_f3_27_3513=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Significance of minor red blood cell antibodies during pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/27/3513/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/27/3513/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/27/3513/contributors\">",
"     Kenneth J Moise Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/27/3513/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/27/3513/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/27/3513/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/27/3513/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/27/3513/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor red blood cell (RBC) antibodies are immunoglobulins associated with RBC antigens other than ABO and Rh(D). They usually develop in response to exposure to foreign RBC antigens, but may occur naturally from exposure to bacteria or viruses. It is important to identify all RBC antibodies in pregnancy to determine whether there is a risk of hemolytic disease of the fetus or newborn and to facilitate crossmatching of maternal blood if an emergency transfusion is required at delivery.",
"   </p>",
"   <p>",
"    The significance of minor RBC antibodies during pregnancy will be reviewed here. Maternal-fetal ABO incompatibility, hemolytic disease of the newborn, and Rh alloimmunization are discussed elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=see_link&amp;anchor=H10#H10\">",
"       \"Red blood cell transfusions in the newborn\", section on 'Hemolytic disease of the newborn'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=see_link\">",
"       \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5464?source=see_link\">",
"       \"Management of pregnancy complicated by Rhesus (Rh) alloimmunization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link\">",
"       \"Prevention of Rh(D) alloimmunization\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor RBC antibodies are more common in reproductive age women than men because sensitization is often due to pregnancy-related events, such as fetomaternal transfusion and blood transfusion for postpartum hemorrhage.",
"   </p>",
"   <p>",
"    The type and frequency of RBC antibodies reported in the literature varies according to the population sampled and the time period when sampling was performed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/1\">",
"     1",
"    </a>",
"    ]. In a large prospective series including over 300,000 consecutive patients, approximately 1 percent of pregnant women had alloantibodies detected in the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/2\">",
"     2",
"    </a>",
"    ]. Of these, about 60 percent were not associated with a risk of hemolytic disease of the fetus and newborn; the remaining 40 percent consisted of anti-D antibodies (8 percent of the total) and non-anti-D antibodies associated with a risk of hemolytic disease of the fetus and newborn (32 percent of the total). The most common non-anti-D antibodies were anti-K and anti-c.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathogenesis of alloimmunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal RBC antibodies develop as a result of exposure to foreign RBC antigens via one or more of the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood transfusion",
"     </li>",
"     <li>",
"      Transplacental fetomaternal hemorrhage. This can occur in conjunction with any pregnancy (miscarriage, ectopic, stillbirth, live birth)",
"     </li>",
"     <li>",
"      Injection with needles contaminated with blood from another person",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Blood transfusion is the most frequent cause of sensitization to minor antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Fetomaternal hemorrhage, the most common cause of Rh(D) alloimmunization, can also cause sensitization to minor RBC antigens, as many of these antigens are expressed on the fetal erythrocyte by the end of the first trimester. Severe Rh(D) alloimmunization has been reported in intravenous drug abusers and, therefore, this mechanism is a potential cause of sensitization to other RBC antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Naturally occurring RBC antibodies are those which occur in the absence of exposure to foreign blood; anti-M and anti-N are the most common examples (other than anti-A and anti-B). Anti-M and anti-N may result from exposure to viruses or bacteria and are present in 2 to 3 percent of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/6\">",
"     6",
"    </a>",
"    ]. However, they are rare causes of hemolytic disease of the",
"    <span class=\"nowrap\">",
"     fetus/newborn",
"    </span>",
"    (see",
"    <a class=\"local\" href=\"#H10\">",
"     'MNS system'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathogenesis of fetal anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of fetal anemia is the same for both major and minor RBC antibodies. The predominant mechanism involves transplacental passage of a maternal IgG antibody directed against a fetal erythrocyte antigen. Red blood cell hemolysis is cell mediated, rather than a complement mediated. Kell alloimmunization involves an additional mechanism whereby erythropoiesis is suppressed at the level of the progenitor cell (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Kell blood group'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33241541\">",
"    <span class=\"h3\">",
"     Factors affecting risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody titer is a major factor affecting risk of development of fetal anemia, but not the only factor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antigen poorly expressed fetal red blood cells &mdash; Some IgG antibodies capable of causing significant hemolytic transfusion reactions in adults are not clinically important in the fetus because their corresponding antigens, Lu(b), Yt(a), and VEL, are not well developed at birth. Thus, even if the corresponding antibody is IgG and present in high titers, it will not attach to fetal or newborn RBCs after crossing the placenta.",
"     </li>",
"     <li>",
"      IgG subclass &mdash; Classifying IgG into its four known subclasses is not commonly performed, but the subclass is an important determinant of the clinical course. IgG1 antibodies tend to cross the placental barrier earlier in gestation and usually are responsible for greater morbidity prenatally; by comparison, IgG3 antibodies cross the placenta later in gestation, but tend to be more hemolytic than IgG1 antibodies, resulting in a more severe neonatal clinical course [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/7\">",
"       7",
"      </a>",
"      ]. IgG2 and IgG4 antibodies do not normally play a significant role in red cell hemolysis.",
"     </li>",
"     <li>",
"      Presence of a high risk antibody &mdash; Anti-Kell is commonly associated with severe hemolytic disease of the fetus and newborn; it causes both hemolytic disease and suppression of erythropoiesis. Rhesus antibodies anti-c and anti-E are other relatively common high risk antibodies. In a study of 110 pregnant mothers with 111 at-risk fetuses and maternal serum titers of 16 or greater, antibodies to D, K, E, and c were present in 84, 18, 8, and 3 fetuses, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IgM antibody &mdash; IgM antibodies do not cross the placenta, thus, they do not cause hemolytic disease of the fetus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MINOR ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following blood group systems have been associated with hemolytic disease of the fetus and newborn (HDFN), or are commonly detected on routine prenatal maternal blood screening. Serological issues regarding identification of these and other rare minor antibodies, and determining their clinical significance are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=see_link\">",
"     \"A primer of red blood cell antigens and antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Minor antibodies associated with HDFN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Kell blood group",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Kell blood group is the most common of the minor RBC antibodies. The major antigen of the Kell group is K; subgroups include k, Kp(a), Kp(b), Ko, Js(a), Js(b) and a large number of other rare associated antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/9\">",
"     9",
"    </a>",
"    ]. The K antigen is present in 9 percent of Caucasian blood donors. The genotype frequencies in Caucasians are approximately: Kk (8.7 percent), kk (91.1 percent), and KK (0.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/10\">",
"     10",
"    </a>",
"    ]. By comparison, the frequencies for African Americans are Kk (2 percent), kk (98 percent), and KK is rare.",
"   </p>",
"   <p>",
"    Anti-Kell antibodies are responsible for approximately 10 percent of cases of severe antibody-mediated anemia in fetuses and newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/11\">",
"     11",
"    </a>",
"    ]. In one large series of 20 affected fetuses and infants among 311 sensitized women, three fetuses required intrauterine fetal transfusions for severe anemia or hydrops, one required an early delivery and multiple neonatal exchange transfusions, four required neonatal exchange transfusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    phototherapy, and 12 did well without any treatment for anemia or hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned above, the mechanism of fetal anemia caused by anti-Kell antibodies (suppression of erythropoiesis) occurs in addition to cell mediated hemolysis. At the same level of fetal anemia, the fetus with Kell alloimmunization has a lower number of circulating reticulocytes and normoblasts and relatively low levels of serum and amniotic fluid bilirubin compared with the fetus with Rh(D) alloimmunization [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. This has been attributed to Kell antibody-mediated suppression of erythropoiesis at the progenitor cell level; cell-mediated hemolysis also occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. As a result, the titer of anti-Kell antibody in maternal serum and the amniotic fluid bilirubin level do not correlate well with the degree of fetal anemia. The suppressive effect of anti-Kell antibodies does not extend to fetal granulocyte or megakaryocyte progenitors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/14\">",
"     14",
"    </a>",
"    ]. Significant thrombocytopenia is uncommon, and possibly less common than in Rh(D) alloimmunization [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood transfusion may be the most common mode of Kell sensitization in reproductive age women, since Kell compatibility is not always considered when blood is crossmatched. In one series, for example, 8 of 12 Kell-sensitized women with Kell-positive babies had a prior blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/18\">",
"     18",
"    </a>",
"    ]. Ideally, women planning pregnancy should be transfused with Kell-negative blood, although this is not currently recommended by the AABB (formerly the American Association of Blood Banks), as it has not been proven cost-effective.",
"   </p>",
"   <p>",
"    The transfusion and obstetrical history should be reviewed in Kell positive women to assess possible modes and risk of sensitization. For a Caucasian woman who was sensitized after a transfusion, the chance the baby's father is Kell-positive (KK or Kk) is only 8.9 percent, thus there is only about a 4.5 percent chance the fetus will be Kell-positive and at risk from maternal antibodies. However, if she has not been transfused and was sensitized from a previous pregnancy with the same partner, then the father must be Kell-positive (KK or Kk) and there is an approximately 51 percent chance the fetus will be Kell-positive and potentially affected by maternal antibody.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Duffy blood group",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Duffy antigens are Fy(a) and Fy(b). They are encoded by codominant alleles giving the phenotypes Fy(a+b+), Fy(a-b-), Fy(a+b-), or Fy(a-b+). Only anti-Fy(a) antibody has been associated with HDFN, which may range from mild to severe [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/19\">",
"     19",
"    </a>",
"    ]. However, both anti-Fy(a) and anti-Fy(b) have been implicated in transfusion reactions. Of interest, 82 percent of blacks are Fy(a-b-) but carry the FYB gene which is expressed in lung, colon, and spleen but not RBCs (the Fy(a) and Fy(b) antigens are encoded by the FY*A and FY*B alleles) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/20\">",
"     20",
"    </a>",
"    ]. The absence of Fy(b) on the erythrocyte protects it from invasion from P. vivax malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24585?source=see_link&amp;anchor=H4#H4\">",
"     \"Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins\", section on 'Duffy blood group system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     MNS system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MNS system is associated with the M, N, S, s, and U antigens and 32 other rare antigens. Anti-M and anti-N are usually naturally occurring antibodies of no clinical significance. These antibodies are being detected more frequently in routine antibody screening with the advent of gel technologies. Anti-N may cause mild HDFN; anti-M rarely causes severe HDFN since it typically remains an IgM antibody. Severe fetal anemia is a possibility only when anti-M is present as high titer IgG antibodies at 37&ordm;C (ie, not room temperature) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/22-26\">",
"     22-26",
"    </a>",
"    ], although a case report of severe hemolysis and death associated with a low titer has been published [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mild to severe fetal and neonatal hemolytic anemia have been related to anti-S, -s, and -U antibodies. Therefore, fetuses of women with these antibodies at high titer are followed for HDFN (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Clinical management'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     P system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The P system consists of the P1 and P2 antigens, present in 79 and 21 percent of Caucasians, respectively. Women with the P2 antigen phenotype commonly produce anti-P1 antibodies, which are IgM antibodies that do not cross the placenta. Women with the very rare p phenotype can produce anti P1+P+P(k), an antibody that has been associated with severe fetal anemia and recurrent early pregnancy loss [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other minor RBC antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many other minor erythrocyte antibodies exist that have the potential for causing mild to severe fetal anemia and HDFN. With the exception of Kell sensitization, these antibodies are rarely present in pregnant women and usually remain at low titer (&le;4). Hemolysis in the fetus or newborn has been described in isolated case reports that have been compiled in tables by various authors for reference (",
"    <a class=\"graphic graphic_table graphicRef82434 graphicRef55421 graphicRef67208 \" href=\"UTD.htm?42/40/43663\">",
"     table 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Minor antibodies not associated with HDFN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal transfusion issues when Lewis or I antibodies are present are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=see_link\">",
"     \"A primer of red blood cell antigens and antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Lewis blood group",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Lewis antigens are Le(a), Le(b), and four rare associated antigens. These antigens are not intrinsic to the RBC membrane; they are carried on plasma glycosphingolipids and subsequently absorbed onto the erythrocyte. Antibodies to the Lewis antigens do",
"    <strong>",
"     NOT",
"    </strong>",
"    cause HDFN since they are IgM antibodies, which do not cross the placenta, and fetal blood does not contain the Lewis antigen, which develops later in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/10\">",
"     10",
"    </a>",
"    ]. Maternal titers and fetal assessment are unnecessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     I antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal and newborn RBCs strongly express the i antigen, with only small amounts of I antigen. In contrast, adult RBCs express the I antigen, with little or no i antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/29\">",
"     29",
"    </a>",
"    ]. Anti-I is a common autoantibody in adults that is usually only present at or below room temperature and usually does not cause hemolysis; it generally appears after an infection such as Mycoplasma pneumoniae. Anti-i is observed transiently in 50 percent of patients with infectious mononucleosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link\">",
"     \"Infectious mononucleosis in adults and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neither anti-I nor anti-i have been associated with fetal hemolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CLINICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited experience upon which to base management of pregnancies complicated by minor RBC antibodies. The American College of Obstetricians and Gynecologists advise that the care of patients with minor RBC antibodies should be the same as for women with Rh alloimmunization [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/30\">",
"     30",
"    </a>",
"    ]. The efficacy of this approach has been demonstrated in multiple series involving various minor RBC antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. Our general approach is illustrated in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef86945 \" href=\"UTD.htm?27/37/28240\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=see_link\">",
"     \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5464?source=see_link\">",
"     \"Management of pregnancy complicated by Rhesus (Rh) alloimmunization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Perform antibody screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine Rh(D) typing and screening for antibodies to RBC antigens should be performed early in pregnancy, typically at the first prenatal visit [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/31\">",
"     31",
"    </a>",
"    ]. The blood test is safe, accurate, and inexpensive and, if antibodies are identified, interventions are available for diagnosing severe fetal anemia and preventing fetal death in affected fetuses.",
"   </p>",
"   <p>",
"    It is not cost effective to repeat antepartum antibody screening in Rh(D)-positive women in whom the initial screen was negative; clinically significant late onset alloimmunization is rare (about 0.18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/32\">",
"     32",
"    </a>",
"    ]) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/2,31,33-36\">",
"     2,31,33-36",
"    </a>",
"    ]. Blood transfusion is the major cause.",
"   </p>",
"   <p>",
"    In contrast, Rh(D)-negative women should undergo another antibody screen at 24 to 28 weeks of gestation, prior to receiving Rh(D) immune globulin prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link\">",
"     \"Prevention of Rh(D) alloimmunization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Follow-up a positive antibody screen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A maternal antibody screen that is positive requires that the antibody be identified and characterized for its potential to cause HDFN. We suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determine whether the antibody has been associated with HDFN (",
"      <a class=\"graphic graphic_table graphicRef82434 graphicRef55421 graphicRef67208 \" href=\"UTD.htm?42/40/43663\">",
"       table 1A-C",
"      </a>",
"      ). If it has never been associated with HDFN, no further evaluation is indicated.",
"     </li>",
"     <li>",
"      If the antibody has been associated with HDFN, then determine the RBC antigen status of the biologic father of the fetus and his zygosity for the antigen causing alloimmunization. If he is antigen negative and paternity is assured, no further evaluation is indicated because the fetus must also be negative for the target antigen. Maternal sensitization must have occurred from a transfusion (including platelets), past pregnancy with a different partner, or use of shared needles.",
"     </li>",
"     <li>",
"      If the father is antigen positive (based on testing or a previous affected pregnancy with this partner) or status unknown, the fetus must be considered at risk of HDFN and further evaluation is indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Obtain a maternal indirect antiglobulin titer (indirect Coombs) to quantitate the level of IgG antibody.",
"     </li>",
"     <li>",
"      Assume the fetus is carrying the antigen and is at risk of HDFN if the father is homozygous for the RBC antigen. If he is heterozygous, the fetus has a 50 percent chance of being at risk. Fetal genotyping for the Kell blood group and Rh C, c, and E has been performed on cell free fetal DNA in maternal plasma [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/37-39\">",
"       37-39",
"      </a>",
"      ]. The accuracy of this procedure is well-established for the Rh(D) blood type and is now available for Rh(D) in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/40\">",
"       40",
"      </a>",
"      ]. Free fetal DNA typing for other red cell antigens is currently available only in Europe [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. Where available, determination of the fetal RBC antigen status is ideal since this information allows the clinician to appropriately monitor fetuses carrying the antigen and thus at risk of HDFN, and avoid monitoring for anemia in those not carrying the antigen and thus not at risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Follow-up titers and the critical titer",
"    </span>",
"    &nbsp;&mdash;&nbsp;A critical titer is that level of antibody below which no cases of severe HDFN have occurred in first sensitized pregnancies. Ideally, each laboratory should determine its own critical titer. In practice, most laboratories consider 16 the critical titer in the absence of standardized testing or outcome data. It is generally agreed that additional evaluation can be deferred at titers of 4 or below, a titer of 16 is borderline (rare cases of severe fetal anemia occur at this level), and at 32 additional evaluation is mandatory because there is a significant possibility of severe fetal anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/30,43\">",
"     30,43",
"    </a>",
"    ]. However, some experts recommend 8 as the critical titer in Kell-sensitized pregnancies because of the unique pathogenesis of this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/12,44,45\">",
"     12,44,45",
"    </a>",
"    ]; we agree with using a lower threshold in these pregnancies (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Kell blood group'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    As long as the antibody titer remains below the critical titer, additional evaluation can be deferred and the patient evaluated with serial antibody titers. The interval between titers varies from two to four weeks, depending upon the level of the titer and gestational age. Titers should be drawn more frequently when the titer is borderline or rising and in the third trimester when the risk of erythroblastosis is highest. It is not necessary to perform serial titers before 18 to 20 weeks of gestation because of the low risk of severe fetal anemia early in pregnancy.",
"   </p>",
"   <p>",
"    If the critical titer is reached, amniotic fluid analysis through amniocentesis should be obtained to determine the fetal blood type if the father is heterozygous for the antigen responsible for alloimmunization [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. After the critical titer has been reached, the fetus has been identified as at risk of severe HDFN and following titers is no longer useful; the fetus should then be evaluated for fetal anemia. Following titers is also not predictive of fetal status after a previous pregnancy in which the fetus was severely anemic. All of these cases are at high risk for recurrence and should have fetal blood type determined and, if the fetus is at risk, the fetus should be evaluated for anemia. As discussed above, noninvasive free fetal DNA typing for non-Rh(D) red cell antigens is ideal, but not currently available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Assessing for fetal anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler assessment of the fetal middle cerebral artery (MCA) peak systolic velocity (PSV) has emerged as the best tool for the determination of fetal anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/8,48-51\">",
"     8,48-51",
"    </a>",
"    ]. This test is based on the principle that the anemic fetus preserves oxygen delivery to the brain by increasing cerebral flow of this low viscosity blood. The sensitivity of increased MCA-PSV (above 1.5 multiples of the median [MoMs]) for the prediction of moderate or severe anemia is approximately 100 percent, either in the presence or absence of hydrops, with a false positive rate of 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast to amniotic fluid bilirubin levels, this sensitivity is independent of the cause of the anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/49\">",
"     49",
"    </a>",
"    ]. Use of amniotic fluid delta OD450 as an indirect measure of fetal hemolysis is a less desirable alternative approach, as it is invasive and less sensitive and specific [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/50\">",
"     50",
"    </a>",
"    ]. Doppler evaluation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5464?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of pregnancy complicated by Rhesus (Rh) alloimmunization\", section on 'Middle cerebral artery-peak systolic velocity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A discussion of fetal blood sampling and therapy, and fetal surveillance is beyond the scope of this review. As discussed above, the care of patients sensitized to minor RBC antigens (except Kell, see below) should be the same as for women with Rh(D) alloimmunization, which is reviewed in detail elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=see_link\">",
"     \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Kell sensitized pregnancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, some experts, including ourselves, recommend 8 as the critical titer in Kell-sensitized pregnancies because of the unique pathogenesis of this disorder. Others believe no threshold can be designated to accurately predict absence of severe fetal anemia (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Kell blood group'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/12,44,45\">",
"     12,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doppler assessment of the fetal MCA-PSV is the preferred tool for determination of fetal anemia in Kell sensitized pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/48,52\">",
"     48,52",
"    </a>",
"    ]. Use of amniotic fluid delta OD450 as an indirect measure of fetal hemolysis in these cases is problematic. Interpretation of delta OD450 is less accurate for assessing anemia in the Kell-positive fetus compared to the Rh(D)-positive fetus because suppression of erythropoiesis rather than hemolysis (which generates bilirubin) is the more prominent cause of anemia in Kell antibody-mediated fetal anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/14,44\">",
"     14,44",
"    </a>",
"    ]. Cases have been reported in which serial delta OD450 values were declining and the fetus subsequently developed hydrops [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/53\">",
"     53",
"    </a>",
"    ]. However, if MCV-PSA is not available, then amniocentesis is used to monitor the fetus.",
"   </p>",
"   <p>",
"    If MCA-PSV is above 1.5 MoMs, then cordocentesis for fetal",
"    <span class=\"nowrap\">",
"     hematocrit/hemoglobin",
"    </span>",
"    and confirmation of blood type should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of pregnancies complicated by alloimmunization has been excellent since the introduction of intravascular techniques for fetal assessment and transfusion. Combined data from several studies that included only cases managed by intravascular fetal transfusion reported fetal survival for nonhydropic and hydropic fetuses of 94 and 74 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/54\">",
"     54",
"    </a>",
"    ]. Comparable data have been presented for Kell-sensitized pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/12\">",
"     12",
"    </a>",
"    ], although some series report a lower survival rate for HDFN due to Kell sensitization than for Rhesus sensitization [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term outcome of survivors of erythroblastosis is associated with an incidence of neurodevelopmental impairment of approximately 4.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/56\">",
"     56",
"    </a>",
"    ]. In a series of 291 children followed to a median age of 8.2 years, 2.1 percent were noted to have cerebral palsy, 3.1 percent exhibited severe developmental delay and 1 percent experienced bilateral deafness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13210?source=see_link&amp;anchor=H33#H33\">",
"     \"Intrauterine fetal transfusion of red blood cells\", section on 'Outcome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=see_link\">",
"     \"Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PREPREGNANCY COUNSELING AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a nonpregnant woman is found to have an anti-RBC antibody, she should be counseled regarding the potential effects of the antibody on a future pregnancy. If the biologic father of the future pregnancy is known, it is reasonable to determine his RBC antigen status and zygosity (if he carries the RBC antigen to which the patient is immunized). A low maternal prepregnancy titer is not predictive of fetal outcome since the titer can rise several-fold during pregnancy. On the other hand, a past history of HDFN or high maternal antibody titer is predictive of adverse fetal outcome.",
"   </p>",
"   <p>",
"    There are only three interventions which can be used to prevent HDFN: (1) donor insemination with sperm from a RBC-antigen compatible donor, (2) if the biologic father is heterozygous for the relevant RBC antigen, in vitro fertilization with preimplantation genetic diagnosis and implantation of only embryos with a compatible blood type, if any are produced, and (3) surrogate pregnancy using the patient's ovum and her partner's sperm [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3513/abstract/57\">",
"     57",
"    </a>",
"    ]. Generally the disadvantages of these procedures outweigh the benefits in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minor red blood cell (RBC) antibodies are immunoglobulins associated with RBC antigens other than ABO and Rh (ie, C, c, D, E, e). They usually develop in response to exposure to foreign RBC antigens, but some result from exposure to bacteria or viruses. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal alloimmunization can result from therapeutic blood transfusion, fetomaternal transfusion of blood, or injection with needles contaminated with blood from another person. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis of alloimmunization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The predominant mechanism of fetal anemia involves placental transfer of maternal IgG alloantibodies directed against one or more RBC antigens carried by the fetus. Some antibodies that are capable of causing significant hemolytic transfusion reactions in adults are not clinically important in the fetus because their corresponding antigens are not well developed at birth. IgM antibodies do not cross the placenta, thus, they do not cause fetal anemia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis of fetal anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend screening women for antibodies to RBC antigens early in pregnancy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). It is not cost effective to repeat antepartum antibody screening in Rh(D)-positive women in whom the initial screen was negative, given that clinically significant new alloimmunization is rare. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Perform antibody screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a maternal alloantibody is identified, the risk for hemolytic disease of the fetus and newborn should be determined (",
"      <a class=\"graphic graphic_table graphicRef82434 graphicRef55421 graphicRef67208 \" href=\"UTD.htm?42/40/43663\">",
"       table 1A-C",
"      </a>",
"      ). Paternal typing is indicated if the fetus is at risk. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Follow-up a positive antibody screen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A critical titer is that level of maternal antibody below which no cases of severe hemolytic disease of the fetus and newborn have occurred in first sensitized pregnancies. When the critical titer is reached and in women with a history of a previous severely anemic fetus, maternal titers are not useful for fetal assessment. All of these cases should have fetal blood type determined by amniocentesis and, if the fetus is at risk of hemolytic disease, it should be evaluated for anemia. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Follow-up titers and the critical titer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Doppler assessment of the fetal middle cerebral artery (MCA) peak systolic velocity (PSV) is the best method for monitoring fetuses for at high risk of anemia. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Assessing for fetal anemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/1\">",
"      Geifman-Holtzman O, Wojtowycz M, Kosmas E, Artal R. Female alloimmunization with antibodies known to cause hemolytic disease. Obstet Gynecol 1997; 89:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/2\">",
"      Koelewijn JM, Vrijkotte TG, van der Schoot CE, et al. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion 2008; 48:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/3\">",
"      Queenan JT, Smith BD, Haber JM, et al. Irregular antibodies in the obstetric patient. Obstet Gynecol 1969; 34:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/4\">",
"      Koelewijn JM, Vrijkotte TG, de Haas M, et al. Risk factors for the presence of non-rhesus D red blood cell antibodies in pregnancy. BJOG 2009; 116:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/5\">",
"      Bowman J, Harman C, Manning F, et al. Intravenous drug abuse causes Rh immunization. Vox Sang 1991; 61:96.",
"     </a>",
"    </li>",
"    <li>",
"     Laros, RK. Erythroblastosis fetalis. In: Blood Disorders in Pregnancy, Laros, RK (Ed), Lea &amp; Febiger 1986. p.106.",
"    </li>",
"    <li>",
"     Schanfield, MS. Human immunoglobulin (IgG) subclasses and their biologic properties. In: Blood Bank Immunology, American Association of Blood Banks, Washington, DC, 1977, p. 97.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/8\">",
"      Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342:9.",
"     </a>",
"    </li>",
"    <li>",
"     Reid, ME, Toy, PTCY. Erythrocyte blood groups in transfusion. In: Hematology of Infancy and Childhood, 5th ed, Nathan, DG, Orkin SH (Eds), WB Saunders, Philadelphia, 1998. p. 1761.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/10\">",
"      Weinstein L. Irregular antibodies causing hemolytic disease of the newborn: a continuing problem. Clin Obstet Gynecol 1982; 25:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/11\">",
"      Vaughan JI, Warwick R, Letsky E, et al. Erythropoietic suppression in fetal anemia because of Kell alloimmunization. Am J Obstet Gynecol 1994; 171:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/12\">",
"      Bowman JM, Pollock JM, Manning FA, et al. Maternal Kell blood group alloimmunization. Obstet Gynecol 1992; 79:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/13\">",
"      Weiner CP, Widness JA. Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia. Am J Obstet Gynecol 1996; 174:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/14\">",
"      Vaughan JI, Manning M, Warwick RM, et al. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med 1998; 338:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/15\">",
"      Daniels G, Hadley A, Green CA. Causes of fetal anemia in hemolytic disease due to anti-K. Transfusion 2003; 43:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/16\">",
"      van den Akker ES, Klumper FJ, Brand A, et al. Kell alloimmunization in pregnancy: associated with fetal thrombocytopenia? Vox Sang 2008; 95:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/17\">",
"      van den Akker ES, de Haan TR, Lopriore E, et al. Severe fetal thrombocytopenia in Rhesus D alloimmunized pregnancies. Am J Obstet Gynecol 2008; 199:387.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/18\">",
"      Caine ME, Mueller-Heubach E. Kell sensitization in pregnancy. Am J Obstet Gynecol 1986; 154:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/19\">",
"      Hughes LH, Rossi KQ, Krugh DW, O'Shaughnessy RW. Management of pregnancies complicated by anti-Fy(a) alloimmunization. Transfusion 2007; 47:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/20\">",
"      Chaudhuri A, Polyakova J, Zbrzezna V, Pogo AO. The coding sequence of Duffy blood group gene in humans and simians: restriction fragment length polymorphism, antibody and malarial parasite specificities, and expression in nonerythroid tissues in Duffy-negative individuals. Blood 1995; 85:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/21\">",
"      Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 1976; 295:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/22\">",
"      De Young-Owens A, Kennedy M, Rose RL, et al. Anti-M isoimmunization: management and outcome at the Ohio State University from 1969 to 1995. Obstet Gynecol 1997; 90:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/23\">",
"      Matsumoto H, Tamaki Y, Sato S, Shibata K. A case of hemolytic disease of the newborn caused by anti-M: serological study of maternal blood. Acta Obstet Gynaecol Jpn 1981; 33:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/24\">",
"      Furukawa K, Nakajima T, Kogure T, et al. Example of a woman with multiple intrauterine deaths due to anti-M who delivered a live child after plasmapheresis. Exp Clin Immunogenet 1993; 10:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/25\">",
"      Duguid JK, Bromilow IM, Entwistle GD, Wilkinson R. Haemolytic disease of the newborn due to anti-M. Vox Sang 1995; 68:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/26\">",
"      Kanra T, Y&uuml;ce K, Ozcebe IU. Hydrops fetalis and intrauterine deaths due to anti-M. Acta Obstet Gynecol Scand 1996; 75:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/27\">",
"      Wikman A, Edner A, Gryfelt G, et al. Fetal hemolytic anemia and intrauterine death caused by anti-M immunization. Transfusion 2007; 47:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/28\">",
"      Levine P. Comments on hemolytic disease of newborn due to anti-PP1 P k (anti-Tj a). Transfusion 1977; 17:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/29\">",
"      MARSH WL. Anti-i: a cold antibody defining the Ii relationship in human red cells. Br J Haematol 1961; 7:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/30\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 75: Management of alloimmunization during pregnancy. Obstet Gynecol 2006; 108:457.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics and the American College of Obstetricians and Gynecologists. Guidelines for Perinatal Care. 2012; 7th ed. Elk Grove Village, Illinois: AAP; Washington, DC: ACOG.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/32\">",
"      Judd WJ. When should tests for unexpected antibodies be done during pregnancy? Transfusion 2011; 51:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/33\">",
"      Andersen AS, Praetorius L, J&oslash;rgensen HL, et al. Prognostic value of screening for irregular antibodies late in pregnancy in rhesus positive women. Acta Obstet Gynecol Scand 2002; 81:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/34\">",
"      Adeniji AA, Fuller I, Dale T, Lindow SW. Should we continue screening rhesus D positive women for the development of atypical antibodies in late pregnancy? J Matern Fetal Neonatal Med 2007; 20:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/35\">",
"      Rothenberg JM, Weirermiller B, Dirig K, et al. Is a third-trimester antibody screen in Rh+ women necessary? Am J Manag Care 1999; 5:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/36\">",
"      Heddle NM, Klama L, Frassetto R, et al. A retrospective study to determine the risk of red cell alloimmunization and transfusion during pregnancy. Transfusion 1993; 33:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/37\">",
"      Finning K, Martin P, Summers J, Daniels G. Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion 2007; 47:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/38\">",
"      Li Y, Finning K, Daniels G, et al. Noninvasive genotyping fetal Kell blood group (KEL1) using cell-free fetal DNA in maternal plasma by MALDI-TOF mass spectrometry. Prenat Diagn 2008; 28:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/39\">",
"      Gutensohn K, M&uuml;ller SP, Thomann K, et al. Diagnostic accuracy of noninvasive polymerase chain reaction testing for the determination of fetal rhesus C, c and E status in early pregnancy. BJOG 2010; 117:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/40\">",
"      Brown, S, Kellner, LH, Munson, M, et al. Non-invasive prenatal testing: technical strategies to achieve testing of cell free fetal DNA (CFFDNA) RhD genotype in a clincal lab. Am J Obstet Gynecol 2007; 167:S173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/41\">",
"      Scheffer PG, van der Schoot CE, Page-Christiaens GC, de Haas M. Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience. BJOG 2011; 118:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/42\">",
"      Geifman-Holtzman O, Grotegut CA, Gaughan JP, et al. Noninvasive fetal RhCE genotyping from maternal blood. BJOG 2009; 116:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/43\">",
"      Spinnato JA. Hemolytic disease of the fetus: a plea for restraint. Obstet Gynecol 1992; 80:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/44\">",
"      McKenna DS, Nagaraja HN, O'Shaughnessy R. Management of pregnancies complicated by anti-Kell isoimmunization. Obstet Gynecol 1999; 93:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/45\">",
"      van Wamelen DJ, Klumper FJ, de Haas M, et al. Obstetric history and antibody titer in estimating severity of Kell alloimmunization in pregnancy. Obstet Gynecol 2007; 109:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/46\">",
"      Spence WC, Maddalena A, Demers DB, Bick DP. Prenatal determination of genotypes Kell and Cellano in at-risk pregnancies. J Reprod Med 1997; 42:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/47\">",
"      Bennett PR, Le Van Kim C, Colin Y, et al. Prenatal determination of fetal RhD type by DNA amplification. N Engl J Med 1993; 329:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/48\">",
"      van Dongen H, Klumper FJ, Sikkel E, et al. Non-invasive tests to predict fetal anemia in Kell-alloimmunized pregnancies. Ultrasound Obstet Gynecol 2005; 25:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/49\">",
"      Mari G. Middle cerebral artery peak systolic velocity: is it the standard of care for the diagnosis of fetal anemia? J Ultrasound Med 2005; 24:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/50\">",
"      Oepkes D, Seaward PG, Vandenbussche FP, et al. Doppler ultrasonography versus amniocentesis to predict fetal anemia. N Engl J Med 2006; 355:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/51\">",
"      Moise KJ Jr. The usefulness of middle cerebral artery Doppler assessment in the treatment of the fetus at risk for anemia. Am J Obstet Gynecol 2008; 198:161.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/52\">",
"      Rimon E, Peltz R, Gamzu R, et al. Management of Kell isoimmunization--evaluation of a Doppler-guided approach. Ultrasound Obstet Gynecol 2006; 28:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/53\">",
"      Berkowitz RL, Beyth Y, Sadovsky E. Death in utero due to Kell sensitization without excessive elevation of the delta OD450 value in amniotic fluid. Obstet Gynecol 1982; 60:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/54\">",
"      Schumacher B, Moise KJ Jr. Fetal transfusion for red blood cell alloimmunization in pregnancy. Obstet Gynecol 1996; 88:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/55\">",
"      van Kamp IL, Klumper FJ, Meerman RH, et al. Treatment of fetal anemia due to red-cell alloimmunization with intrauterine transfusions in the Netherlands, 1988-1999. Acta Obstet Gynecol Scand 2004; 83:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/56\">",
"      Lindenburg IT, Smits-Wintjens VE, van Klink JM, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. Am J Obstet Gynecol 2012; 206:141.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3513/abstract/57\">",
"      Seeho SK, Burton G, Leigh D, et al. The role of preimplantation genetic diagnosis in the management of severe rhesus alloimmunization: first unaffected pregnancy: case report. Hum Reprod 2005; 20:697.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6818 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_27_3513=[""].join("\n");
var outline_f3_27_3513=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathogenesis of alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathogenesis of fetal anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33241541\">",
"      - Factors affecting risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MINOR ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Minor antibodies associated with HDFN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Kell blood group",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Duffy blood group",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - MNS system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - P system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other minor RBC antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Minor antibodies not associated with HDFN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Lewis blood group",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - I antigens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CLINICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Perform antibody screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Follow-up a positive antibody screen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Follow-up titers and the critical titer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Assessing for fetal anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Kell sensitized pregnancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PREPREGNANCY COUNSELING AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6818\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6818|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?27/37/28240\" title=\"algorithm 1\">",
"      Algorithm for management of the red cell alloimmunized pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6818|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/25/12702\" title=\"table 1A\">",
"      Non RhD antibodies and HDFN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/4/15437\" title=\"table 1B\">",
"      Minor RBC antibodies pregnancy1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/37/7773\" title=\"table 1C\">",
"      Minor RBC antibodies pregnancy2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13210?source=related_link\">",
"      Intrauterine fetal transfusion of red blood cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5464?source=related_link\">",
"      Management of pregnancy complicated by Rhesus (Rh) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=related_link\">",
"      Overview of Rhesus (Rh) alloimmunization in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=related_link\">",
"      Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24585?source=related_link\">",
"      Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=related_link\">",
"      Red blood cell transfusions in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_27_3514="Gamma hydroxybutyrate (GHB) dependence and withdrawal";
var content_f3_27_3514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gamma hydroxybutyrate (GHB) dependence and withdrawal",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/27/3514/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/27/3514/contributors\">",
"     Deborah L Zvosec, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/27/3514/contributors\">",
"     Stephen W Smith, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/27/3514/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/27/3514/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/27/3514/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/27/3514/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/27/3514/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/27/3514/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma hydroxybutyrate (GHB) is a drug of abuse that is used for its euphoric, stimulant, sedative, and sexual effects. Gamma butyrolactone (GBL) and 1,4 butanediol (BD) are analogs or precursors of GHB which, when ingested, are rapidly metabolized to GHB, with the same clinical effects. All three compounds, GHB, GBL and BD, are used as dietary &ldquo;supplements&rdquo; for purported health benefits, including bodybuilding and treatment of insomnia, anxiety, and alcohol dependence. Tolerance, psychological and physical dependence, and withdrawal have been reported among individuals using GHB, GBL, and BD for both recreational purposes and purported health benefits. [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/1-9\">",
"     1-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GHB is also used as a therapeutic agent in the United States and Europe. In the US, GHB is available as Xyrem&reg; (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15990?source=see_link\">",
"     sodium oxybate",
"    </a>",
"    ), which has been approved by the Food and Drug Administration (FDA) for treatment of narcolepsy with cataplexy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    excessive daytime sleepiness. In Europe, GHB is available as Xyrem&reg;, as Alcover&reg;, which has been studied for treatment of alcohol and drug dependence, and as Somsanit&reg;, which has been approved as an anaesthetic. Craving, abuse, dependence, and withdrawal have been reported in therapeutic trials in which",
"    <span class=\"nowrap\">",
"     GHB/Alcover&reg;",
"    </span>",
"    was administered under close supervision [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/10-12\">",
"     10-12",
"    </a>",
"    ], as well as among patients treated with Xyrem&reg; [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The clinical features and management of GHB withdrawal are reviewed here. Acute intoxication with GHB and its management are discussed elsewhere, as is the general management of the poisoned patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31130?source=see_link\">",
"     \"Gamma hydroxybutyrate (GHB) intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Throughout this review we use the term \"GHB\" to refer to GHB and its analogs, GBL and BD, unless specifically noted. The pharmacology of GHB and its analogs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31130?source=see_link&amp;anchor=H3#H3\">",
"     \"Gamma hydroxybutyrate (GHB) intoxication\", section on 'Pharmacology and cellular toxicology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the absence of surveillance and systematic reporting mechanisms, little is known of the prevalence of chronic GHB abuse or dependence. Cases of GHB dependence and withdrawal have been reported in the United States (US), Canada, Europe, and Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/1-8,15-21\">",
"     1-8,15-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Texas Department of State Health Services has reported a steady increase in the number of patients admitted for treatment of GHB dependence, from 2 in 1998 to a peak of 113 in 2008 and 91 in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/22\">",
"     22",
"    </a>",
"    ]. According to this report, GHB dependent users were slightly older than other users of club drugs (average age 29 to 32 years), often had a history of injection drug use, and frequently had primary dependency problems with amphetamines or methamphetamines. Users also reported using GHB&rsquo;s sedative effects to counteract the stimulant effects of methamphetamine, and vice versa. Combined data from Texas and the California Poison Control System (CPCS) suggest that GHB dependence is more common among men and occurs in a wide age range (17 to 60 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. According to CPCS data, common reasons for starting to use GHB are bodybuilding and treatment of insomnia.",
"   </p>",
"   <p>",
"    Although total exposures declined over the course of the CPCS study, the proportion of patients with severe outcomes from GHB withdrawal increased from 10 of 130 cases in 1999 to 2001 to 10 of 37 cases in 2002 to 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/23\">",
"     23",
"    </a>",
"    ]. Of 167 total cases, 80 (48 percent) were admitted to a hospital for treatment of withdrawal. The median hospital stay was three days, with 27 of 80 (34 percent) admitted for five or more days. A review of 38 cases of withdrawal from GHB reported a mean duration of nine days (range 3 to 15) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY, CELLULAR TOXICOLOGY, AND PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacology, cellular toxicology, and kinetics of gamma hydroxybutyrate are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31130?source=see_link&amp;anchor=H3#H3\">",
"     \"Gamma hydroxybutyrate (GHB) intoxication\", section on 'Pharmacology and cellular toxicology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31130?source=see_link&amp;anchor=H5#H5\">",
"     \"Gamma hydroxybutyrate (GHB) intoxication\", section on 'Kinetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In brief, GHB exerts agonist effects on GHB-specific receptors and on GABA-B receptors resulting in neuroinhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/25\">",
"     25",
"    </a>",
"    ]. Similar to frequent ethanol and benzodiazepine use, chronic GHB use is believed to lead to tolerance associated with down-regulation of inhibitory GABA and GHB receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2,26-28\">",
"     2,26-28",
"    </a>",
"    ]. Subsequent decreased GHB consumption results in decreased GABA- and GHB-mediated neuroinhibition, resulting in unopposed excitatory neurotransmission (glutamate, norepinephrine and dopamine systems) and the onset of a withdrawal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2,27\">",
"     2,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gamma butyrolactone (GBL) and 1,4 butanediol (BD) are GHB analogs that are rapidly metabolized to GHB after ingestion, with the same toxic and recreational effects. Addicts use the three compounds interchangeably. GHB tolerance, dependence, and withdrawal develop subsequent to chronic BD and GBL use and manifest with the same symptomatology as GHB dependence and withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/5,6,9,29\">",
"     5,6,9,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF WITHDRAWAL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11176244\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients withdrawing from GHB may present specifically for treatment of withdrawal symptoms or may develop symptoms of withdrawal while in the emergency department (ED), hospital, or intensive care unit (ICU) after presenting with acute GHB intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/9\">",
"     9",
"    </a>",
"    ], trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/3\">",
"     3",
"    </a>",
"    ], or other unrelated medical conditions. GHB withdrawal can also occur in patients admitted to psychiatric, detoxification, and correctional facilities [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/5,17\">",
"     5,17",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Questionnaire data collected from 52 patients with a history of GHB dependency lasting from 1.5 to 6 years found that 26 (50 percent) had a combined 57 ED presentations for acute overdose or associated trauma, 49 (94 percent) reported experiencing multiple episodes of overdose involving loss of consciousness, and eighteen (35 percent) had sustained injuries from falls, including 18 head and facial injuries requiring medical treatment, 7 extremity fractures, and 14 extremity sprains [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/1,30\">",
"     1,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31130?source=see_link&amp;anchor=H9403071#H9403071\">",
"     \"Gamma hydroxybutyrate (GHB) intoxication\", section on 'GHB-associated trauma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many individuals who are dependent on GHB take doses throughout the day and night to prevent the onset of withdrawal and therefore are at increased risk of GHB toxicity, sudden loss of consciousness, and falls and other trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/9,16,30,31\">",
"     9,16,30,31",
"    </a>",
"    ]. GHB dependent individuals are at significant risk for impaired driving and motor vehicle collisions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. The diagnosis and management of GHB intoxication is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31130?source=see_link\">",
"     \"Gamma hydroxybutyrate (GHB) intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15398272\">",
"    <span class=\"h2\">",
"     Risk factors for development of GHB dependence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of gamma hydroxybutyrate (GHB) for bodybuilding or to treat insomnia may increase the risk for dependence. According to data from United States&rsquo; poison control centers, such use was four times greater among GHB users who developed dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GHB &ldquo;supplements&rdquo; have been promoted as non-addictive and have included directions to take daily and nightly doses for optimal anabolic effects. There are multiple case reports of bodybuilders who develop dependence on GHB [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2,6,33,34\">",
"     2,6,33,34",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Likewise, there are multiple case reports of individuals who use GHB &ldquo;supplements&rdquo; and street products, subsequently use the drug to treat insomnia, and then ultimately develop dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/8,21,35-37\">",
"     8,21,35-37",
"    </a>",
"    ]. In one such study, 44 percent of individuals who began using GHB for purported health benefits subsequently used the drug to treat insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cases of GHB abuse and dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/14\">",
"     14",
"    </a>",
"    ], severe withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/13\">",
"     13",
"    </a>",
"    ], and death [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/38\">",
"     38",
"    </a>",
"    ] have been reported among patients prescribed Xyrem&reg; for insomnia. Of note,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15990?source=see_link\">",
"     sodium oxybate",
"    </a>",
"    (Xyrem&reg;) has not been approved by the United States Food and Drug Administration (FDA) for treatment of insomnia. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    A history of drug abuse and escalating dosing frequency also appear to be risk factors for the development of GHB dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dosing patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most gamma hydroxybutyrate (GHB)-dependent patients who develop withdrawal engage in frequent dosing (ie, every one to six hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/24\">",
"     24",
"    </a>",
"    ]. Nevertheless, some users report symptoms consistent with withdrawal after once nightly use for sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/1,6\">",
"     1,6",
"    </a>",
"    ] and following cessation of Xyrem&reg; (GHB) dosed twice nightly for treatment of cataplexy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. The effects of Xyrem&reg; cessation, including possible withdrawal, have not been prospectively evaluated in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dosing frequency among 14 reported GHB-dependent patients ranged from once or twice nightly to every 30 to 60 minutes around-the-clock [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2,5-7,9,29,33,35,43\">",
"     2,5-7,9,29,33,35,43",
"    </a>",
"    ]. Addicts report increased dosing due to the development of craving or tolerance, and ultimately chronic use to control symptoms of withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although many reported cases of withdrawal follow a history of use ranging from several months to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/24\">",
"     24",
"    </a>",
"    ], cases of severe withdrawal have occurred after use for as little as seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reported dose size among GHB-dependent patients ranges from 1 to 6 grams per dose, with daily totals ranging from 2 to 144 grams [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2,5,6,44\">",
"     2,5,6,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Common symptoms, onset, and course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of GHB withdrawal symptoms occurs rapidly, typically within one to six hours of cessation or significantly decreased dosing. Delirium may also develop rapidly, beginning within 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial symptoms most often include anxiety, tremor, diaphoresis, tachycardia, nausea, vomiting, and insomnia. Within 24 hours symptoms may progress to severe withdrawal, with refractory agitation, hallucinations, delusions, and delirium. The symptom course is often unpredictable: apparent initial improvement may be followed by dramatic deterioration or the recurrence of symptoms, including hallucinations, delirium, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2,5,45,46\">",
"     2,5,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Profound insomnia is common among patients with GHB withdrawal and has been reported to play a key role in ongoing use and relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/16,24,34,47\">",
"     16,24,34,47",
"    </a>",
"    ]. Severe insomnia, occurring prior to presentation and persisting for several days after hospitalization, despite the administration of antipsychotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ) and benzodiazepines, can occur and may exacerbate psychosis and delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/4,6,35,46\">",
"     4,6,35,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Significant variability has been noted in the presentation and treatment response of patients withdrawing from GHB [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/24,48\">",
"     24,48",
"    </a>",
"    ]. In a series of 38 patients with documented GHB withdrawal, the duration of symptoms ranged from 4 to 15 days (mean 9 days) and delirium occurred in 20 cases (53 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with more frequent and higher dosing experienced higher rates of delirium and more prolonged withdrawal. Delirium did not appear to be associated with years of total use or time since last use. The duration of severe withdrawal was 8 to 10 days. Treatment may require stays in the intensive care unit of up to 15 days and in-patient care for up to 32 days [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Specific signs and symptoms",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vital signs &ndash; Although tachycardia and hypertension have been reported, autonomic disturbances from GHB withdrawal may be mild to moderate, show only transient spikes, or be absent entirely, despite profound delirium and a protracted hospital stay [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2,27,43,50\">",
"       2,27,43,50",
"      </a>",
"      ]. This stands in contrast to the severe autonomic instability seen with delirium tremens in alcohol withdrawal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"       \"Management of moderate and severe alcohol withdrawal syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central nervous system (CNS) effects &ndash; Agitated delirium, including confusion, anxiety, agitation and combativeness, is common in early or mild GHB withdrawal. Hallucinations (auditory, visual, tactile, or olfactory), disorientation, paranoid delusions, and profound delirium may develop quickly, often within the first 24 hours, and may persist for up to 14 days [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/27\">",
"       27",
"      </a>",
"      ]. Recurrent hallucinosis has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/43,46,51\">",
"       43,46,51",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Tremor is an early and often persistent sign of GHB withdrawal [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/24,27\">",
"       24,27",
"      </a>",
"      ]. Increased muscle tone, including myoclonic jerks, hypertonia, cogwheel rigidity, and opisthotonos have been reported, as well as full body rigidity and intermittent flailing of extremities [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2,49,52\">",
"       2,49,52",
"      </a>",
"      ]. Tonic-clonic seizures have been reported in a small number of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/13,29,53\">",
"       13,29,53",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Wernicke-Korsakoff's disease has been reported in two GHB withdrawal patients. They exhibited gait ataxia, Cranial Nerve VI palsy, and altered mental status (confusion, hallucinations, and delirium). Thiamine was administered to both patients, but symptoms persisted for 5 to 10 days [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40328?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of the chronic neurologic complications of alcohol\", section on 'Wernicke's encephalopathy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40328?source=see_link&amp;anchor=H3#H3\">",
"       \"Overview of the chronic neurologic complications of alcohol\", section on 'Korsakoff's syndrome'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Occasional lateral, rotatory, and horizontal nystagmus have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/5,52,56\">",
"       5,52,56",
"      </a>",
"      ]. Diaphoresis is common in early or mild GHB withdrawal.",
"     </li>",
"     <li>",
"      Cardiovascular effects &ndash; Hypertension and tachycardia have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/24\">",
"       24",
"      </a>",
"      ]. Generally, autonomic instability tends to be mild to moderate [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2,27\">",
"       2,27",
"      </a>",
"      ]. An unspecified arrhythmia has been reported in one case [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/4\">",
"       4",
"      </a>",
"      ]. Diffuse ST segment changes on an electrocardiogram were reported in one case [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gastrointestinal symptoms &ndash; Gastrointestinal symptoms including nausea and vomiting [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2\">",
"       2",
"      </a>",
"      ], abdominal cramps [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/8,37\">",
"       8,37",
"      </a>",
"      ], diarrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/45\">",
"       45",
"      </a>",
"      ], constipation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/6,57\">",
"       6,57",
"      </a>",
"      ], and urinary retention [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/57\">",
"       57",
"      </a>",
"      ] have been reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe and refractory agitation increases the risk of hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation. Elevated creatine kinase levels have been reported in several cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/5,6,17,29,33,49\">",
"     5,6,17,29,33,49",
"    </a>",
"    ]. Pneumonia has been reported in patients with severe withdrawal hospitalized for extended periods [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2,33\">",
"     2,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lethality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death can occur from GHB withdrawal. Death from cardiac arrest was reported in a patient whose hospital course was complicated by pneumonia, persistent hallucinosis, and recurrent delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2\">",
"     2",
"    </a>",
"    ]. Another GHB-dependent male died while incarcerated; GHB withdrawal was untreated, resulting in severe rhabdomyolysis, hyperkalemia, and cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/58\">",
"     58",
"    </a>",
"    ]. A third GHB-dependent male died while hospitalized with concurrent trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/59\">",
"     59",
"    </a>",
"    ]. Deaths due to hydrocodone toxicity and water intoxication with resultant hyponatremia have occurred in patients attempting self-treatment of GHB withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma hydroxybutyrate (GHB) withdrawal is uncommon and the diagnosis is made clinically based upon the presence of typical symptoms in an individual with a known history of prolonged or habitual GHB abuse. Without obtaining a clear history of GHB abuse and discontinuation, the clinician must evaluate the patient for other, more common causes of agitated delirium, for which the differential diagnosis is broad. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of note, the autonomic disturbances associated with GHB withdrawal are typically mild when compared with withdrawal or acute intoxication syndromes associated with other sedative-hypnotic agents, alcohol, or sympathomimetic agents. Conversely, agitation and delirium is often prolonged with GHB withdrawal.",
"   </p>",
"   <p>",
"    The differential diagnosis of GHB withdrawal includes other sedative-hypnotic or alcohol withdrawal syndromes, acute GHB intoxication, acute intoxication with sympathomimetics (including drugs of abuse, ephedrine, ma huang,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    ), anticholinergic syndrome, hypoglycemia, seizure disorder, serotonin syndrome, thyroid storm, neuroleptic malignant syndrome, head injury, CNS infection (encephalitis, meningitis), and any of the medical etiologies of altered mental status, as well as functional psychosis. These topics are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Specific testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gas chromatography or mass spectrometry is necessary to detect gamma hydroxybutyrate (GHB). The results of such testing often require 7 to 10 days, precluding their use in acute management. Furthermore, the rapid disappearance of GHB in blood (four to six hours) means that blood levels are likely to be negative, unless the patient presents with acute intoxication and progresses directly into withdrawal. While confirmation of GHB in urine may confirm GHB ingestion and support the diagnosis, it is unlikely to be positive if the urine specimen is collected longer than 6 to 12 hours after ingestion. Laboratory confirmation is unnecessary for the diagnosis of GHB withdrawal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     General testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;GHB withdrawal is a clinical diagnosis; no laboratory tests are necessary. Tests are obtained on the basis of the history and examination to investigate alternative diagnoses or complications. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients withdrawing from GHB may suffer from poor nutrition and may experience symptoms, such as vomiting, hyperthermia, diaphoresis, and agitation, that increase their risk for rhabdomyolysis, renal failure, and other complications [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In patients experiencing GHB withdrawal, we generally obtain the following studies: basic electrolytes, BUN and creatinine, creatine kinase, and a complete blood count. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Coingestants are common among GHB abusers so it is reasonable to perform the basic studies done on all potentially poisoned patients, including fingerstick glucose,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and salicylate levels, electrocardiogram, and a pregnancy test in women of childbearing age. Additional studies are obtained as needed based upon the patient&rsquo;s presentation.",
"   </p>",
"   <p>",
"    Testing for other drugs of abuse can identify drug or alcohol codependency as well as the presence of alcohol, benzodiazepines, or opiates that may have been used for self-detoxification. Toxicologic screening may identify the presence of sympathomimetics, whose effects can mimic GHB withdrawal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of gamma hydroxybutyrate (GHB) withdrawal is primarily supportive, with administration of sedatives to control agitation, delirium, hyperthermia, and seizures, and careful monitoring for respiratory depression and potential complications.",
"   </p>",
"   <p>",
"    Early symptoms of anxiety, tremor, diaphoresis, insomnia, and tachycardia may progress rapidly to severe withdrawal delirium, requiring intensive care. Aggressive efforts to control agitation and delirium may require tracheal intubation and mechanical ventilation. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Severe withdrawal, with delirium'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Data on the management of GHB withdrawal is limited to individual case reports and small case series. The approach described below is based upon a review of this limited evidence and our clinical experience. Controlled prospective studies are needed to develop better protocols for the treatment of GHB withdrawal and dependence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Mild to moderate withdrawal, without delirium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have anxiety, insomnia, and tremor, but remain oriented and appropriately interactive (without delirium or hallucinations), are at less immediate risk for severe complications but may acutely progress to agitated delirium. We recommend in-patient detoxification for such patients.",
"   </p>",
"   <p>",
"    To prevent acute decompensation, it is important to treat patients' symptoms (eg, anxiety, tremor, diaphoresis, insomnia) aggressively with sedative-hypnotic agents.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     Diazepam",
"    </a>",
"    is an excellent choice. Intravenous diazepam can be titrated, but is more likely to result in respiratory depression than oral diazepam. Barbiturates such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/31/4601?source=see_link\">",
"     pentobarbital",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    can also be used.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    has been used successfully used in refractory cases. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Benzodiazepines'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Barbiturates'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Propofol'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Pulse oximetry or capnography monitoring of respiratory status is recommended while sedatives are given, especially if administered intravenously. Frequent monitoring of mental status and vital signs (approximately every two hours) should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link\">",
"     \"Carbon dioxide monitoring (capnography)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although out-patient management of mild withdrawal is performed, we believe it is safer to manage these patients in the hospital. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Outpatient detoxification'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Severe withdrawal, with delirium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe withdrawal increases the risk of self-harm and complications (eg, hyperthermia, rhabdomyolysis, seizures), and requires treatment with large doses of sedatives (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ). Therefore, close monitoring in an intensive care unit (ICU) is needed. Respiratory depression, due to the high doses of sedatives necessary to control the withdrawal state, may necessitate tracheal intubation and mechanical ventilation. Continuous cardiac and pulse oximetry monitoring are needed. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Complications'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'Benzodiazepines'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When intravenous sedatives are no longer necessary, the patient's agitation well controlled, and delirium resolved, the patient no longer requires ICU-level care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11174437\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines are the mainstay of treatment for GHB withdrawal and dependency. A long-acting benzodiazepine is recommended. We give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    10 mg IV every 5 to 10 minutes and titrate to restfulness [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/63\">",
"     63",
"    </a>",
"    ]. Patients with extreme agitation may require more frequent and larger doses. Very large doses may be given, provided respiratory status is closely monitored and tracheal intubation can be performed immediately if necessary. Massive doses of diazepam may be needed: in one case, dosing equivalents of 2655 mg of diazepam were administered over 90 hours for control of severe GHB withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/56\">",
"     56",
"    </a>",
"    ]. With less severe symptoms, treatment with oral diazepam may suffice.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     Diazepam",
"    </a>",
"    has a rapid onset of action (maximum effect in five minutes), but rapidly redistributes into adipose tissue, so its sedative effects may diminish rapidly, necessitating repeat doses until total body loading is achieved. Although loading doses (oral or IV) may not decrease the likelihood of withdrawal delirium, they reduce the severity of delirium and control agitation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/27\">",
"     27",
"    </a>",
"    ]. Once adequately loaded, patients generally need smaller additional amounts to control symptoms. Diazepam's high lipid solubility and slow metabolism and elimination create a long duration of action.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    have been used to treat GHB withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/27\">",
"     27",
"    </a>",
"    ]. There is no advantage to these agents over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Although symptom-triggered therapy protocols, similar to those used in the treatment of alcohol and benzodiazepine withdrawal, have not been validated for GHB withdrawal, we believe this is a reasonable approach and concur with the use of rapidly escalated doses until control of agitation or delirium is achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/61,62,64-66\">",
"     61,62,64-66",
"    </a>",
"    ]. The use of an alcohol or benzodiazepine withdrawal scale can aid in establishing a baseline and enabling ongoing assessment of symptoms and the response to sedatives (",
"    <a class=\"graphic graphic_table graphicRef64835 \" href=\"UTD.htm?20/61/21470\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once acute withdrawal symptoms are controlled, benzodiazepine treatment may be continued over several weeks in severe cases, with the dose gradually tapered [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/33\">",
"     33",
"    </a>",
"    ]. A general guideline for tapering is to reduce the daily dose approximately 10 percent per week. If symptoms recur, the previous week's dose is given. Benzodiazepines may be used alone or in combination with adjunctive treatments such as barbiturates or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    in cases of benzodiazepine resistance. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Barbiturates'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Propofol'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Barbiturates",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/31/4601?source=see_link\">",
"     pentobarbital",
"    </a>",
"    have been used successfully alone and in combination with benzodiazepines in the treatment of GHB withdrawal. Barbiturates are particularly useful in cases of GHB withdrawal resistant to benzodiazepines [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. If 200 mg of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    over 30 minutes fails to achieve control of agitation, it is reasonable to add a barbiturate or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    . Patients must be monitored closely for respiratory depression, particularly when barbiturates are administered with benzodiazepines.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    has a longer half-life than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/31/4601?source=see_link\">",
"     pentobarbital",
"    </a>",
"    and can be titrated for symptom control in increments of 250 mg IV to achieve a serum level of 5 to 15",
"    <span class=\"nowrap\">",
"     micrograms/mL.",
"    </span>",
"    Most patients require approximately 500 mg for immediate symptom control. Tapered oral doses of benzodiazepines and phenobarbital may then be utilized over several weeks until the patient has stabilized [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/31/4601?source=see_link\">",
"     Pentobarbital",
"    </a>",
"    may be titrated for symptom control in 100 to 200 mg IV increments [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/27\">",
"     27",
"    </a>",
"    ]. Some clinicians report administration of pentobarbital in accordance with their protocol for benzodiazepine-resistant ethanol withdrawal, utilizing 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV doses every 30 to 60 minutes, for symptom control [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Propofol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    has been used to treat delirium tremens from alcohol withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/68,69\">",
"     68,69",
"    </a>",
"    ], and refractory agitation in severe GHB withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2,9,43,70\">",
"     2,9,43,70",
"    </a>",
"    ]. It is used primarily in withdrawal patients who require mechanical ventilation for respiratory depression, and we adhere to this approach. Theoretically, intensive monitoring without mechanical ventilation is acceptable if airway management can be instituted at a moment's notice. In practice, this is rarely if ever advisable.",
"   </p>",
"   <p>",
"    An initial IV infusion of 5",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    per minute (0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour) for 5 to 10 minutes until the patient is sedated to the desired level is the recommended dosage for treatment of withdrawal. Sedation is maintained with infusion rates of 5 to 50",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    per minute, titrated to effect [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/62\">",
"     62",
"    </a>",
"    ]. Doses up to 80",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    per minute may be necessary to control refractory agitation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/43\">",
"     43",
"    </a>",
"    ]. Dosage must be titrated to symptom control with careful monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of cases of seizure associated with GHB withdrawal have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/13,29,53\">",
"     13,29,53",
"    </a>",
"    ]; additional reports document twitching and tonic-clonic movements.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    has been used anecdotally to treat such seizures. The dose given was 300 mg three times per day on day one, with the dose increased to 2 to 3 grams over the course of one week [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/4,27\">",
"     4,27",
"    </a>",
"    ]. We know of no reason to select gabapentin over a benzodiazepine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15398320\">",
"    <span class=\"h3\">",
"     Baclofen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     Baclofen",
"    </a>",
"    , a GABA B agonist, has been used for in-patient treatment of several patients with GHB withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/4,13\">",
"     4,13",
"    </a>",
"    ] and for out-patient treatment of patients with GBL dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/16\">",
"     16",
"    </a>",
"    ]. However, the independent effects of baclofen are difficult to determine because in all cases the drug was administered in conjunction with benzodiazepine and in two cases with additional therapies, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    , and valproic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/4\">",
"     4",
"    </a>",
"    ]. Further study is needed before baclofen can be recommended as a treatment for dependence or withdrawal from GHB or its analogues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Antihypertensives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension can occur with GHB withdrawal as a result of central sympathetic stimulation. Therefore, the treatment of hypertension is best accomplished by controlling such stimulation with sedatives (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Only preexisting essential hypertension should be managed using antihypertensive medications. Beta blocking medications are",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in GHB withdrawal. They are ineffective in treating or preventing withdrawal delirium and may worsen hypertension and coronary ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    and other neuroleptic agents are",
"    <strong>",
"     not",
"    </strong>",
"    recommended for the treatment of GHB withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/27,61\">",
"     27,61",
"    </a>",
"    ]. These agents are ineffective for the control of withdrawal symptoms and may have adverse effects, including dystonic reactions, anticholinergic effects, lowered seizure threshold, cardiac dysrhythmia, neuroleptic malignant syndrome, and hyperthermia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Restraints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical restraints may be necessary initially to control severe agitation and prevent injury to the patient and staff. Chemical restraint is much preferred, and physical restraints should be removed as soon as sedation is achieved. Appropriate monitoring is crucial, particularly while physical restraints are in place.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Vitamins and fluids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor nutrition and vitamin deficiencies may occur in GHB-dependent patients. Wernicke-Korsakoff syndrome has been reported in patients experiencing GHB withdrawal, abusing both GHB and alcohol, and using GHB to reduce alcohol intake [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/54,55,71\">",
"     54,55,71",
"    </a>",
"    ]. As with alcohol withdrawal, we recommend empiric treatment with thiamine, magnesium, and folate. Thiamine 100 mg may be given daily, with initial dose by injection, along with other vitamins as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40328?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the chronic neurologic complications of alcohol\", section on 'Wernicke's encephalopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40328?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the chronic neurologic complications of alcohol\", section on 'Korsakoff's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Poor nutrition and withdrawal symptoms (vomiting, diaphoresis, agitation) may contribute to fluid, glucose, and electrolyte imbalances, placing patients at increased risk for rhabdomyolysis, renal failure, and arrhythmias. Glucose, electrolytes, CPK, and fluid status should be evaluated and corrected. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Laboratory evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Outpatient detoxification",
"    </span>",
"    &nbsp;&mdash;&nbsp;We believe that treatment of GHB withdrawal and detoxification from GHB dependence should be performed in an in-patient setting. We feel the risks entailed in out-patient treatment are unacceptable [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/35\">",
"     35",
"    </a>",
"    ]. The clinical course of GHB withdrawal is variable and unpredictable, can entail prolonged delirium, and is potentially lethal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2\">",
"     2",
"    </a>",
"    ]. There are several reports of patients treated for GHB withdrawal with low doses of benzodiazepines and then discharged who have required readmission within 24 to 48 hours after representing in florid withdrawal and requiring chemical and physical restraints for prolonged periods [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2,6\">",
"     2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, on occasion, supervised out-patient detoxification may be necessary. Economic realities render some patients unable to pay for inpatient therapy, while others are unwilling to undergo in-patient detoxification. Supervised out-patient treatment is safer than unsupervised self-treatment, which has proven fatal in some instances [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Literature describing out-patient GHB detoxification is limited. In one case series, out-patient treatment of GBL-dependent patients was offered only to those patients who: (1) had a responsible adult at home capable of providing help; (2) were able to attend clinic for daily monitoring and dosage adjustment during the first two to three days of treatment; and (3) were not dependent on other drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/16\">",
"     16",
"    </a>",
"    ]. Management focused on preventing delirium by initiating treatment immediately at the first sign of withdrawal.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     Diazepam",
"    </a>",
"    was titrated to symptom control;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    was also given. Monitoring was performed with daily clinic appointments for three days followed by weekly appointments for four weeks. Although 15 of 17 patients completed out-patient treatment, study authors found outpatient management of withdrawal to be difficult due to erratic patient response to phone calls and missed clinic appointments. They also noted that many patients experienced post-withdrawal anxiety, panic attacks, depression, insomnia, and social withdrawal, with symptoms lasting weeks to months.",
"   </p>",
"   <p>",
"    One other outpatient protocol has been reported for the treatment of patients with mild GHB withdrawal (ie, no psychotic symptoms and vital signs that normalize rapidly with treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/72\">",
"     72",
"    </a>",
"    ]. This approach used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    as part of a symptom-driven substitution-taper protocol originally developed for sedative-hypnotic drug detoxification, along with other interventions, including relapse prevention training, counseling, medical and psychiatric services, and screening for drug use [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Persistent symptoms post-detoxification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few data exist on the long term effects of chronic GHB use. Impairment in recall has been reported subsequent to GHB detoxification, as well as tremor, depression, anxiety, and insomnia, which may persist for weeks or months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/4,33\">",
"     4,33",
"    </a>",
"    ]. Permanent cerebellar dysfunction has been attributed to chronic GHB abuse in one case [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     CHEMICAL DEPENDENCY TREATMENT AND RELAPSE PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little published data on the treatment of GHB dependency and its outcome. Reports suggest that relapse is common, sometimes within hours of discharge, and multiple detoxifications are often necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/4,9,20,48\">",
"     4,9,20,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relapse may be related to several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent symptoms of acute withdrawal in prematurely discharged patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intense cravings for GHB [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/10,11,67\">",
"       10,11,67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inability to remember the effects of severe GHB withdrawal, because of delirium, sedative agents, and denial [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Persistent depression, anxiety, and insomnia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/4,33\">",
"       4,33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Recurrence of preexisting psychiatric disorders (anxiety, depression, obsessive compulsive disorder) for which GHB was used for relief [",
"      <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adequate control of symptoms, including depression, anxiety, agitation, and insomnia, is imperative prior to discharge. Early and intensive involvement of psychiatric specialists is critical for prompt diagnosis and management of comorbid conditions. Appropriate psychiatric follow-up must be arranged. General management of drug abuse treatment is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intensive outpatient treatment for chemical dependency should be discussed as soon as possible with the patient and family members, and initiated immediately upon discharge. Such treatment may be needed immediately following detoxification, as denial may be profound, particularly in patients convinced of GHB's health benefits. Some recovering GHB addicts describe difficulties in treatment due to counselors' and other addicts' lack of familiarity with GHB and past promotion of GHB as natural, healthful, and nontoxic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PITFALLS IN MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple drug dependencies have been reported among GHB dependent users and these must be addressed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/62\">",
"     62",
"    </a>",
"    ]. Codependencies may result from concurrent recreational abuse of GHB and other drugs, or from use of benzodiazepines, alcohol, or opiates for self-treatment of GHB withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Conversely, GHB may be used as an alcohol or drug substitute, or for self-treatment of alcohol or drug dependence or withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/27/3514/abstract/2,5,54\">",
"     2,5,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Illicit use of gamma hydroxybutyrate (GHB) occurs for recreation and for a number of alleged health benefits, including bodybuilding and treatment of insomnia, generalized and social anxiety, and alcohol dependence. GHB use can lead to severe dependence. Cessation can lead to withdrawal, which may be lethal. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Onset of GHB withdrawal symptoms occurs rapidly, typically within one to six hours of cessation or decrease. Initial symptoms include anxiety, tremor, diaphoresis, tachycardia, vomiting, and insomnia. Insomnia can be profound. Within 24 hours symptoms may progress to severe withdrawal, with refractory agitation, hallucinations, delusions, and delirium. Delirium may develop rapidly and persist as long as 14 days. Symptom course often progresses unpredictably. Autonomic instability, if present, is usually mild to moderate. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features of withdrawal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe and refractory agitation increases the risk of hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of GHB withdrawal is made clinically based on the presence of typical symptoms in an individual with a known history of prolonged or habitual GHB abuse. Without such a history, the clinician must evaluate the patient for other, more common causes of agitated delirium, for which the differential diagnosis is broad. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"       \"Diagnosis of delirium and confusional states\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"       \"General approach to drug poisoning in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      No laboratory tests are necessary to diagnosis GHB withdrawal. Tests are obtained on the basis of the history and examination to investigate alternative diagnoses or complications. In patients experiencing GHB withdrawal, we generally obtain the following studies: basic electrolytes, BUN and creatinine, creatine kinase, and a complete blood count. Coingestants are common among GHB abusers so it is reasonable to perform the basic studies done on all potentially poisoned patients, including fingerstick glucose,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      and salicylate levels, electrocardiogram, and a pregnancy test in women of childbearing age. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of GHB withdrawal is primarily supportive, with administration of sedatives to control agitation, delirium, hyperthermia, and seizures, and careful monitoring for respiratory depression and potential complications. We suggest clinicians use long-acting benzodiazepines for the control of symptoms due to GHB withdrawal (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We give",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      10 mg IV every 5 to 10 minutes and titrate to restfulness. Patients with extreme agitation may require more frequent and larger doses. Very large doses may be administered, provided respiratory status is closely monitored and tracheal intubation can be performed immediately if necessary. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Benzodiazepines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      and other neuroleptic agents",
"      <strong>",
"       not",
"      </strong>",
"      be used in the treatment of GHB withdrawal (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Such agents are ineffective for symptom control and increase the risk for major adverse reactions. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Antipsychotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical course of withdrawal is unpredictable, even with optimal treatment. For this reason, patients with mild withdrawal are treated in an in-patient setting, while patients with severe withdrawal require admission to an intensive care unit. Management of withdrawal and dependency is reviewed in detail in the text. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/1\">",
"      Zvosec, DL, Smith, SW. Gamma hydroxybutyrate (GHB) addiction and withdrawal. From the GHB Addiction Study (Abstract). Ann Emerg Med 2004; 44:S91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/2\">",
"      Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001; 37:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/3\">",
"      Slagel B, Kingstone E, Bhalerao S. Gamma hydroxybutyrate withdrawal in an orthopedic trauma patient. Can J Psychiatry 2003; 48:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/4\">",
"      McDaniel CH, Miotto KA. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies. J Psychoactive Drugs 2001; 33:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/5\">",
"      Schneir AB, Ly BT, Clark RF. A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol. J Emerg Med 2001; 21:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/6\">",
"      Sivilotti ML, Burns MJ, Aaron CK, Greenberg MJ. Pentobarbital for severe gamma-butyrolactone withdrawal. Ann Emerg Med 2001; 38:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/7\">",
"      Trendelenburg G, Heinz A, Str&ouml;hle A. Gamma-hydroxybutyrate dependence with social phobia. Am J Psychiatry 2004; 161:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/8\">",
"      Mycyk MB, Wilemon C, Aks SE. Two cases of withdrawal from 1,4-Butanediol use. Ann Emerg Med 2001; 38:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/9\">",
"      Zvosec DL, Smith SW, McCutcheon JR, et al. Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 2001; 344:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/10\">",
"      Gallimberti L, Spella MR, Soncini CA, Gessa GL. Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence. Alcohol 2000; 20:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/11\">",
"      Addolorato G, Castelli E, Stefanini GF, et al. An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group. Alcohol Alcohol 1996; 31:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/12\">",
"      Addolorato G, Caputo F, Capristo E, et al. Gamma-hydroxybutyric acid efficacy, potential abuse, and dependence in the treatment of alcohol addiction. Alcohol 2000; 20:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/13\">",
"      LeTourneau JL, Hagg DS, Smith SM. Baclofen and gamma-hydroxybutyrate withdrawal. Neurocrit Care 2008; 8:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/14\">",
"      Wang YG, Swick TJ, Carter LP, et al. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med 2009; 5:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/15\">",
"      Miotto K, Darakjian J, Basch J, et al. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 2001; 10:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/16\">",
"      Bell J, Collins R. Gamma-butyrolactone (GBL) dependence and withdrawal. Addiction 2011; 106:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/17\">",
"      Stijnenbosch PJ, Zuketto C, Beijaert PJ, Maat A. [GHB withdrawal delirium]. Ned Tijdschr Geneeskd 2010; 154:A1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/18\">",
"      Addolorato G, Caputo F, Capristo E, Gasbarrini G. Diazepam in the treatment of GHB dependence. Br J Psychiatry 2001; 178:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/19\">",
"      Degenhardt L, Copeland J, Dillon P. Recent trends in the use of \"club drugs\": an Australian review. Subst Use Misuse 2005; 40:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/20\">",
"      O'Toole JG, Kristian MR, Devereux L, Kurien R. Gamma-hydroxybutyrate dependence in a rural setting in Wales. J Subst Abuse 2009; 14:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/21\">",
"      Wojtowicz JM, Yarema MC, Wax PM. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review. CJEM 2008; 10:69.",
"     </a>",
"    </li>",
"    <li>",
"     Maxwell JC. Substance Abuse Trends in Texas: June 2010: Addiction Research Institute, Gulf Coast Addiction Technology Transfer Center and U.T. Center for Social and Behavioral Research 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/23\">",
"      Anderson IB, Blanc PD, Kim SY, et al. Reports of gamma hydroxybutyrate (and precursor) dependence and withdrawal: A five-year review of Poison Control Center Data [abstract]. Clin Toxicol 2005; 43:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/24\">",
"      McDonough M, Kennedy N, Glasper A, Bearn J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004; 75:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/25\">",
"      Snead OC 3rd, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med 2005; 352:2721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/26\">",
"      Gianutsos G, Suzdak PD. Evidence for down-regulation of GABA receptors following long-term gamma-butyrolactone. Naunyn Schmiedebergs Arch Pharmacol 1984; 328:62.",
"     </a>",
"    </li>",
"    <li>",
"     Miotto K, Roth B. GHB withdrawal syndrome. Texas Commission on Alcohol and Drug Abuse. Austin, TX 2001. Available online at: file://www.dshs.state.tx.us/WorkArea/DownloadAsset.aspx?id=10417.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/28\">",
"      Van Sassenbroeck DK, De Paepe P, Belpaire FM, et al. Tolerance to the hypnotic and electroencephalographic effect of gamma-hydroxybutyrate in the rat: pharmacokinetic and pharmacodynamic aspects. J Pharm Pharmacol 2003; 55:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/29\">",
"      Catalano MC, Glass JM, Catalano G, et al. Gamma butyrolactone (GBL) withdrawal syndromes. Psychosomatics 2001; 42:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/30\">",
"      Zvosec, DL, Smith, SW. Acute complications of Gamma hydroxybutyrate addiction. (Abstract). Acad Emerg Med 2005; 12:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/31\">",
"      Bennett WR, Wilson LG, Roy-Byrne PP. Gamma-hydroxybutyric acid (GHB) withdrawal: a case report. J Psychoactive Drugs 2007; 39:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/32\">",
"      Couper FJ, Logan BK. Addicted to driving under the influence--a GHB/GBL case report. J Anal Toxicol 2004; 28:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/33\">",
"      Rosenberg MH, Deerfield LJ, Baruch EM. Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: recommendations for management. Am J Drug Alcohol Abuse 2003; 29:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/34\">",
"      Herold AH, Sneed KB. Treatment of a young adult taking gamma-butyrolactone (GBL) in a primary care clinic. J Am Board Fam Pract 2002; 15:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/35\">",
"      Galloway GP, Frederick SL, Staggers FE Jr, et al. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 1997; 92:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/36\">",
"      Perez E, Chu J, Bania T. Seven days of gamma-hydroxybutyrate (GHB) use produces severe withdrawal. Ann Emerg Med 2006; 48:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/37\">",
"      Hoffman, RJ, Hoffman, RS, Nelson, L. Cross tolerance of gamma-butyrolactone (GBL) and benzodiazepines. J Tox Clin Toxicol 2000; 38:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/38\">",
"      Zvosec DL, Smith SW, Hall BJ. Three deaths associated with use of Xyrem. Sleep Med 2009; 10:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/39\">",
"      The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol 2003; 41:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/40\">",
"      Zvosec DL, Smith SW. Comment on \"The abrupt cessation of therapeutically administered sodium oxybate (GHB) may cause withdrawal symptoms\". J Toxicol Clin Toxicol 2004; 42:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/41\">",
"      Hornfeldt, CS. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not produce withdrawal symptoms (Abstract). J Tox Clin Toxicol 2001; 39:516.",
"     </a>",
"    </li>",
"    <li>",
"     Xyrem&reg; (sodium oxybate) oral solution. Available online at: jazzph.isat-tech.com/media/PI.pdf (Accessed on March 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/43\">",
"      Wiegand, TJ, Zvosec, DL, Smith, SW. Use of propofol for severe GHB withdrawal: Two cases (Abstract). J Tox Clin Tox 2005; 43:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/44\">",
"      Greene, T, Dougherty, T, Rodi, A. Gamma butyrolactone (GBL) withdrawal presenting as acute psychosis (Abstract). J Tox Clin Toxicol 1999; 37:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/45\">",
"      Reeves, J, Duda, R. GHB/GBL intoxication and withdrawal: A review and case presentation. Addictive Disorders and their Treatment 2003; 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/46\">",
"      Hutto B, Fairchild A, Bright R. gamma-Hydroxybutyrate withdrawal and chloral hydrate. Am J Psychiatry 2000; 157:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/47\">",
"      Stein LA, Lebeau R, Clair M, et al. A web-based study of gamma hydroxybutyrate (GHB): patterns, experiences, and functions of use. Am J Addict 2011; 20:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/48\">",
"      Glasper A, McDonough M, Bearn J. Within-patient variability in clinical presentation of gamma-hydroxybutyrate withdrawal: a case report. Eur Addict Res 2005; 11:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/49\">",
"      Bialer PA. Designer drugs in the general hospital. Psychiatr Clin North Am 2002; 25:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/50\">",
"      Zvosec, D, Smith, S, Ladmer, D. Gamma Hydroxybutyrate withdrawal syndrome in the Emergency Department: Clinical course and autonomic instability (Abstract). Ann Emerg Med 2006; 48:S100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/51\">",
"      Mahr G, Bishop CL, Orringer DJ. Prolonged withdrawal from extreme gamma-hydroxybutyrate (GHB) abuse. Psychosomatics 2001; 42:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/52\">",
"      Bowles TM, Sommi RW, Amiri M. Successful management of prolonged gamma-hydroxybutyrate and alcohol withdrawal. Pharmacotherapy 2001; 21:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/53\">",
"      Chew G, Fernando A 3rd. Epileptic seizure in GHB withdrawal. Australas Psychiatry 2004; 12:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/54\">",
"      Friedman J, Westlake R, Furman M. \"Grievous bodily harm:\" gamma hydroxybutyrate abuse leading to a Wernicke-Korsakoff syndrome. Neurology 1996; 46:469.",
"     </a>",
"    </li>",
"    <li>",
"     Jacobs, K, Bain, B. Delirium with Wernicke's disease after abrupt cessation of 1,4 butanediol. Med Psychiatry 1999:41.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/56\">",
"      Craig K, Gomez HF, McManus JL, Bania TC. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000; 18:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/57\">",
"      Su, M, Traub, S, Hussain, E, et al. 1,4-Butanediol withdrawal complicated by urinary retention. (Abstract). J Tox Clin Toxicol 2001; 39:542.",
"     </a>",
"    </li>",
"    <li>",
"     Benjamin DM. Gamma-hydroxybutyrate (GHB) - Withdrawal with severe rhabdomyolysis, hyperkalemia, and cardiac arrest.  (Abstract K4), Proceedings of the American Academy of Forensic Sciences, San Antonio, TX, February 2007. Vol. XIII.",
"    </li>",
"    <li>",
"     Zvosec DL, Smith SW. GHB withdrawal fatalities: two cases. 2011 (in press).",
"    </li>",
"    <li>",
"     Dyer, JE, Haller, CA. Gamma hydroxybutyrate and the comatose patient. Pulmonary and Critical Care Update, Chest Online 2001, Lesson 22. Available online at: www.chestnet.org/education/online/pccu/vol14/index.php (Accessed on August 22, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/61\">",
"      Tarabar AF, Nelson LS. The gamma-hydroxybutyrate withdrawal syndrome. Toxicol Rev 2004; 23:45.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson IB, Dyer JD. Withdrawl: Central nervous system depressants. In: Medical Toxicology, 3rd, Dart RC.  (Ed), Lippincott, Williams, &amp; Wilkins, Philadelphia 2004. p.135.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/63\">",
"      Dill C, Shin S. High-dose intravenous benzodiazepine. Acad Emerg Med 2000; 7:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/64\">",
"      Daeppen JB, Gache P, Landry U, et al. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med 2002; 162:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/65\">",
"      Busto UE, Sykora K, Sellers EM. A clinical scale to assess benzodiazepine withdrawal. J Clin Psychopharmacol 1989; 9:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/66\">",
"      Saitz R, Mayo-Smith MF, Roberts MS, et al. Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial. JAMA 1994; 272:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/67\">",
"      Gonzalez A, Nutt DJ. Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol 2005; 19:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/68\">",
"      Coomes TR, Smith SW. Successful use of propofol in refractory delirium tremens. Ann Emerg Med 1997; 30:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/69\">",
"      Olmedo, RE, Nelson, L, Howland, M, Hoffman, RS. Propofol safely controls delirium tremens (Abstract). J Tox Clin Tox 2000; 38:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/70\">",
"      Sharma, AN, Nelson, L, Hoffman, RS. Refractory sedative-hypnotic withdrawal treated with propofol (Abstract). J Tox Clin Tox 2000; 38:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/71\">",
"      Glisson JK, Norton J. Self-medication with gamma-hydroxybutyrate to reduce alcohol intake. South Med J 2002; 95:926.",
"     </a>",
"    </li>",
"    <li>",
"     Stalcup, SA, Stalcup, J. GHB addiction and outpatient treatment of GHB withdrawal. Presentation at the 2003 National GHB Conference, \"Spotlight on GHB,\" Orlando, Florida, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/73\">",
"      Hayner G, Galloway G, Wiehl WO. Haight Ashbury free clinics' drug detoxification protocols--Part 3: Benzodiazepines and other sedative-hypnotics. J Psychoactive Drugs 1993; 25:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/74\">",
"      Stalcup SA, Christian D, Stalcup J, et al. A treatment model for craving identification and management. J Psychoactive Drugs 2006; 38:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/27/3514/abstract/75\">",
"      Barth KS, Hines S, Albanese RP. Permanent neurologic damage from chronic gamma hydroxybutyrate abuse. Am J Addict 2006; 15:483.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 309 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_27_3514=[""].join("\n");
var outline_f3_27_3514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOLOGY, CELLULAR TOXICOLOGY, AND PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES OF WITHDRAWAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11176244\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15398272\">",
"      Risk factors for development of GHB dependence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dosing patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Common symptoms, onset, and course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Specific signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lethality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Specific testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      General testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Mild to moderate withdrawal, without delirium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Severe withdrawal, with delirium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11174437\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Barbiturates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Propofol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15398320\">",
"      - Baclofen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Antihypertensives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Restraints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Vitamins and fluids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Outpatient detoxification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Persistent symptoms post-detoxification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      CHEMICAL DEPENDENCY TREATMENT AND RELAPSE PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PITFALLS IN MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/309\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/309|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/61/21470\" title=\"table 1\">",
"      CIWA-Ar withdrawal scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31130?source=related_link\">",
"      Gamma hydroxybutyrate (GHB) intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40328?source=related_link\">",
"      Overview of the chronic neurologic complications of alcohol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_27_3515="E nodosum and hilar adenopathy";
var content_f3_27_3515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions that may present with erythema nodosum and hilar adenopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Sarcoidosis (bilateral ankle involvement in most cases; uveitis practically diagnostic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculosis (occurs in primary infection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coccidioidomycosis (prominent cause in endemic areas)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histoplasmosis (suggested by epidemiologic factors, but also the concurrent presence of erythema multiforme)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blastomycosis (accompanied by respiratory symptoms and the presence of lung parenchymal radiologic findings)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yersiniosis (probably rare outside of Northern Europe)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlamydia pneumoniae (usually accompanied by respiratory symptoms)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_27_3515=[""].join("\n");
var outline_f3_27_3515=null;
var title_f3_27_3516="EUS gallbladder polyps";
var content_f3_27_3516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Endoscopic ultrasonography for the differential diagnosis of polypoid gallbladder lesions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Histologic diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Cholesterol polyp",
"       </td>",
"       <td class=\"subtitle2\">",
"        Adenomyomatosis",
"       </td>",
"       <td class=\"subtitle2\">",
"        Neoplastic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Pre-operative diagnosis with endoscopic US",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cholesterol polyp",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adenomyomatosis",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neoplastic",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Pre-operative diagnosis with transabdominal US",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cholesterol polyp",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adenomymatosis",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neoplastic",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Sugiyama, M, Xie, XY, Atomi, Y, Saito, M, Ann Surg 1999; 229:498.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_27_3516=[""].join("\n");
var outline_f3_27_3516=null;
var title_f3_27_3517="US findings antibiotic colitis";
var content_f3_27_3517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sonographic findings in patients with penicillin-induced segmental hemorrhagic colitis and antibiotic-related pseudomembranous colitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Segmental hemorrhagic colitis",
"(n=9)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pseudomembranous colitis (n=10)",
"       </td>",
"       <td class=\"subtitle1\">",
"        p",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">",
"        Distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pancolitis",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        7/10 (70 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Terminal Ileum",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Small intestine*",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ascending colon",
"       </td>",
"       <td class=\"sublist_other\">",
"        9/9 (100 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        7/10 (70 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        n.s.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Transverse colon",
"       </td>",
"       <td class=\"sublist_other\">",
"        3/9 (33 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        7/10 (70 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        n.s.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sigmoid",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/9",
"       </td>",
"       <td class=\"sublist_other\">",
"        10/10 (100 percent)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;0.001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bowel wall thickening [mm]",
"       </td>",
"       <td>",
"        8 &plusmn; 2 (6 - 12)",
"       </td>",
"       <td>",
"        8 &plusmn; 2 (4 - 10)",
"       </td>",
"       <td>",
"        n.s.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Longitudinal bowel wall involvement [cm]",
"       </td>",
"       <td>",
"        20 &plusmn; 7 (15 - 35)",
"       </td>",
"       <td>",
"        all &gt;30 cm",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymmetric bowel wall thickening",
"       </td>",
"       <td>",
"        9/9 (100 percent)",
"       </td>",
"       <td>",
"        0/10 (100 percent)",
"       </td>",
"       <td>",
"        &lt;0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thickening of the mesentery",
"       </td>",
"       <td>",
"        2/9 (22 percent)",
"       </td>",
"       <td>",
"        8/10 (80 percent)",
"       </td>",
"       <td>",
"        &lt;0.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abscess",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        n.s.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fistula",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0 (82)",
"       </td>",
"       <td>",
"        n.s.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesenteric lymphadenopathy&bull;",
"       </td>",
"       <td>",
"        1/9",
"       </td>",
"       <td>",
"        6/10 (60 percent)",
"       </td>",
"       <td>",
"        &lt;0.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascites",
"       </td>",
"       <td>",
"        6/9 (66 percent)",
"       </td>",
"       <td>",
"        6/10 (60 percent)",
"       </td>",
"       <td>",
"        n.s.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     n.s.: not significant.",
"     <br>",
"      * Small intestine except terminal ileum.",
"      <br>",
"       &bull; Defined as more than 2 mesenteric lymph nodes.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Dietrich, CF, Lembcke, B, Seifert, H, et al. Dtsch Med Wochenschr 2000; 125:755; Dietrich, CF, Zeuzem, S, Caspary, WF, et al. Ultraschall Med 1998; 19:265; Downey, DB, Wilson, SR. Radiology 1991; 180:61.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_27_3517=[""].join("\n");
var outline_f3_27_3517=null;
var title_f3_27_3518="Neoadjuvant therapy rectal CA";
var content_f3_27_3518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Preoperative therapy in patients prospectively declared to require an APR",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        (1)",
"       </td>",
"       <td class=\"subtitle1\">",
"        (2)",
"       </td>",
"       <td class=\"subtitle1\">",
"        (3)",
"       </td>",
"       <td class=\"subtitle1\">",
"        (4)",
"       </td>",
"       <td class=\"subtitle1\">",
"        (5)",
"       </td>",
"       <td class=\"subtitle1\">",
"        (6)",
"       </td>",
"       <td class=\"subtitle1\">",
"        (7)",
"       </td>",
"       <td class=\"subtitle1\">",
"        (8)",
"       </td>",
"       <td class=\"subtitle1\">",
"        (9)",
"       </td>",
"       <td class=\"subtitle1\">",
"        (10)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"       <td>",
"        CMT",
"       </td>",
"       <td>",
"        CMT",
"       </td>",
"       <td>",
"        CMT",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"       <td>",
"        CMT",
"       </td>",
"       <td>",
"        CMT",
"       </td>",
"       <td>",
"        CMT",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total no. enrolled",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        59*",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        201",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        392&bull;",
"       </td>",
"       <td>",
"        &nbsp;54",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No. who underwent surgery",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No. judged to need an APR",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        34*",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        No. with T3 disease",
"       </td>",
"       <td>",
"        31 (86%)",
"       </td>",
"       <td>",
"        12 (32%)",
"       </td>",
"       <td>",
"        NR (100%)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        NR",
"       </td>",
"       <td>",
"        83 (66%)&nbsp;",
"       </td>",
"       <td>",
"        62 (44%)",
"       </td>",
"       <td>",
"        72 (100%)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        NR",
"       </td>",
"       <td>",
"        52 (96%)",
"       </td>",
"       <td>",
"        0 (all cT2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        No. who underwent LAR and/or coloanal anastomosis",
"       </td>",
"       <td>",
"        27 (77%)",
"       </td>",
"       <td>",
"        17 (63%)",
"       </td>",
"       <td>",
"        30 (75%)",
"       </td>",
"       <td>",
"        28 (78%)",
"       </td>",
"       <td>",
"        31 (66%)",
"       </td>",
"       <td>",
"        15 (44%)",
"       </td>",
"       <td>",
"        68 (94%)",
"       </td>",
"       <td>",
"        41 (39%)",
"       </td>",
"       <td>",
"        13 (65%)",
"       </td>",
"       <td>",
"        21 (78%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percent local failure",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Percent survival",
"       </td>",
"       <td>",
"        64%- 5-yr",
"       </td>",
"       <td>",
"        83%- 2-yr",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        NR",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        87%&loz;",
"       </td>",
"       <td>",
"        72%- 5-yr",
"       </td>",
"       <td>",
"        75%- 3-yr",
"       </td>",
"       <td>",
"        95%- 3-yr&nbsp;",
"       </td>",
"       <td>",
"        78%- 5-yr",
"       </td>",
"       <td>",
"        92%- 2-yr",
"       </td>",
"       <td>",
"        86%- 5-yr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        No. evaluable for sphincter function analysis",
"       </td>",
"       <td>",
"        27 (77%)",
"       </td>",
"       <td>",
"        14 (52%)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        NR",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        NR",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        63",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        82&sect;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        21",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        NR",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        NR",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Sphincter function",
"       </td>",
"       <td>",
"        85%- good to excellent",
"       </td>",
"       <td>",
"        75%- perfect",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        NR",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        NR",
"       </td>",
"       <td>",
"        6%- moderate soilage",
"       </td>",
"       <td>",
"        78%- normal",
"       </td>",
"       <td>",
"        81%- good to excellent",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        NR",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        NR",
"       </td>",
"       <td>",
"        77%- good to excellent at 2-3 yr",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     APR: abdominoperineal resection; RT: radiation therapy; CMT: combined modality therapy; NR: data not reported; cT2: clinical (and endoscopy) stage T2; %: percent.",
"     <br>",
"      * These data from an early report of NSABP R-03 that included 59 patients randomized to the preoperative arm, 40 of whom were judged to require APR, 22. Data on patients in the postoperative arm not included.",
"      <br>",
"       &bull;&nbsp;Data from a preliminary report of the preoperative therapy arm of a randomized German study comparing preoperative and postoperative chemoradiotherapy.",
"       <br>",
"        &Delta; 15 percent underwent a local excision therefore a total of 78 percent had a sphincter preservation.",
"        <br>",
"         &loz; Disease free survival with a median follow-up of 12 months.",
"         <br>",
"          &sect; Includes all patients in the trial who underwent sphincter preservation.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     1. (MSKCC) Wagman, R, et al. Int J Radiat Oncol Biol Phys 1998; 42:51. 2. (Montpellier) Rouanet, P, et al. Dis Colon Rectum 2002; 45:305. 3. (NSABP R-03) Hyams, DM, et al. Dis Colon Rectum 1997; 40:131. 4. (Ellis Fischel) Kuvshinoff, B, et al. Ann Surg Oncol 2001; 8:163. 5. (Cath Univ) Valentini, V, et al. Int J Radiat Oncol Biol Phys 1998; 40:1067. 6. (Lyon R90-01) Francois, et al. J Clin Oncol 1999; 17:23296. 7. (MSKCC) Grann, A, et al. Int J Radiat Oncol Biol Phys 2001; 49:987. 8. (German) Sauer, R, et al. Int J Radiat Oncol Biol Phys 2003; 57(2 suppl): S124. 9. (Italian) Gambacorta, M, et al Int J Radiat Oncol Biol Phys 2004; 60:130. 10. (MSKCC) Rengan, R, et al. J Clin Oncol 2005; 23:4905.",
"     <br>",
"      Data from a preliminary report of the preoperative therapy arm of a randomized German study comparing preoperative and postoperative chemoradiotherapy.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_27_3518=[""].join("\n");
var outline_f3_27_3518=null;
var title_f3_27_3519="Flow by triggering";
var content_f3_27_3519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Flow-by triggering in mechanical ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 324px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flow-by triggering involves the monitoring of gas flow through the circuit as it is passed by the patient. The machine is triggered once the return flow is less than delivered flow, due to the patient's inspiratory effort. The ventilator monitors return flow (left upper panel), which decreases as patient effort begins (left middle panel). The airway pressure and inspiratory flow required by flow triggering (red dashed arrows) are less than those required to trigger a demand valve (black solid arrows). Once the return flow has diminished, the base flow increases as the machine is triggered; increased gas flow is then delivered to the patient as shown in the graph in the upper right",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Puritan Bennett 1994, Form AA-1495",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_27_3519=[""].join("\n");
var outline_f3_27_3519=null;
        